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Natural plant products are increasingly being used in cancer 
therapeutic studies due to their reduced normal cell toxicity. In this study, 
the anti-cancer properties of Plumbagin, a naphthoquinone derivative 
extracted from the roots of Plumbago, in breast cancer cells was 
evaluated. According to the first part of the findings of this study, 
Plumbagin induced specific cytotoxicity in human breast cancer cells 
along with DNA damage and cell death leading to apoptosis. Plumbagin 
was also found to suppress the telomerase activity in cancer cells 
accompanied by telomere attrition. Telomere shortening was 
substantiated by reduced telomere fluorescence on chromosome ends. 
In the next part, through a microarray-based study, the molecular 
mechanism of action of Plumbagin was investigated in human breast 
cancer. It was shown that this plant chemical dysregulates multiple 
cancer-related pathways at genetic level and plays a crucial role in 
suppressing breast cancer cell proliferation, survival, telomere 
dynamics, invasion and metastasis. 
This study analyzed different aspects of cellular and molecular 
responses triggered upon Plumbagin treatment and it showed that 
Plumbagin significantly suppresses the tumour activity of the triple 
negative MDA-MB-231 and luminal ER+ MCF-7 breast cancer cells, as 
compared to the breast epithelial MCF-10A cell type. Gene expression 
profiles and cellular response studies of cells treated with this pleiotropic 
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phyto-compound revealed that even after short term treatment, 
Plumbagin significantly inhibits metastasis and cell growth, leading to 
apoptosis in the invasive MDA-MB-231 cells. While in favour of cancer 
treatment in the luminal MCF-7 cells, Plumbagin was shown to activate 
the DNA damage response systems through gene expression analyses 
and kinetic studies after short term treatment, and was revealed to 
significantly modify the telomere/telomerase machinery of these cells 
following long term exposure.  
Finally, based on the kinetic investigations of Plumbagin, three 
signalling pathway specific inhibitors were selected to explore their 
combinatory effects along with Plumbagin treatment. Inhibition of DNA-
PKcs along with Plumbagin treatment exerted synergistic effects on 
cancer cells, while PARP-1 inhibitor seemed to induce cell resistance 
towards Plumbagin’s cytotoxic effects. Combination of two plant 
products, Plumbagin and telomerase inhibitor MST-312, was 
complementary. During the lag phase of telomerase inhibition, 
Plumbagin caused DNA damage, and this dual effect appeared to be 
lethal to cancer cells. 
It is proposed that application of Plumbagin, in both single and 
combination studies, with certain molecular inhibitors, may suggest 
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1.1. Breast cancer 
1.1.1. Breast cancer incidence and mortality rate 
 
Breast cancer is one of the three commonly diagnosed types of 
cancer and the foremost cause of cancer death among women with a  
global burden exceeding other cancers (Jemal et al., 2011). Incidence 
rates of breast cancer are increasing in most countries. Since the 
estimates for 1990, there has been an overall increase in incidence rates 
of about 0.5% annually. However, in China and eastern Asia, according 
to the cancer registries the annual increases in incidence of breast 
cancer is reported to be 3% to 4%. Nevertheless, the worldwide mortality 
rate is significantly less than the incidence rate, due to favourable 
survival in the more affluent developed countries and poor survival in 
some of the least affluent developing countries. Therefore, the estimated 
mortality rates in Africa and the Pacific (Micronesia and Polynesia), for 
example, are not greatly inferior to those in Europe. (Parkin et al., 2005). 
In 2012, in United States alone, the number of new incidences for breast 
cancer was 229,060 beside the approximate number of 39,510 cases 
leading to death (Siegel et al., 2012).  
There is a higher frequency of breast cancer in women than in 
men, even though men have shown less survival rates due to delay in 
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diagnosis (American-Cancer-Society, 2013, Gomez-Raposo et al., 
2010). 
In spite of the notable reduction in the rate of breast cancer 
mortality over the past two decades, incidence rates have grown swiftly 
in countries with lower historical rates. The relevance of geographical 
location of the patient, lifestyle modifications, screening interventions, 
cancer type, stage and treatment are all factors determining prognosis 
and survival rates of this disease (Benson and Jatoi, 2012).  
 
1.1.2. Breast cancer stages and subtypes 
Staging the breast cancer facilitates the treatment by means of 
using clinical, imaging, and pathological diagnostic tests. In breast 
cancer if the tumour is localized, the major treatment is surgery, followed 
by chemotherapy, radiotherapy, and adjuvant hormonal therapy. If the 
cancer spreads beyond the breast and the lymph nodes then it is 
classified as stage 4 or metastatic cancer, which needs a systemic 
treatment to be rendered. Therefore, the patient may benefit from local 
treatment, usually for tumours at early stages. Nevertheless, years after 
having their primary tumours removed many patients will need 
chemotherapy for metastatic disease that occurs in distal sites such as 
lung and brain (McLaughlin, 2013, Yang and Ho, 2013, Benson and 
Jatoi, 2012). 
Breast cancer is known as a heterogeneous disease with a variety 
of genetic and molecular alterations driving its growth and survival as 
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well as response to therapy. From a comprehensive gene expression 
profiling perspective, three different subtypes of breast cancer are: 
luminal, human epidermal growth factor receptor 2 positive (HER2+), and 
triple-negative breast cancers. This labelling is based on the expression 
pattern of hormone receptors Estrogen (ER), Progesterone (PR) and 
(HER2) (Polyak, 2011).  
In light of the fact that breast cancer is one of the few tumours 
with molecular classification, personalized therapy will be feasible 
leading to improved survival.  
1.1.3. Diagnosis, conventional treatment and limitations 
Both luminal tumours, which are known to express ER and PR 
receptors; and HER2+ tumours, could be efficiently controlled through 
their respective targets. Patients with ER+ tumours will usually 
receive hormonal therapy following their chemotherapy. Typical 
hormonal treatments include Tamoxifen, which is normally given to 
premenopausal women to inhibit the ER receptors. Aromatase 
inhibitors are usually given to postmenopausal women to lower the 
amount of ER in their bodies. As for HER2+ tumours, which consist of 
amplified ERBB2 oncogene, these tumours can be treated with 
therapies that target the HER2 protein such as the monoclonal antibody 
Herceptin (Trastuzumab) (Ignatiadis and Sotiriou, 2013, Jelovac and 
Emens, 2013).  
Lastly, basal-like tumours in general lack hormone receptors, 
hence they are also known as triple-negative breast cancers (TNBC). 
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With regard to this deficiency, serious challenge is met for these highly 
aggressive tumours comprising poor outcome. Besides chemotherapy 
as the only accessible systemic therapy where only 20% of TNBC 
respond well to its standard format, currently there is no hormonal 
therapy available for TNBC (Perou et al., 2000, Dent et al., 2007). It is 
estimated that about 3 million women in the United States have a history 
of invasive breast cancer (Siegel et al., 2012). Women with basal-like 
breast cancer have significantly shorter period of relapse-free survival 
than women suffering from other types of breast cancer (Perou et al., 
2000). In light of this fact, developing enhanced therapy for TNBC is one 
of the most crucial concerns of modern breast cancer research 
modalities (Reis-Filho and Tutt, 2008, Polyak, 2011).  
1.2. The hallmarks of cancer 
Cancer arises through a complex and mutagenic cascade 
whereby the normal cells are converted into cancer cells attaining 
common set of properties such as unrestricted proliferation ability, 
independence in growth signal production, and resistance to anti-
proliferative and apoptotic processes. Furthermore tumour cells adopt 
and control the vital support from adjacent stromal cells, escape immune 
system, attract new blood vessels to carry nutrients and oxygen, and 
eventually metastasize to distant organs in favour of their own benefit. 
Several of these phenotypic traits, which are brought to overcome 
natural anti-tumourigenic cellular constraints, are achieved by genetic 
alterations that involve the gain-of-function mutation, amplification, 
5 
 
and/or overexpression of key oncogenes together with the loss-of-
function mutation, deletion, and/or epigenetic silencing of key tumour 
suppressors (Luo et al., 2009, Hanahan and Weinberg, 2000).  
These acquired biological capabilities are classified as six 
hallmarks of cancer that are comprised of sustaining proliferative 
signalling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, and activating invasion 
and metastasis. Genome instability is the essence of these hallmarks, 
which causes the genetic diversity. Reprogramming of energy 
metabolism and evading immune destruction are the other two novel 
hallmarks of potential generality to this list. Tumor microenvironment is 
the other profound dimension of complexity in cancer cells survival. 
Having known such varied perturbations for cancer orientation, 
developing successful human cancer therapeutics will become more 
complex (Luo et al., 2009, Hanahan and Weinberg, 2011). As a 
consequence, a key to effective therapy is to identify significant, useful 
joints in the oncogenic network whose inhibition will result in tumour 
system failure, by apoptosis, necrosis, senescence, or differentiation 
(Figure 1).  
As described in later sections, inhibitors contributing to cancer 
treatment modalities targeting genome instability and replicative 
immortality are of great concern (Frias et al., 2012). The eventual 
immortalization of up to 90% of tumour cells has been attributed to their 
capacity of maintaining telomeric DNA at lengths sufficient to avoid 
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triggering senescence or apoptosis. This trait is achieved mostly by 
reactivating the enzyme telomerase. By taking this fact into account, this 
enzyme is more than an enabler of the hallmark capability for infinite cell 
replicative ability, but must be assumed as a fundamental element in 





Figure 1. Hallmarks of cancer and their therapeutic targeting. Most cancer 
cells have acquired same set of biological traits including sustaining proliferative 
signalling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, and activating invasion and metastasis. 
Drugs that interfere with each of the obtained capabilities have been developed, 
requiring further studies. They are in clinical trials or in some cases approved for 
clinical use in treating certain forms of human cancers. Adapted with permission 
from (Hanahan and Weinberg, 2011).  
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1.3. Telomerase and cancer 
Telomerase activity is detected in majority of cancer cells but not 
in adjacent normal cells to mediate the telomere length maintenance 
mechanism during cancer cell proliferation (Hanahan and Weinberg, 
2011). Noteworthy is the fact that this enzyme is the best well-
documented tumour associated factor, which is widely expressed in 
cancer (Kim et al., 1994, Shay and Bacchetti, 1997). Despite the fact that 
telomerase is not essential for tumour initiation, but is required to sustain 
continuous cell proliferation in most cancers, making telomerase 
inhibition as an attractive target for cancer therapy (Chen and Chen, 
2011).   
1.3.1. Telomeres and telomerase 
Telomeres consist of repetitive DNA sequences and associated 
proteins at the ends of chromosomes, enrolling as protective caps that 
avoid chromosomal end-to-end fusion and prohibit disclosing the 
chromosomal ends as damaged DNA. By a progressive shortening the 
telomere will eventually lose the ability to protect the ends of 
chromosomal DNAs. However, in a vast majority of immortalized cells, 
the telomerase enzyme maintains and elongates the telomeric DNA 
(Blackburn, 1991, Lu et al., 2013b).  
1.3.1.1. Telomere biology 
Telomeres are DNA-protein structures that safeguard eukaryotic 
chromosome ends (Blackburn et al., 2006) and are required to preserve 
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genome integrity, chromosome stability, nuclear architecture and 
chromosome pairing during meiosis (Londono-Vallejo, 2008).  
Notwithstanding the preserved function of telomeres in different 
organisms, the architecture and composition of telomere-associated 
proteins are markedly different and apparently have changed through 
evolution (Linger and Price, 2009) .  
Double stranded telomeric repeat lengths might vary from 3 to 50 
Kb pairs in human and end in a short single-stranded G-rich 3’-
overhangs or G-tails. These G-tails turn back into the duplex portion of 
the telomere to form a loop called t-loop. In telomeres, this combination 
of tandem non-coding TTAGGG repeats is stabilised by associating to a 
specialized protein complex known as shelterin. In mammalian cells, the 
six-subunit shelterin protein comprises TRF1 and TRF2 which in turn 
recruits RAP1, TIN2, TPP1 and POT1 that interacts with both single and 
double strand telomeric DNA (Gomez et al., 2012, Osterhage and 
Friedman, 2009) (Figure 2) .  
In human cells, the best known telomeric binding proteins are 
TRF1 and TRF2, which are both negative regulators of telomere length 
(Smogorzewska et al., 2000). Having a distinctive role at the telomeres, 
TRF2 also stabilizes the protruding G string and prevents telomeric 
fusions (van Steensel et al., 1998). It has been demonstrated that 
mutation in the DNA-binding domain of TRF2 exhibits telomere damage, 
leading to the activation of the ataxia telangiectasia mutated (ATM) 
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kinase and non-homologous end-joining (NHEJ) of chromosome ends 
(Konishi and de Lange, 2008). 
1.3.1.2. Hayflick limit and end replication problem 
Telomeres, similar to a clocking device, modulate cellular lifespan 
with limited proliferative capacity; meaning when they become too short, 
the chromosome will reach a "critical length" and can no longer replicate. 
By losing telomeres’ function and the lack of DNA damage response, a 
cell becomes "old" and dies by a process called apoptosis (Harley et al., 
1990, Levy et al., 1992, Rodier et al., 2005).  
Figure 2. Schematic interpretation of telomere. A telomere in a T-loop 
configuration with a displacement D-loop, consisting telomeric binding proteins. 
Telomeres are DNA-protein structures that protect chromosome ends. They consist 
of TTAGGG repeats that are bound by a specialized protein complex known as 




During every round of cell cycle the terminal sequences 
progressively shorten due to the end replication problem which results 
in loss of telomeric DNA of 50 - 200bp length. The Hayflick limit (or 
Hayflick Phenomenon), discovered by Leonard Hayflick in 1961 
(Hayflick and Moorhead, 1961), is the number of times a normal cell will 
divide before the telomeres reach the critical length and eventually stops 
proliferation.  
In human somatic cells proliferation potential is strictly limited and 
senescence follows approximately 50 - 70 cell divisions. Once the 
telomeres reach this limit, they trigger a DNA damage checkpoint 
response and the cells undergo senescence or mortality 1 (M1) 
(Hayflick, 1965, Harley et al., 1990, Hayflick and Moorhead, 1961). Cell 
cycle checkpoint activities involving p53, p21, pRB and ATM play critical 
roles in initiation and maintenance of the senescence state (Herbig et 
al., 2004, Shay et al., 1991). Cells that lose the function of these critical 
cell cycle checkpoints escape the initial growth arrest and continue to 
divide until they reach the second growth arrest state called crisis (M2). 
At this point, chromosomal instability is observed due to end-to-end 
fusions or chromosome breakage (McClintock, 1942). Uncompensated 
telomere shortening leads to telomere dysfunction and subsequent 
chromosome rearrangement, cell cycle arrest, and apoptosis (Hemann 
et al., 2001, Royle et al., 2009) (Figure 3).  
However, according to the reports, it is the shortest telomere, not 
average telomere length, that constitutes telomere dysfunction and limit 
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cellular survival in the absence of telomerase (Hemann et al., 2001). 
Finally, the expansion of highly unstable cells due to telomere 
dysfunction enhances the genetic diversity needed to fuel specific 
mutations that may promote cell immortalization and the acquisition of a 
tumour phenotype (Genesca et al., 2011).  
Critically shortened telomeres are recognized as damaged DNA 
(Lehmann et al., 2011) resulting in replicative cell senescence. Normal 
cells would not survive as the telomeres are unstable, however, some 
rare cells including cancer cells, bypass senescence and continue to 
divide. Indeed replicative senescence and crisis are two important 
telomere-dependent pathways of cellular mortality, which are subjugated 
by cancer cells to become immortalized. This is mainly achieved by the 
up-regulation of the enzyme telomerase or by an alternative 
recombination-based telomere maintenance (ALT) mechanism (Cheung 
and Deng, 2008, Zou et al., 2009, Royle et al., 2009). In most cancer 
cells, the activation of telomerase will prevent the replicative senescence 
(Figure 3). 
1.3.1.3. Telomerase enzyme, structure and function  
Telomerase is a ribonucleoprotein, first discovered by Carol 
Greider and Elizabeth Blackburn (Greider and Blackburn, 1985).  
The telomerase enzyme is composed of an RNA component (hTR 
or hTERC) (Feng et al., 1995, Greider and Blackburn, 1987), a catalytic 
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subunit of telomerase reverse transcriptase (hTERT) protein (Nakamura 
et al., 1997) and dyskerin protein complex z(Mitchell et al., 1999, 
Vulliamy et al., 2001) (Figure 4). 
The RNA component consists of a nucleotide template with 11 
sequences, which functions as the complementary model for the 
telomeric repeats in a reverse transcriptase reaction (Shippen-Lentz and 
Blackburn, 1990, Greider and Blackburn, 1989, Yu et al., 1990). This 
RNA will be modified, followed by three additional proteins from the 
H/ACA motif, Nop10, Nhp2 and Gar1, binding to that, as reviewed by 




Figure 3. Hayflick phenomenon and telomere maintenance mechanism. In 
normal somatic cells, the telomere length will shorten upon each cell division, 
leading to senescence (M1) or apoptosis (M2). While cancer cells bypass these 
stages, by means of telomerase activity or ALT mechanisms and continue to divide. 
Adapted with permission from (Royle et al., 2009). 
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Studies on the rare congenital disorder called X-linked 
dyskeratosis have shown mutations in the dyskerin gene (DKC1) in this 
fatal premature aging syndrome, which is characterized by defective 
telomere maintenance. Dyskerin is a highly conserved nucleolar protein 
and a component of the human telomerase complex that is vital for the 
hTR stability (Mochizuki et al., 2004).  
Despite the fact that telomerase activity is absent in most human 
somatic cells, this enzyme is detected primarily in embryonic cells, 
gametes, hematopoietic stem cells, activated lymphocytes, basal cells 
of the epidermis, intestinal crypt cells and for the most part in 85 to 90 % 
of cancer cells (Kim et al., 1994, Shay and Bacchetti, 1997, Shay and 
Wright, 2005, Shay and Wright, 2002, Zvereva et al., 2010).  
In fact, cells that have escaped crisis have two significant 
hallmarks: reactivation of telomerase and telomere stability conferred by 
telomerase’s role in conserving the structural integrity at the 
chromosome ends (Kim et al., 1994, Shay and Bacchetti, 1997). By 
extending telomeric DNA, telomerase compensates the progressive 
telomere erosion that would otherwise occur in its absence. This role of 
telomerase at telomeres is considered as its classical or canonical 
function. 
The hypothesis that telomerase may have further roles in tumour 
progression other than telomeres emerged from early observations 
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whereby mouse models of epidermal or mammary carcinogenesis 
displayed superior telomerase activity despite the massive telomere 
reserves in these cells (Bednarek et al., 1995, Chadeneau et al., 1995, 
Broccoli et al., 1996). In view of the non-canonical functions of 
telomerase, this hypothesis started to gain support from the evidence 
that TERT contributes to chromatin at multiple sites along the 
chromosomes and not just at the telomeres (Masutomi et al., 2005, Park 
et al., 2009). Few of the discovered non-canonical functions of 
telomerase involve correct response to DNA damage, the induction of 
neoplasia in both epidermis and mammary gland, and insensitivity to 
Figure 4. Human telomerase structure. Telomerase enzyme in human consist of 
the human telomerase reverse transcriptase (hTERT), human telomerase RNA 
(hTR), heat shock protein 90 (Hsp90), the Hsp90-associated protein (p23), 
telomerase-associated protein 1 (TEP1), dyskerin, members of the H/ACA small 
nucleolar ribonucleoproteins such as NHP2, NOP10, GAR1. However, in vivo 
telomerase complex is composed of additional multiple proteins that facilitate the 
function of the enzyme. Adapted with permission from (Wojtyla et al., 2011). 
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transforming growth factor β (TGF-β) (Parkinson et al., 2008, Martinez 
and Blasco, 2011) . 
1.3.1.4. Telomerase regulation in humans 
It is revealed in many studies that regulation of telomerase in 
mammalian cells is a multi-factorial process, involving expression of 
telomerase subunits coding genes, post-translational protein–protein 
interactions, and protein phosphorylation (Holysz et al., 2013, Li et al., 
2011, Papanikolaou et al., 2011). 
Telomerase activity needs the localization of telomerase in the 
nuclei, near the telomeres. The major part of telomerase activity occurs 
in the cytoplasmatic extracts, rather than nuclear ones, in vitro (Morin, 
1989). In contrast, in vivo GFP-containing telomerase is located in the 
nuclei (Wong et al., 2002). By the time that NF-kB (p65 subunit) protein 
binds with the hTERT, the tumour necrosis factor α (TNF α) induces the 
transfer of NF-kB-bound hTERT from the cytoplasm to the nuclei 
(Akiyama et al., 2003). 
Several oncogenes and oncogenic pathways have also been 
shown to regulate telomerase activity, possibly indicating that 
telomerase activity could be downstream to various oncogenic events 
that enable cancer cells to proliferate indefinitely in the presence of 
mutations (Skvortzov et al., 2009). 
At the transcriptional level, the oncogene c-MYC was found to 
positively regulate the hTERT gene (Wang et al., 1998). Other cellular 
transcriptional activators such as Sp1, HIF-1, AP2, ER and Ets have also 
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been identified to regulate the hTERT promoter in cancers. ER activates 
telomerase via direct and indirect effects on the hTERT promoter(Kyo et 
al., 1999).  
The MAPK-signalling pathway also triggers the hTERT 
transcription regulation by means of number of effectors which bind to 
the regions in its main promoter, including the transcription factors c-
MYC, AP-1 and Ets  (Skvortzov et al., 2009). The inhibition of the MAPK-
cascade leads to a weakening of the phosphorylation of the ERβ, to a 
decrease of the binding of ERβ to the hTERT promoters, and to the 
respective decrease in the level of hTERT expression (Kondoh et al., 
2007, Cairney and Keith, 2008). Protein Sp1 regulates several specific 
promoters which initiate transcription by RNA-polymerase II in 
vertebrates. Sp1 binds to the sequence GGGGCGGGGC and similar 
sequences that are called GC-boxes. It regulates both hTERT and hTR 
promoters (Kyo et al., 2000). Additionally, the hTERT promoter is 
modulated by chromatin structural alterations such as DNA methylation 
and regulation of nucleosome histones (Kyo et al., 2008). In addition, 
three well-known oncoproteins, HER2, Ras, and Raf, assist in the 
expression of hTERT in hTERT-negative normal cells (Goueli and 
Janknecht, 2004). 
Through phosphorylation of TERT, Akt has also been shown to 
enhance telomerase activity (Kang et al., 1999). Besides, telomerase 
activity is enhanced by growth factors such as insulin-like growth factor 
1 (IGF-1), fibroblast growth factor 2 (FGF2), vascular endothelial growth 
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factor (VEGF) and epidermal growth factor (EGF), and also by 
interleukins, all of which are implicated in tumour initiation and 
progression, as well (Liu et al., 2010, Skvortzov et al., 2009). Proteins 
such as TPP1 and POT1 which indirectly regulate telomerase by 
recruiting it to telomeres are also now being considered possible anti-
cancer targets (Wang and Lei, 2011).  
1.4. Targeting telomerase in breast cancer  
The association between high levels of telomerase in human 
cancers; inability to maintain telomeres with age, and the consequent 
declining health, including the increased risk of degenerative diseases 
and cancer; has suggested telomerase as an attractive target for anti-
cancer treatment (Domchek et al., 2007, Cerone et al., 2006, Herbert et 
al., 2001). In human cancers, expression of telomerase is positively 
correlated with tumour aggressiveness and metastatic potential. There 
is accumulating evidence that hTERT favours an immortal phenotype by 
blocking apoptosis independently of its protective function at the 
telomere ends. As reviewed by (Lamy et al., 2013), existing evidence for 
the antiapoptotic role of TERT is summarized in the context of tumour-
cell resistance against DNA damage and TERT is put in the context of 
cell-signal-transduction pathways leading either for survival or cell death. 
As such telomerase is also cross-linked with many different signalling 
pathways that regulate cell proliferation, DNA damage repair, and also 
cell death. Therefore, beside the telomere stabilization role, TERT 
comes into view to preserve genome stability by modulating DNA 
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damage response signalling via ATM, breast cancer gene 1 (BRCA1) 
and gamma-H2AX, as well as histone and heterochromatin 
modifications (Masutomi et al., 2005). Despite the described fact that 
genome instability is a hallmark of cancer (Hanahan and Weinberg, 
2011), TERT’s level of contribution in favour of genome stability seems 
sufficient for continuous cellular proliferation, which is supported by the 
regulation of telomerase activity in human cancer gene amplification, 
alternative splicing, and changes in sub-cellular localization and 
phosphorylation (Aisner et al., 2002). 
Among tumours, of specific concern is breast cancer, in light of 
the fact that almost all the adenocarcinomas, including breast cancer 
cells, express this enzyme (Holysz et al., 2013). It has been established 
that telomerase inhibition enhances the response to anti-cancer drug 
treatment in human breast cancer cells (Cerone et al., 2006). 
The likelihood of developing resistance mechanisms against such 
targeted therapy is low, as telomerase is encoded by a non-redundant 
gene. In addition, the different telomerase expression levels, as well as 
the generally longer telomeres in healthy cells versus tumour cells, 
suggest a high degree of tumour specificity and a low risk of toxicity to 
normal tissues (Hanahan and Weinberg, 2011, Harley, 2008).  
Different strategies have been designed in the search for effective 
catalytic telomerase inhibitors: either by denying the access of 
telomerase to the telomere in situ or perturbing the telomere structure 
(Parkinson and Minty, 2007).  
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Among the investigated drugs are those, which inhibit telomerase 
enzymatic activity; active immunotherapy or gene therapy using 
telomerase promoter-driven expression of a suicide gene, agents that 
block telomerase biogenesis and G-quadruplex-stabilizing molecules as 
telomere-disrupting agents. Promising hTERT-based therapies have 
also been developed, such as immunotherapy, suicide gene therapy, 
and small-molecule interfering therapy (Lu et al., 2012). However, only 
drugs that inhibit telomerase enzymatic activity and immunotherapy-
based drugs have so far reached clinical trials (As reviewed by (Harley, 
2008)) (Figure 5). There are also studies reporting synergism between 
telomerase inhibitors and traditional cancer therapeutic agents 
(Cunningham et al., 2006). 
Antisense oligonucleotides, dominant negative mutant hTERT 
and reverse transcriptase inhibitors have been studied in breast cancer 







1.4.1. Telomerase inhibitors 
The initial function of telomerase is to synthesize telomeric DNA, 
therefore the most obvious approach, which has proven successful for 
many drug targets, is direct enzyme inhibition. There are a number of 
telomerase inhibitors available such as active site inhibitors that mimic 
telomeres or the nucleotide substrates; and allosteric inhibitors, which 
target structural features of hTERT or hTR, such as Imetelstat sodium 
(GRN163) (Cohn et al., 2012), small molecules such as Azidothymidine, 
Figure 5. Five telomerase-related pharmaceutical approaches in confronting 
cancer. 1) Active site inhibitors that imitate telomeres or the nucleotide substrates, 
and allosteric inhibitors, which target hTERT or hTR. 2) Active immunotherapy to 
attack and kill telomerase-positive tumour cells that express TERT, through classical 
major histocompatibility complex (MHC) presentation. 3) Telomere-disrupting agents 
to modify the arrangement of the telomere resulting in failure of telomerase to access 
the telomere, or to a telomere length-independent damage signal causing immediate 
cell arrest or death. 4) Using telomerase promoter-driven expression of a suicide 
gene. 5) Blocking telomerase expression or biogenesis, which is based on the 
knowledge the processes of telomerase formation, from transcription to post-




chemicals including retinoids, epigalocatechin gallate (EGCG) (Cohn et 
al., 2012) such as MST-312 and G-quadruplex stabilizers (Cunningham 
et al., 2006, Harley, 2008). 
1.4.1.1. Telomerase inhibitor, MST-312  
MST-312, is a synthetic derivative of green tea-catechin, 
epigalocatechin gallate, which has been shown to be a potent 
telomerase inhibitor (Seimiya et al., 2002) (Figure 6). While being more 
stable than EGCG, it possesses a direct and reversible inhibitory effect 
on telomerase activity. Though it’s mechanism of action is not fully 
elucidated, it is known to reduce telomerase activity even 15 - 20 times 
more than EGCG. It was reported by Seimiya and colleagues that MST-
312 exhibits a dose-dependent, specific inhibition of telomerase 
(Seimiya et al., 2002). Nonetheless, telomerase inhibition may hold long 
lag phase prior to observable responses. Despite the fact that 
telomerase is inhibited, still adequate time is required for the telomere 
attrition with every round of cell cycle due to end replication problem 
(Harley, 2008).  
1.5. DNA damage response, pathways and checkpoints 
DNA damage response (DDR) system is a cellular reaction 
directly related to cancer, since cancer is a consequence of damage to 
DNA and deficiency in DDR mechanisms. When cells are exposed by 
DNA damage threats, they set off complex cascade of reactions to signal 
their presence and promote their repair (Harrison and Haber, 2006, 
Rouse and Jackson, 2002). 
22 
 
As depicted in Figure 7, mismatch repair (MMR) happens by 
detection of mismatches and insertion/deletion loops, which will 
eventually be maintained by nuclease, polymerase and ligase enzymes 
(Jiricny, 2006). In base-excision repair (BER), when overlapped with 
single strand breaks (SSB) (Hoeijmakers, 2001), a DNA glycosylase 
enzyme will identify the damaged base and get into action to remove it 
prior to the nuclease, polymerase and ligase proteins terminate the 
repair (David et al., 2007). The nucleotide excision repair (NER) 
machinery recognizes helix-distorting base lesions. The major highlight 
of NER function is that upon removal of the injured 22–30-base 




Molecular Formula: C20H16N2O6    
Molecular Weight: 380.35084 
 
Figure 6. Chemical structure and compound information of MST-312. MST-312 
or Telomerase Inhibitor IX is a green-tea catechin derivative, which is known for its 
anti telomerase properties (Seimiya et al., 2002). 
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oligonucleotide section, the DNA polymerases and associated factors 
will act upon a single-stranded DNA (ssDNA) before ligation develops 
(Loeb and Monnat, 2008). 
Double strand break (DSB) repair, is mainly subdivided into two 
principal mechanisms: non homologous end-joining (NHEJ) (Lieber, 
2008) and homologous recombination (HR) (San Filippo et al., 2008). In 
NHEJ, DSBs are detected by the Ku protein, which binds and activates 
the protein kinase DNA-PKcs, leading to recruitment and activation of 
end-processing enzymes, polymerases and DNA ligase IV. Despite the 
fact that NHEJ is error-prone, it is able to mediate in any phase of the 
cell cycle. However, in contrary HR operation is commonly limited to S 
and G2 phases due to its repair function requiring the sister chromatid 
sequences as the template. The initiator of HR is always a ssDNA (San 
Filippo et al., 2008), which might be prompted by means of different 
proteins such as the MRE11–RAD50–NBS1 (MRN) complex. In the 
cascades activated by the breast-cancer susceptibility proteins BRCA1 
and BRCA2, or RAD51, initially, the ssDNA attaches to the undamaged 
template and, subsequently operation of DNA ligation components, 
polymerases, nucleases and helicases will lead to repair. HR also acts 
to restart stalled replication forks and to repair inter-strand DNA cross-
links, the repair of which also involves the Fanconi anaemia (FA) protein 
complex (Kennedy and D'Andrea, 2005) (Figure 7). FA is a genetic 
disorder caused by genetic defects in a cluster of DNA repair proteins. 
Studies on FA patients have revealed that majority of them develop 
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cancer, most frequently acute myelogenous leukemia (Grompe and 
D'Andrea, 2001, Kaddar and Carreau, 2012). 
The prominent components of DDR-signalling in mammalian cells 
are the protein kinases ATM and ATR (ATM and Rad 3 related). 
(Cimprich and Cortez, 2008, Bartek and Lukas, 2007, Shiloh, 2003, 
Kastan and Bartek, 2004). Notably, ATM activation leads to chromatin 
relaxation at DSB locations (Ziv et al., 2006).  CHK1 and CHK2 protein 
kinases are two well-documented ATM/ATR targets which, all together 
form a complex to decrease the cyclin-dependent kinase (CDK) activity. 
This operation occurs through different pathways, some of which are 
mediated by activation of the p53 transcription factor (Riley et al., 2008, 
Bartek and Lukas, 2007). Inhibition of CDKs restrains or cut down the 
cell-cycle progression at the G1–S, intra–S and G2–M cell-cycle check-
points. This will help the DNA repair machinery to increase the repair 
time before the replication or mitosis starts (Jackson and Bartek, 2009). 
If DNA repair functions accurately, it will bring the resumption of normal 
cell activity. Alternatively, if the damage cannot be removed, chronic 
DDR signalling triggers cell death by apoptosis or cellular senescence, 
both of which have potential anti-tumour functions (Halazonetis et al., 
2008).  
DNA-dependent protein kinase (DNA-PK), a key component of 
the NHEJ pathway, was the first DSB repair protein shown to be required 
for capping the ends of mammalian chromosomes (Gilley et al., 2001). 
It is becoming increasingly clear that chromatin structure has an impact 
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on the DDR and is modulated in response to DNA damage (Misteli and 
Soutoglou, 2009). 
DNA-PK belongs to a super family of phosphoinositol kinase-
related kinase (PIKK), which also comprises the gene products of ATM 
and ATR kinases (Durocher and Jackson, 2001, Falck et al., 2005) and 
decreased levels of this protein kinase have been found in various 
human cancers (Bailey and Cornforth, 2007). DNA-PK is a nuclear 
serine/threonine kinase made up of two components, a 465-kDa 
catalytic subunit (DNA-PKcs) and the Ku heterodimer (Ku70/ Ku80) (Hill 
and Lee, 2010, Neal and Meek, 2011).  
DNA-PK has revealed to phosphorylate ERα at Ser-
118.  (Medunjanin et al., 2010). The other important protein which is 
involved in both SSB- and DSB-signalling pathways is the poly (ADP-
ribose) polymerase (PARP) enzyme (Masutani and Fujimori, 2013). In 
response to DNA damage, PARP-1 is the main PARylation acceptor 
(automodification), including more than 90% of the PAR (Poly(ADP-
ribosylation)) (Redon et al., 2010). PAR functions as a docking polymer 
for a variety of chromatin and DNA repair proteins, such as histones, 
XRCC1, Ku, DNA-dependent protein kinases (DNA-PKc), and DNA 
topoisomerases (Schreiber et al., 2006). 
The histone H2A variant, H2AX, tyrosine 142 phosphorylation 
was recently shown to function in the DDR (Xiao et al., 2009, Cook et 
al., 2009). The ATM/ATR/DNA-PK complex is able to mediate 
phosphorylation of serine 139 of H2AX on chromatin flanking DSB sites.  
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1.5.1. Role of DNA repair proteins in telomere maintenance 
DNA repair factors are known to possess essential roles in the 
maintenance of telomeres, thereby loss of DNA repair factors will render 
the cells to lose telomeres and a majority of these cells exhibit premature 
senescence [for reviews (Hande, 2004) and (Slijepcevic, 2008, d'Adda 
di Fagagna, 2008)]. 
It has been shown that strains defective in DNA-PK and Ku70 or 
Ku80 lose the majority of their terminal telomere repeats [for review 
(Hande, 2004)] and (Bailey et al., 1999). It is also established that NHEJ 
deficiency not only impairs DSB repair, but also promotes inappropriate 
chromosomal end fusions of unprotected telomeres to other 
dysfunctional telomeres, and DSB produced ends (Bailey et al., 2004, 
d'Adda di Fagagna et al., 2001, Hsu et al., 2000, Hande et al., 1999). 
The ATM and ATR signalling kinases are capable of inducing 
DNA damage response at telomeres in conditions where shelterin 
activity is impaired or reduced, for example due to telomeres shortening 
in senescent cells (Herbig et al., 2004, Hande et al., 2001). ATM has a 
complex role at telomeres interacting with both TRF1 and TRF2, having 





Figure 7.1. The DNA damage response (DDR) pathways involved in human 
tumourigenesis. Five major DNA damage repair pathways are engaged in cancer 
treatment. These include homologous recombination repair (HR), non-homologous 
end joining (NHEJ), nucleotide excision repair (NER), base excision repair (BER), 
mismatch repair (MMR) and fanconi anemia (FA). Adapted with permission from 





Figure 7.2. The DNA damage response (DDR) pathways involved in human 
tumourigenesis. Five major DNA damage repair pathways are engaged in cancer 
treatment. These include homologous recombination repair (HR), non-homologous 
end joining (NHEJ), nucleotide excision repair (NER), base excision repair (BER), 
mismatch repair (MMR) and fanconi anemia (FA). Adapted with permission from 
(Bartek and Lukas, 2010).  
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On the other hand, ATR pathway is triggered in response to DNA 
replication stress, ssDNA replication stress and ssDNA accumulation 
(Gong and de Lange, 2010). A list of DNA damage response proteins 
performing in the telomere maintenance, and mostly interrelated with 
shelterin complex, is represented in Table 1 (Slijepcevic, 2006). 
 
Table 1. DNA damage response proteins functioning in the telomere 
maintenance. The association between alterations in number of DNA damage 
response proteins, most of which interact with shelterin, and the telomere 
dysfunction and subsequent chromosomal instability has revealed interactions 
between telomere maintenance and DNA damage response mechanisms 
(Slijepcevic, 2006) . 
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1.6. DNA repair proteins and cancer 
Inhibition of DNA repair proteins are recommended as proper 
strategy to increase the sensitivity of DNA damaging chemotherapeutic 
agents in cancer. Human ssDNA binding proteins are essential for 
maintaining genomic stability (Ashton et al., 2013). It has been 
demonstrated that deficiency in DNA-PKcs may contribute to 
persistence of oxidatively induced clustered DNA lesions 
in human tumour cells (Peddi et al., 2010). DNA-PKcs is revealed to be 
a potential molecular therapeutic target for glioblastoma (Carminati et 
al., 2013).  
Familial forms of breast, ovarian and pancreatic cancers are also 
connected with loss-of-function mutations in HR modifying genes, such 
as BRCA1, BRCA2, PALB2, ATM, RAD51C and RAD51D. A number of 
rare disorders also exist in which the fundamental genetic determinant 
is a loss-of-function mutation in a gene that mediates the response to 
DSBs. These cancer or cancer predisposing syndromes include Ataxia 
Telangiectasia, Bloom’s syndrome, Fanconi anaemia, Rothmund–
Thomson syndrome, Werner syndrome and Nijmegen breakage 
syndrome. Though all of them harbour different clinical phenotypes, but 
interestingly exhibit similar high levels of radiosensitivity, which is a 
characteristic of the incapability to encounter DSBs effectively (Lord and 
Ashworth, 2012). 
 PARP is reported to assist p53 in telomere function, chromosome 
stability, and tumour suppression (Tong et al., 2001, d'Adda di Fagagna 
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et al., 1999). Increasing evidence has established association of PARP-
1 to breast cancer, including PARP-1-deficient mice exhibit improved 
spontaneous mammary carcinoma formation, the latency of which is 
augmented by mutations in TP53 (Tong et al., 2007). Low levels of 
PARP-1 gene expression are related to increased genetic instability in 
breast cancer (Bieche et al., 1996). PARP-1 expression levels are 
amplified in triple-negative breast cancer (Ribeiro et al., 2013).  
1.6.1. Targeting DNA repair proteins in breast cancer  
Recent molecular approaches to breast cancer targeted therapy 
are focusing on development of new investigational drugs, which 
indirectly target DNA repair pathways through DNA-binding or DNA-
damage induction (Crown et al., 2012). Two major DNA repair proteins, 
which are being widely targeted and inhibited in terms of breast cancer 
treatment, either in situ or in combination with other therapeutic 
approaches, are PARP (Orlando et al., 2012, Rios and Puhalla, 2011, 
Irshad et al., 2011) and DNA-PKcs (Kim et al., 2002, Yoon et al., 2012, 
Munck et al., 2012).  
Implementation of PARP inhibitors is emerging as highly 
promising “targeted” strategies to treat TNBC cells or breast tumours 
with defective HR pathways (Anders et al., 2010). It has been revealed 
that PARP inhibition sensitizes p53-deficient breast cancer cells to 
doxorubicin-induced apoptosis (Munoz-Gamez et al., 2005). This 
adjuvant therapy selectively kills breast cancer cells with hereditary 
inactive mutations in BRCA1 and BRCA2, which encode proteins critical 
32 
 
for HR (Drew and Calvert, 2008). From the other hand the PARP 
inhibitor, Olaparib, at safely administrable doses with minimal side 
effects has established anti-tumour activity in breast and ovarian 
cancers, which harbour BRCA1 and BRCA2 mutations (Fong et al., 
2009). 
Phenanthridine-derived PARP inhibitors are shown to cause cell 
cycle arrest and subsequent cell death in non-hereditary breast cancer 
cells (Inbar-Rozensal et al., 2009). Studies conducted since the 1980s 
on the development of 3-substituted benzamides as PARP-1 inhibitors 
have shown the cytotoxicity of PARP-1 inhibitors in proliferative cells 
which are treated with genotoxic agents (Peralta-Leal et al., 2009).  
According to initial findings, the response rates and overall survival of 
patients is enhanced when treated with PARP inhibition together with 
DNA-damaging chemotherapeutics of less toxicity (O'Shaughnessy, 
2009, O'Shaughnessy, 2008, Hastak et al., 2010). 
Previously in our laboratory, it was demonstrated that combined 
inhibition of PARP-1 and telomerase in mouse embryonic fibroblasts 
resulted in enhanced genomic instability and decreased cell survival with 
associated telomere shortening (Gurung et al., 2010). Inactive PARP-1 
has shown the potency to inhibit DNA-PK activity, and vice versa 
(Veuger et al., 2004).  
Proposing the DNA repair as the target, many investigations have 
been carried out to deplete or inhibit DNA-PK function in different 
tumours including breast cancer cells. These studies included the 
33 
 
application of antisense oligonucleotides, small interfering RNAs, peptid-
based inhibition of C terminus of Ku80, which suggested the DNA 
binding activity of Ku leads to inhibition of DNA-PK activity in breast 
cancer (Sak et al., 2002, Eriksson et al., 2002, Omori et al., 2002, Kim 
et al., 2002). The first recognized inhibitor for the PIKK enzyme family, 
(DNA-PK, ATM, ATR, and number of other proteins), was the fungal 
metabolite Wortmannin, which alike the other PIKK family inhibitor, 
LY294002, both potentiate ionizing radiation -induced cytotoxicity and 
inhibit DNA-PK (Rosenzweig et al., 1997, Boulton et al., 1996).  
Wortmannin is a noncompetitive, irreversible inhibitor of DNA-PK, 
whereas NU7026 inhibits DNA-PK as competitive with ATP (Willmore et 
al., 2004) 
1.6.1.1. PARP inhibitor, PJ-34 
[N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,Ndimethylacetamide 
HCl], also known as PJ-34, is a specific inhibitor of PARP-1(Jagtap et 
al., 2002), holding the ability to potentiate sensitivity towards 
chemotherapeutic effects in certain types of tumours (Huang et al., 2008, 
Chevanne et al., 2010) (Figure 8). PJ-34 has demonstrated to promote 
cell cycle arrest at G2/M and cell death in MCF-7 and MDA-MB-231 
breast cancer cell types, with far less side effects on the normal breast 
epithelial, MCF-10A, cells (Inbar-Rozensal et al., 2009). Additionally, in 
immunocompromised nude mice, this phenanthridine-derived PARP 
inhibitor prohibited the growth of subcutaneous xenografts tumours of 




1.6.1.2. DNA-PKcs inhibitor, NU7026 
NU7026, 2-(morpholin-4-yl)-benzo[h]chomen-4-one, is a 
competitive and highly selective inhibitor of DNA-PK (Figure 8), known 
to sensitize breast cancer cells towards ionizing radiation (Kim et al., 
2002). 
NU7026 holds an effectiveness of 60-fold more against DNA-PK 
than PI3-K. NU7026 strength point is to be inactive against both ATM 













yl) acetamide;hydrate; hydrochloride 
 
Molecular Formula: C17H20ClN3O3    
Molecular Weight: 349.812 
 
 
IUPAC Name: 2-morpholin-4-ylbenzo[h]chromen-4-one 
 
Molecular Formula: C17H15NO3 





Figure 8. Chemical structure and compound information of PJ-34 and 
NU7026. (A) PJ-34 hydrochloride hydrate is a recent-generated drug reported to 
specifically inhibit PARP-1 (Jagtap et al., 2002)  (B) NU7026, is an effective DNA-
PK inhibitor potentiating sensitivity to chemotherapeutic effects of drugs (Willmore 
et al., 2004). 
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1.7. Complementary and alternative medicine in cancer 
Complementary and Alternative Medicine (CAM) approach uses 
natural medical products and methodology in clinical practices, which 
complement or provide a substitute to the conventional medicinal 
methods (Molassiotis et al., 2005, Frenkel et al., 2010). It was shown on 
average, half of all cancer patients experience the benefits of CAM 
(Horneber et al., 2012); among whom, patients with breast cancer were 
increasingly reported to use CAM treatment in the recent past (Boon et 
al., 2007, Horneber et al., 2012). CAM treatments based on natural plant 
products have been reported to have much potential in palliative therapy 
and supportive strategies of current cancer modalities with lesser 
cytotoxicity to normal cells compared to conventional chemotherapy 
(Cragg and Newman, 2005, Mondal et al., 2012).  
1.7.1. Natural product based- treatments in cancer 
Over the past century, natural plant chemicals called 
phytochemicals have been the main resource of chemical diversity and 
materials of pharmaceutical development. Initially plant extracts have 
been implemented in order to achieve basic therapeutic formulations, 
however, by employing the advancement of antibiotics in the mid-
twentieth century, the current purified phyto-compounds have gained 
more characteristic formulations (Firn and Jones, 2003). Nowadays, 
natural products are exhibiting promising clinical use as probes to 
interrogate biological systems as part of chemical genomics or related 
researches in particular human tumour treatment modalities (Mishra and 
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Tiwari, 2011). Phytochemicals can be categorized into carotenoids, 
phenolics, alkaloids, nitrogen-containing compounds, and organosulfur 
compounds (Liu, 2004). 
1.7.1.1. Phenolic phytochemicals and breast cancer treatment 
Phenolic plant compounds are identified to have both 
preventative and therapeutic potential in combating cancer. It is 
interesting that their anti-cancer effects resemble consequences of 
certain fatty acids such as omega-3 PUFA and conjugated linoleic acids 
(Wahle et al., 2010), which were reported to be potential protective 
factors in preventing breast cancer (Bialek and Tokarz, 2013). Phenolic 
extracts from medicinal herbs and dietary plants consist of phenolic 
acids, flavonoids, tannins, stilbenes, curcuminoids, coumarins, lignans 
and quinones (Huang et al., 2010).  
One of the interesting mechanisms in overcoming the breast 
tumour therapeutic side effects is synthesis of quinone drugs in an 
inactive form, which by entering the cell, they transform to a toxic 
metabolite through their naturally occurring pathway. Human breast 
cancer cells produce high levels of the flavoprotein quinone reductase 
enzyme NQO1, [NAD (P) H: quinone oxidoreductase], also known as 
DT-diaphorase (DTD), as compared to normal cells of the same origin 
(Belinsky and Jaiswal, 1993), which can catalyze the two-electron 
reduction of quinones. It has been revealed that quionones that are 
substrates for NQO1 may be selectively toxic to breast tumours with high 
NQO1 activity (Beall et al., 1995). NQO1 polymorphism that leads to the 
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enzyme inactivity has been found to be a strong prognostic and 
predictive factor in the poor outcome of breast cancer (Fagerholm et al., 
2008). It was established that NQO1 could be activated by anti-ER drugs 
(Montano et al., 2005) and its expression correlates inversely with NFκB 
activation in human breast cancer (Jamshidi et al., 2012). Thus a range 
of natural and synthetic quinones, including analogues of mitomycin C, 
benzimidazolequinones, benzothiazolequinones, quinolinequinones and 
naphthoquinons have been scrutinized to understand the metabolism of 
this enzyme (Colucci et al., 2008). 
 Amongst naphthoquinone agents, 1, 4-naphthoquinones are 
characterized with potent anti-cancer abilities by their aromatic stability 
(Kayashima et al., 2009, Lu et al., 2013a). These structures form yellow 
triclinic crystals and constitute the central chemical structure of many 
natural compounds, most notably the K vitamins. 
1.8. Plumbagin 
Numerous types of naphthoquinones are found in nature, all sharing the 
same nucleus, while differing in their substituent and substitution 
patterns (Figure 9). Plumbagin (5-Hydroxy-2-methyl-1,4-
naphthoquinone) is a naphthoquinone from the plants of the 
Plumbagineae and Droseracea families (Thomson, 1971) with well 
established anti-microbial and anti-fungal properties (Figure 9) (Padhye 
et al., 2012, Cesari et al., 2013). The compound was originally extracted 
from the roots of Plumbago species, which have been credited with 
notable medicinal properties (Cesari et al., 2013, Padhye et al., 2012).  
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1.8.1. Impact of Plumbagin in cancer treatment modalities 
This yellow pigment is recognized as a colourless combined 
compound that can be processed to Plumbagin by acid treatment 
(Harborne, 1966) and like other phenolic product members of 
naphthoquinons (Table 2), holds anti-tumour properties. There has been 
an increasing interest in using this traditional plant drug as a candidate 
chemotherapeutic agent for different human tumours including lung, 
breast, prostate, ovarian, and pancreatic cancers  (Hafeez et al., 2013, 
Lee et al., 2012, Lu et al., 2013a, Sinha et al., 2013, Wang et al., 2008).   
Plumbagin is a naturally occurring structural analogue of Vitamin 
K3 (menadione; 2-methyl-1,4-naphthoquinone), which both were 
reported to be substrates and inhibitors of the breast cancer resistance 
protein (BCRP), also known as multidrug resistance-linked ATP binding 
cassette drug transporter, ABCG2 (Shukla et al., 2007). Both Plumbagin 
and Vitamin K3 have manifested to be potential anti-cancer agents 
against breast cancer via the mithocondria-related pathway (Akiyoshi et 
al., 2009, Kawiak et al., 2012). Plumbagin treatment has resulted in the 
induction of G2/M arrest and autophagy by restraining the 
AKT/mammalian target of rapamycin, leading to apoptosis in breast 





IUPAC Name: 5-hydroxy-2-methylnaphthalene-1,4-dione 
 
 Molecular Formula: C11H8O3  
Molecular Weight: 188.17942    
 
 
Table 2. .Structurally related naphtoquinones (Plumbagin, 1999). 
 
Figure 9. Chemical structure and compound information of Plumbagin. 
Plumbagin or  5-Hydroxy-2-methyl-1,4-naphthoquinone, is a plant chemical extracted 




Plumbagin was shown to down-regulate the expression of 
epidermal growth factor receptor-neu (EGFR/Neu) and its downstream 
signalling pathway phosphatidylinositol 3-kinase/AKT (PI3K/AKT) 
(Hafeez et al., 2012). Following treatment with Plumbagin, the induction 
of protein tyrosine phosphatase, SHP-1, has also been demonstrated to 
trigger the inhibition of signal transducers and activators of transcription 
3 (STAT3) (Sandur et al., 2010). It also inhibits the activation of the 
transcription factor nuclear factor-kappa B (NFκB) leading to further 
decrease in the expression of anti-apoptotic and proliferation genes such 
as Inhibitor of Apoptosis (IAP), BCL2, BIRC5, and Cyclin D1 
(Gomathinayagam et al., 2008). 
 Plumbagin induces cell cycle arrest at G2/M phase, up-regulates 
p21/WAF1, and down-regulates Cyclin B1 (Kuo et al., 2006, Wang et al., 
2008, Sand et al., 2012). It was reported that Plumbagin also enhances 
the JNK/p38 signalling, leading to caspase-3 activation resulting in the 
induction of apoptosis. As mentioned earlier, it also triggered the 
mitochondrial apoptotic pathway indicated by a change in Bax/Bcl-2 
ratios, cytochrome c release, and caspase-9 activation (Hsu et al., 2006, 
Demma et al., 2009, Ahmad et al., 2008). In our earlier approaches, it 
was found for the first time that Plumbagin induces cytotoxic and 
genotoxic effects in human brain tumour cells, followed by inhibitory 
effects on the telomere/telomerase dynamics (Khaw et al., Manuscript in 
preparation).   
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1.9. Significance of the study 
The literature has highlighted thus far the relevance and 
significance of the specific targeting drugs for breast cancer cells. 
Plumbagin is a multifaceted plant chemical, which elicits many anti-
cancer roles implicated in cellular processes, but yet there is limited 
knowledge about the efficacy of this phythochemical in the genome 
stability and telomere/telomerase equilibrium with special reference to 
breast cancer.  
This study hopes to provide a better understanding of the cellular 
and molecular mechanisms, by which Plumbagin may affect breast 
tumour cells. This study will also generate information on the gene and 
protein expression profiles regulated by Plumbagin especially those 
involved in cell cycle control, DNA damage response, apoptosis, 
telomere attrition, senescence, signal transduction and transcription.  
To systematically understand how it impacts the main elements 
involved in DNA damage response pathways and telomere/telomerase 
dynamics, this investigation will be extended to long-term kinetics of 
Plumbagin in addition to short-term effects. 
This study also aims to make the breast cancer treatment more 
targeted by using Plumbagin. Therefore, the synergistic effects of 
Plumbagin together with inhibition of key molecular mediators will be 




Gene expression profiling, using microarray analysis, will 
highlight the genetic modulation of cells upon Plumbagin treatment with 
special interest to unravel alterations in cell cycle, DNA damage and 
repair, invasion and telomere dynamics pathways.  
This study employs breast cancer cells as model to explore the 
genetic and cellular alterations upon Plumbagin treatment.  In order to 
streamline the effectiveness of treatment, basal characteristics and gene 
expression patterns of breast cancer cells will be determined as well.  
1.10. Objectives 
To understand the mechanisms by which Plumbagin 
modulates the breast cancer cell growth and proliferation, It was set 
out to achieve the following objectives:  
 
1) To evaluate the alteration of different cancer related cellular 
pathways, upon Plumbagin treatment in luminal and triple 
negative breast cancer cell types compared to a relative normal 
breast epithelial cells. 
2) To explore the genetic alterations of breast cancer cells upon 
Plumbagin treatment, gene expression analysis will be carried 
out using microarray technology. 
3) To determine the efficacy of combinatorial approach of 
Plumbagin in breast cancer, dual inhibition of each of the main 
molecular signalling elements: PARP-1, DNA-PKcs and 
telomerase will be performed in the selected cancer cell types. 
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In this study, the breast cancer cell types MDA-MB-231 
(TNBC) and MCF-7 (ER+) will be used as compared to the relatively 
normal MCF-10A cells, using the half maximal inhibitory doses of 
Plumbagin. Subsequently assays will be performed related to cell 
survival, telomere dynamics, invasion, DNA damage, genome 
stability, and growth kinetics. 
Concurrently we wish to explore the synergistic effects of 
Plumbagin in combination studies, with particular emphasize on cell 
survival, cell cycle and telomere-telomerase homeostasis. Following 
pre-incubation of cells with the inhibitory drugs for PARP-1, DNA-
















CHAPTER 2  
2. MATERIALS AND METHODS 
2.1. Cell lines and cell culture  
All cells were grown and incubated at 37°C in a humidified 5% 
CO2 incubator. All the supplements used were from Gibco, USA, unless 
otherwise stated.  
2.1.1. Non-cancerous human cells  
MCF-10A cells as the human immortalized normal breast 
epithelial cells (Clontech, USA) were grown in complete mammary 
epithelial growth medium (MEGM) (Clonetics™; Lonza, USA) 
supplemented with bovine pituitary extract (BPE) (Clonetics™; Lonza), 
10% fetal bovine serum (FBS) and 0.5% penicillin/ streptomycin. IMR-
90 (Coriell Cell Repository, USA), as primary human diploid fibroblasts, 
were maintained in minimal essential medium (MEM) (Gibco™, 
Invitrogen Corporation, USA), supplemented with 15% (FBS), 1% 
vitamins, 2% essential and 1% non-essential amino acids and 0.5% 
penicillin/streptomycin. These two cell types were used as normal 
controls for this study. 
2.1.2. Human breast cancer cells  
Two human mammary epithelial carcinoma cell types MDA-MB-
231, known as a typical triple negative breast cancer cell type and MCF-
7, as an ER+/PG+ luminal tumour, were obtained from American Type 
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Culture Collection (ATCC, Rockville, MD. USA). Both cell types were 
grown in RPMI-1640 (Roswell Park Memorial Institute medium) (Gibco), 
supplemented with 10% fetal bovine serum (FBS) and 0.5% 
penicillin/streptomycin. These two breast cancer cell types have formed 
the breast cancer models of this study.  
2.2. Drug treatment  
2.2.1. Plumbagin treatment 
Plumbagin (Sigma-Aldrich, Missouri, USA) was dissolved in 100 
% sterile dimethyl sulfoxide (DMSO) (Sigma, USA) to prepare 100 mM 
stock solution from which, working concentrations were prepared later. 
One μl of the working concentrations in 0.0, 1.0, 2.0, 3.0 and 4.0 mM 
were added in the cell culture to achieve 0.0, 1.0, 2.0, 3.0 and 4.0 μM 
final concentrations, respectively. Short term studies were performed 
following 48 hours treatment with different concentrations of Plumbagin, 
mainly at the IC50 dose. As for chronic long term studies, they were 
carried out for either 14 or 32 days with 2/3rd of IC50 doses. This range 
of concentration has been reported to be practicable in vivo and with low 
or no toxicity to normal cells (Hsieh et al., 2006, Padhye et al., 2012). 
2.2.2. Telomerase inhibition  
Telomerase inhibitor, MST-312 (Merck, USA), was dissolved in 
sterile DMSO to prepare the stock solution of 10 mM and thereafter it 
was more diluted to achieve different working concentrations. 
Appropriate amounts of these stocks were added to the cultured cells to 
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obtain the desired final concentrations. Twenty four hours prior to 
exposure of cells to Plumbagin, cells were treated with 0.5 and 1 μM of 
MST-312 for long-term and short-term treatments, unless otherwise 
stated. Both mentioned concentrations are known to be non-toxic to 
normal cells (Seimiya et al., 2002). 
2.2.3. PARP inhibition  
PJ-34 (Sigma, USA), which is a potent poly (ADP-ribose) 
polymerase (PARP) inhibitor dissolved in deionised water, is known to 
effectively inhibit the DNA repair of breast cancer cells (Hastak et al., 
2010, Chalmers, 2009). For the purpose of this study 10 μM of final 
concentration of PJ-34 was added to cells, 24 hours before treatment 
with Plumbagin. Based on the previous findings, this dosage does not 
exert cytotoxicity to normal cells (Szepes et al., 2013, Radnai et al., 
2012). 
2.2.4. DNA-PKcs inhibition  
The DNA-PK inhibitor II, NU7026 (Calbiochem, USA), was diluted 
in DMSO to obtain 10 mM stock solutions, from which working 
concentrations of 5, 10, 15 and 20 μM were prepared by further dilutions. 
Nu7026 was shown to be a highly selective inhibitor of DNA-dependent 
protein kinase (DNA-PK), with a 60-fold greater potency against this 
enzyme than PI 3-K, which inactive against both ATM and ATR (Veuger 
et al., 2003). This inhibitor was found to sensitize breast cancer cells to 
DSB-inducing agents and be suggested as an effective adjuvant therapy 
for breast cancer treatment (Medunjanin et al., 2010, EA Bey, 2009). 
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2.3. Cell line characteristics 
2.3.1. Short-term and long-term population doubling studies 
Population doubling assay was employed by first monitoring the 
cells for short term to estimate the ideal treatment time that cells undergo 
at least one round of cell cycle. As for short term studies, 0.2 X 106 cells 
were seeded on 6-well plates, thereafter 24, 48 and 72 hours crystal 
violet staining was performed followed by absorbance reading through 
ELISA reader.  
The formula used in the cell cycle period calculation is based on 
exponential regression where y = a.ebx; (while a = amplitude; b = 
exponent). Doubling time is designed from the equation ln(2)/b and the 
value unit is in hours per doubling (hr/PD). 
Proliferation rate of the cell types was also performed for long 
term studies of Plumbagin to evaluate the viability of cells after 28 days 
treatment in culture. This assay was carried out by using trypan blue dye, 
which is able to stain the dead cells to blue and leaving the impermeable 
viable cells intact. In three experimental sets 50,000 cells were seeded 
and Plumbagin was added at the two third IC50 doses. Fresh drug was 
added every 48 hours to the cultures and the process of counting was 
performed once a week. After counting the live cells by means of 
haemocytometer, cumulative population doubling number (PDN) was 
calculated by using this formula: 




2.3.2. Microarray gene expression analysis  
Gene expression study was carried out by performing microarray 
analysis of two independent experiments, each being replicated twice. 
Initially the total RNA was extracted (QIAmp RNA Mini Kit, Qiagen, 
Hilden, Germany) and quantified by means of NanoDrop 1000 (Thermo 
Scientific, USA). Five hundred nanograms of extracted RNA were 
subjected to cRNA amplification process (Ambion Inc., USA) and the 
product was purified (RNeasy kit, Qiagen), and then hybridized at 58°C 
with HumanRef8 V3.0, Human Whole-Genome Expression BeadChips 
(Illumina Inc., USA) for 16 hours. Followed by staining with Streptavidin-
Cy3 (GE Healthcare, Bio-Sciences, UK), the arrays were scanned using 
the Illumina Bead Array Reader and obtained data were analyzed 
through PartekH Genomics SuiteTM (Partek Incorporated, MO, USA).  
Probes were set and those showing variation between treated 
samples at the 0.05 level of statistical significance and showing at least 
1.5-fold change or greater were identified. The difference in mean 
expressions of subgroups was further studied through contrast analysis. 
The contrast tests included Plumbagin-treated cell type group versus 
control (all pairwise comparisons). Differentially expressed genes from 
these comparisons were also identified as those that were significant at 
the P < 0.05 level and showed at least 1.5-fold change or greater. The 
data was shown as differential percentage of gene expression. Gene 
expression similarities/dissimilarities among arrays were also examined 
by principal components analysis (PCA). Each array is shown as a single 
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point on the 3-D plot, and the distance between the points represents a 
measure of dissimilarity of expression patterns between the arrays. 
Statistical analysis were performed using 2-way ANOVA. Significantly 
expressed genes with significant differential expression patterns were 
selected based on a false discovery rate of 5% between the treated and 
non-treated samples for each cell type. Selected groups of differentially 
regulated genes were then clustered using the DAVID Functional 
Annotation Tool (Huang da et al., 2009). 
2.4. Cell viability assays 
2.4.1. MTT 
The MTT assay is based on using the tetrazolium salt, MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma). 
Metabolically active cells are able to reduce this salt to formazan, which 
is unsolvable in water.  Regarding the difference between the efficacies 
of viable and dead or damaged cells in metabolism, later in this 
experiment, the relative number of viable cells is assayed by dissolving 
and quantification of the colored formazan salt.  
Cells were seeded in 96-well plates and after 48 hours treatment 
with Plumbagin at the dose range of 0 to 5 µM, cells were washed with 
1X phosphate buffered saline (PBS) followed by exposure to 50 μL MTT 
(4 mg/mL) in the dark together with 50 μL of their respected cell culture 
media. Following two hours incubation at 37oC in dark, the MTT with 
media solution was carefully aspirated and the obtained formazan 
crystals were dissolved in 200 μL of DMSO. Subsequently cell viability 
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was examined by absorbance at 570 nm using the μQuant Microplate 
Spectrophotometer. 
2.4.2. Measurement of ATP content 
ATP as an indicator of metabolically active cells could be 
quantitated through the CellTiter-Glo (Promega, Madison, WI, USA) 
luminescent cell viability assay. The purpose of this assay is to convert 
this indicator molecule into a detectable signal. Therefore first cell lysis 
of viable cells is prepared followed by production of a "glow-type" 
luminescent signal relative to the amount of ATP present, which directly 
represents the number of live cells. 
Cells were seeded in a 96-well plate and after 48 hours of 
treatment with Plumbagin, the medium was aspirated and 100 μL of the 
CellTiter-Glo reagent with 100 μL of fresh medium was added into each 
well, mixed, and then incubated in the dark for 10 minutes. Afterwards, 
the contents of the plate were transferred into a white-bottomed 96-well 
plate, and the generated luminescent signal was quantified by an ELISA 
luminescence plate reader, which stood for the number of viable cells.  
2.4.3. Crystal violet assay 
This assay was performed to verify how Plumbagin or other 
treatments affect the density of cells by modulating their cell growth or 
inducing cell death. Growing cells were treated with a range of drug 
concentrations, following which the inhibitory concentration at 50% cell 
viability (IC50) was obtained and selected for further studies. Through 
three independent set of experiments, cells were seeded in 6-well culture 
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plates and following treatment, they were washed with 1X PBS and 
incubated for 15 minutes at 37oC with the crystal violet solution (Sigma-
Aldrich) (0.75% crystal violet in 50% ethanol: distilled water, 1.75% 
formaldehyde and 0.25% NaCl), which stains the DNA by binding 
electrostatically to nuclear proteins. Thereafter, the non-adherent cells 
were washed away by PBS for few times to remove the extra stains. The 
dilution of 1% Sodium dodecyl sulphate (SDS) in PBS was added and 
mixed evenly on a rotator to lyse the cells and solubilise the dye. When 
the stain was completely dissolved, difference in cell density was 
displayed on an ELISA reader (TECAN SpectraFluor Plus) by the 
quantity of crystal violet taken at 595 nm absorbance. In order to 
calculate the IC50 doses, the absorbance readings were translated into 
percentage of viable cells. Throughout the study, the treatment 
conditions were 48 hours with IC50 doses and 32 days with two third of 
IC50 doses, for short term and the long term studies, respectively.  
2.4.4. Cytotoxicity assay for DMSO 
DMSO is the drug vehicle for Plumbagin and some of the other 
drugs applied in this study, representing the control dose. Therefore 
cytotoxicity of DMSO was carried out to ensure that the final 
concentration of DMSO in all controls and treated samples does not 
exert cytostatic or cytotoxic effects. Cells were seeded in 6-well plate at 
density of 0.2 X 106 per well. Twenty-four hours later, DMSO at final 
concentrations of 0.0, 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 % were added to the 
cell culture. After 48 hours of exposure, crystal violet assay was 
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performed as described in section 2.4.3 to study if DMSO influences cell 
density either by inducing cell growth arrest or cell death. The drug 
vehicle DMSO at the final concentration of 0.1% [v/v] is considered as 
zero doses throughout the findings. 
2.5. Cell morphology  
For morphological observations, light microscopy was utilized. 
After treatment of cells with appropriate agents, images of cell 
morphology were captured at 40X, 100X and 200X magnifications of 
microscope, using an Olympus C-7070 WZ digital camera (Japan). 
2.6. Colony formation assay 
To determine the effects of drug treatments on the colony 
formation ability, clonogenic or colony formation assay was performed. 
In four independent sets, cells were seeded and after 48 hours 
treatment, 2 x 103 cells were allowed to grow for 14 days in fresh 
medium. Colonies were then stained with crystal violet solution (Sigma, 
USA) (as described above), and dried at room temperature. Thereafter 
large colonies (> 50,000 cells) were detected and counted as survived 
number of colonies. 
2.7. Cell cycle analysis by flow cytometry 
Cell cycle analysis was performed by fluorescence-activated cell 
sorting (FACS) methodology. Following treatment with drugs, cells were 
collected, fixed in 70% ethanol: 1X PBS, resuspended in 0.4 mL of 
1xPBS containing propidium iodide (PI) (Sigma, USA), RNase A (Roche, 
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USA) and 0.1% Triton X (Biorad, USA);  (2 mg propidium iodide and 2 
mg RNaseA/100 mL 1X PBS), incubated in the dark for 30 minutes at 
37oC. For each treatment, two independent sets were used and for each 
10,000 events per sample were analyzed using flow cytometry 
(FACSCalibur™, Becton Dickinson, USA) at 488 nm excitation λ and 610 
nm emission λ. Obtained data was analysed using Summit 4.3 software 
(Beckman Coulter, USA). 
2.8. DNA Damage Assays 
2.8.1. Alkaline single cell gel electrophoresis (Comet) assay 
Total amount of damaged DNA, upon Plumbagin treatment, was 
assessed by alkaline single cell gel electrophoresis (also known as 
Comet assay). Plumbagin treated cells were harvested and 
resuspended in Hank’s balanced balt bolution (HBSS) (Sigma, USA), 
supplemented with 10% DMSO and 500 mM EDTA. Cells were then 
embedded in 0.7% low melting agarose (Conda, Spain) at 37°C on 
comet slides (Trevigen, USA) and lysed in lysis solution containing 2.5 
M NaCl, 100 mM pH 8.0 EDTA, 10 mM Tris-HCL, 1% Triton X at 4°C for 
1 hour. Samples were denatured for 40 minutes, followed by 
electrophoresis in alkaline buffer (pH 13–13.7) for 20 minutes. 
Neutralization was performed in neutralization buffer (500 mM Tris-HCL, 
pH 7.4) and DNA was stained with SYBR Green (Trevigen). Hundred 
and fifty randomly selected cells per sample from three independent sets 
were captured and analyzed respectively using Zeiss Axioplan 2 imaging 
fluorescence microscope (Carl Zeiss, Germany) and Comet Analysis 
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Software (Metasystems, Germany). The extent of damaged DNA is 
represented by investigating two indexes of total DNA content and the 
DNA tail moment, which attributes to the fraction of the DNA in the tail of 
the comet. 
2.8.2. Immunocytochemistry detection of γH2AX 
 To specifically identify the amount of double strand breaks (DSB) 
triggered by Plumbagin treatment, γH2AX protein as an indicator of this 
phenomenon was assessed. Cells were seeded on 12mm cover slips in 
six well plates, treated with Plumbagin, washed in PBS and fixed in 4% 
paraformaldehyde for 15 minutes in an orbital shaker. Following 
permeabilization with 0.2% of Triton-X-100 for 10 minutes at 4ºC, cells 
were blocked in 5% BSA: PBS and immunostained with anti-γH2AX (Ser 
139) (Millipore.,USA) for 1 hour. After washing with PBS, FITC-
conjugated anti-mouse antibody (eBioscience, USA) was applied to 
each slide. Then the incubation for 1 hour in the dark was succeeded by 
washing three times with 1X TBS-T, 15 minutes each. The nuclei were 
counterstained by DAPI solution with mounting media (Vectashield®, 
Vector Laboratories, Burlingame, CA, USA). Fluorescent images of 150 
randomly selected samples of three different experimental set were 
obtained by confocal microscopy (Olymps Fluoview FV1000). 
2.8.3. Peptide nucleic acid-fluorescence in-situ hybridization (PNA-
FISH) 
PNA-FISH was carried out on the treated cells as outlined before 
(d'Adda di Fagagna et al., 1999, Hande et al., 1999). After a variety of 
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time-dependant and dose-dependent optimizations, the suitable 
arresting time and agent for mitosis arresting of different cell lines were 
obtained as follows. Accordingly, after the drug treatment, breast cancer 
cell types and MCF-10A cells were respectively treated with  0.1 mg/mL 
of Colcemid (KaryoMAX®, Gibco, Invitrogen, USA) and Nocodazol 
(Sigma, USA); for 19, 20 and 22 hours for MCF-10A, MDA-MB-231 and 
MCF-7 cell lines, correspondingly. Subsequent to arresting the cells at 
the mitosis stage, harvested cells were hypotonically swollen in pre-
warmed 0.075 M potassium chloride (KCl) as the hypotonic solution for 
17 minutes at 37°C with continuous agitation. Immediately cells were 
centrifuged at 800 rpm for 8 minutes, and KCl was aspirated. 
Subsequently, cells were fixed in fresh Carnoy’s fixative (3:1 Methanol: 
Acetic Acid), followed by centrifugation at 1000 rpm for 8 minutes. As the 
final round, fresh Carnoy’s fixative was added to cells and they were 
dropped from a height onto clean slides that were washed with 1N HCl: 
100% Ethanol (1:1) and deionised water. After slide preparation the 
PNA-FISH was performed and the samples were first rehydrated with 1x 
PBS for 15 minutes, followed by two minutes fixation in 4% 
formaldehyde. Thereafter slides were washed in 1XPBS before 
dehydrating in ethanol series of dilution (70%, 90% and 100%). After air 
drying, the metaphase spreads were denatured at 80°C for 3 minutes 
with hybridization mixture containing deionized formamide (F9037; 
Sigma), 0.5 μg/mL Cy-3-conjugated- (CCCTAA)3 PNA probe 
complementary to telomeric sequence, 3 μg/mL Fluorescein 
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isothiocyanate (FITC)-conjugated- indicative of the centromeric PNA 
probe (Panagene, South Korea), 10 mM Tris (pH 7) and 5% MgCl2. 
Following denaturation, the cells were hybridized in the dark for 2 hours 
at room temperature. Slides were then washed two times in the wash I 
solution (70% v/v formamide (Merck)/0.1% w/v BSA/10 mM Tris (pH 
7.4)) for 15 minutes. Thereafter they were washed trice for 5 minutes in 
wash II solution (0.1 M Tris, 0.15 M NaCl (pH 7.2), 0.08% v/v Tween 20 
(Sigma)). Subsequently the slides were dehydrated in ethanol series 
(70%, 90% and 100%), and air-dried in the dark. The slides were then 
finally stained in 0.0375 μg/mL of 4’, 6-diamino-2-phenylindole (DAPI) 
mixed in mounting media (Vectashield®). Approximately 50 metaphase 
spreads were captured by means of the imaging fluorescence 
microscope (Zeiss Axioplan ǁ, Germany). The acquired fluorescence 
signals were analyzed with Isis Imaging software (Metasystems, 
Germany) to measure chromosomal aberrations such as breaks, 
telomere signal loss, chromosome fusions and multiple telomere signals 
which are indicative of genomic instability.  
2.8.4. Immunofluorescence staining for γH2AX and telomere 
dysfunction induced foci (TIF)  
Cells were seeded on 12 mm cover slips in 6-well plates and 
treated for 48 hours. Similar to the descriptions of Immunocytochemistry 
detection of γH2AX in the section 2.8.2, all the steps were performed 
and FITC-conjugated anti-mouse antibody (eBioscience, USA) was 
added to the slides for 1 hour. Thereafter, the washing was carried out 
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with TBS-T, 4 % formaldehyde for 15 minutes and 0.2 % Triton-X-100, 
samples were hybridized with Cy3-labelled telomere sequence-specific 
peptide nucleic acid (PNA) probes by first denaturing at 80 °C for 6 
minutes and incubation for 2 hours in dark at room temperature. 
Following hybridization, the slides were washed in formamide and 10 % 
Tween-20 for 5 minutes. Finally the cells were stained with DAPI 
(Vectashield®). Approximately 100 images were captured on 
fluorescence microscope (Carl Zeiss Axioplan ǁ, Germany) with triple 
filters for simultaneous observation of DAPI (blue), FITC (green) and Cy3 
(red). 
2.9. Protein expression and western blot studies 
To study the function of genes followed by drug treatments, 
western blotting was carried out for all experiments. After drug exposure, 
the total cellular proteins of control and treated cells were isolated using 
lysis buffer (distilled water containing 50 mM Tris HCL, pH 8, 5mM 
EDTA, 0.15 M sodium chloride, 0.5% NP40, 0.5 mM DTT, 1× PhosSTOP 
(Phosphatase inhibitor cocktail tablets, ROCH, Germany), 1X Protease 
cocktail tablet (ROCH, Germany), following which lysates were rotated 
at 4°C at 14,000 rpm for 30 minutes. Protein concentration was 
determined by the colorimetric Bradford assay (Bio-Rad,USA) with 
bovine serum albumin (BSA) as a standard. Equal amounts of protein 
were resolved by SDS–PAGE at different gel densities (6-12%) and 
transferred to polyvinylidene difluoride (PVDF) membranes. After 
blocking in 5% non-fat dry milk : TBST, membranes were incubated with 
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primary antibodies specific to many different pathways, including cell 
proliferation, cell cycle regulatory proteins (p21 , p53 , Cyclin B1, Cyclin 
D), apoptosis related agents (caspases 8 and 9), DNA damage response 
pathways (Phospho-H2AX (Millipore, USA), PARP, ATM (Gene Tex, 
USA), Phospho-ATM (Gene Tex), DNA-PKcs, Phospho-DNA-PKcs and 
telomere-telomerase equilibrium (hTERT (Epitomics, USA), POT1, 
TRF1, TRF2). Following incubation, secondary antibodies such as 
donkey anti-goat IgG-HRP, goat anti-rabbit IgG-HRP, and sheep anti-
rabbit IgG-HRP were added for 1 hour and subsequently the membranes 
were sprayed by chemiluminescent substarte (ECL biotechnology, 
USA). Following the film exposures, bands were quantified using Image 
J Molecular Imaging Software (Schneider et al., 2012). Thereafter, 
expression of all protein band intensities was compared as a ratio 
relative to the house keeping internal control, β-actin band. Antibodies 
were purchased from Santa Cruz Biotechnology, USA, unless otherwise 
stated. For different protein expression profiles the experiments were 
repeated between two to six times. 
2.10. Measurement of cell migration through the wound healing 
assay 
Cell migration ability after Plumbagin treatment was evaluated by 
migration assay, also known as wound healing assay. Sixty-mm dishes 
were marked on the outer bottom as reference points and cells were 
dispersed gently and seeded equally among the plates. After 6 hours of 
adherence, the confluent monolayer of cells was scraped manually in 
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straight lines according to the reference point and a wound was 
generated by a p200 pipette tip. In three independent sets, cells were 
treated with Plumbagin and images were acquired at time 0, 24 and 48 
hours of incubation with the drug. The photographed regions were 
analyzed quantitatively by the Image J Molecular Imaging Software 
(Schneider et al., 2012) and the migration of cells after 48 hours was 
identified by the number of cells that crossed into the wound area from 
their reference point at time zero. 
2.11. Telomerase activity detection using Telomerase Repeat 
Amplification Protocol (TRAP) 
To measure the telomerase activity, TRAP assay was carried out 
using TRAPeze® XL Telomerase Detection Kit (Millipore, USA) with 
some modifications. Cells were plated in 6-well plates and after 
treatment of cells with drugs, media was aspirated and cells were 
washed with 1XPBS, trypsinised and pelleted by centrifugation at 260 g 
for 5 minutes. TRAP assay was performed by lysing every 106 cells in 
200 μL of CHAPS lysis buffer as per manufacturer’s instructions. After 
extracting the lysates, 1.5 µg of total cell extract was mixed with 10 μL 
5X TRAPEZE XL Reaction Mix, 0.4 μL of the Taq Polymerase (5 
units/μL) and 37.6 μL of PCR-grade water. The polymerase chain 
reaction (PCR) amplification step was carried out using fluorescein 
primer pairs to amplify the telomeric DNA repeats. After telomerase 
elongation of the TTAGGG hexameric repeats onto the 3' end of the 
telomeric primer (TS) for 30 minutes at 30°C, samples were amplified for 
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36 cycles of  94°C for 30s , 59°C for 30s and 72°C for 1 minute. The 
reaction was later terminated at 72°C for three minutes and 55°C for 25 
minutes. Fluorescence signals of PCR products were measured using 
fluorescence plate reader (TECAN SpectraFluor Plus, Männedorf, 
Switzerland).  
2.12. Telomere length measurement  
2.12.1. Terminal Restriction Fragment (TRF) 
Following treatment with drugs, the total DNA was extracted by 
DNeasy Tissue Kit (Qiagen, USA). To measure the telomere length, the 
TeloTAGGG Telomere Length Assay kit (Roche Molecular Systems, 
USA) was utilized. Hinf1 and Rsa1 restriction enzymes were used to 
digest the whole genomic DNA except the sub-telomeric and telomeric 
regions, 2 μg of digested DNA fragments was resolved on 0.8% agarose 
gel at 60V. Southern blotting was carried out and DNA fragments were 
transferred to a positively charged nylon membrane by overnight 
capillarity. Following a UV-cross-link of blotted telomeric DNA fragments, 
samples were hybridized with digoxigenin (DIG) labeled probe, specific 
for telomeric repeats, and incubated with Anti-DIG alkaline phosphatase 
according to manufacturer’s protocol. The chemiluminescence telomere 
signals were developed onto x-ray films and the telomere lengths were 
calculated and analyzed by the Molecular Imaging Systems software 
(Kodak MI application, Eastman©, V4.00, USA). 
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2.12.2. Quantitative-Fluorescence in-situ hybridization (Q-FISH) 
Q-FISH was shown to provide the accuracy and sensitivity to 
uncover associations between telomere length and human disease 
(Canela et al., 2007). This assay was carried out on Plumbagin treated 
cells, similar to PNA-FISH as outlined before (section 2.8.3) and 
described in our earlier approaches (Gurung et al., 2010). Fifteen 
metaphases were then captured and analyzed using the in situ imaging 
software (Metasystems, Germany) to measure the fluorescence 
intensity of telomere signals. 
2.13. Gene expression studies (Microarray analysis) 
Further to gene expression analysis described in section 2.3.2 to 
study the cell lines characteristics at the basal level, microarray studies 
were carried out to determine the effects of Plumbagin treatment at the 
genetic level. 
2.14. Statistical analysis  
Statistical significance of the difference between and among the 
groups was assessed by Student’s t-test using Microsoft Excel 2010 
(Microsoft Corporation, USA) and two-way ANOVA using GraphPad 
Prism (version 4.00 for Windows, GraphPad software, San Diego 
California USA, www.graphpad.com). P values lower than 0.05 were 
considered statistically significant (P ˂0.05). Wherever applicable, the 
mean values are expressed as mean ± standard deviation (SD) from two 




CHAPTER 3  
3. Plumbagin induces cell arrest and death, triggers the DNA 
damage response mechanisms, telomere/telomerase dynamics 
and genome stability of human breast cancer cells 
3.1. Background 
Plumbagin is a naturally occurring plant chemical known for its 
anti-tumour properties (Hafeez et al., 2013, Lee et al., 2012, Lu et al., 
2013a, Sinha et al., 2013, Wang et al., 2008). Previous studies on 
Plumbagin have mainly focused on molecular signalling pathways 
(Ahmad et al., 2008, Kawiak et al., 2012, Kuo et al., 2006) and there is 
still no information about the role of Plumbagin in telomere/telomerase 
dynamics and genome instability of breast cancer cells.  We had earlier 
observed that Plumbagin induces cytotoxic and genotoxic effects in 
human brain tumour cells and for the first time studied its contribution to 
telomere attrition and inhibition of telomerase activity (Khaw et al., 
Manuscript in preparation). In the present study, a variety of anti-cancer 
effects of Plumbagin treatment in luminal (MCF-7) and TNBC (MDA-MB-
231) cell types is investigated, compared to relatively normal breast 
epithelial cells (MCF-10A). It is aimed to further investigate the inhibitory 
effects of this phythochemical on telomerase activity and telomere 
length, along with its consequences on DNA strand damage and 
genome instability in breast cancer cells. Having known the fact that the 
efficacy will depend on both targeted molecular pathways and 
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characteristics of the cells in all tumour treatment modalities (Ross et al., 
2000, Neve et al., 2006, Perou et al., 2000), the experiments were 
designed to understand basal characteristics of these breast cancer cell 
lines which may influence their sensitivity towards Plumbagin treatment. 
3.2. Results 
3.2.1. Characteristics of cell lines 
3.2.1.1. MDA-MB-231 and MCF-7 cell lines exhibit differential 
patterns of gene expression profiles at the basal level 
As in any kind of therapy, the effectiveness of treatments is not 
solely based on the pathways that are triggered upon drug treatment, 
but also dependent on the characteristics of tumour cell types. 
Therefore, this study is designed to use breast cancer cells as model to 
explore the genetic and cellular alterations upon Plumbagin treatment, 
microarray analysis was performed to examine and compare 
fundamental genetic differences in the MDA-MB-231 and MCF-7 cell 
types at the basal level.  
As illustrated in Figure 10, a total number of 3171 genes 
(approximately 10% of all the analyzed genes) were found to be 
differentially expressed in the MDA-MB-231 and MCF-7 cancer cells 
according to the volcano plot. This endorses the previous genetic studies 
on these two cell lines exerting that TNBC cells are clearly distinct from 
luminal cells (Neve et al., 2006). These 3171 genes were clustered using 
the Partek Functional Annotation tool focusing on   apoptosis and cell 
65 
 
death, cell cycle, DNA damage and repair regulation, signal 
transductions, angiogenesis, migration and invasion. These groups of 
differentially regulated genes are presented as forest plot in Figure 11A 
and the quality and quantity of their alterations are exhibited as a gene 
ontology chart (Figure 11B). This diversity might suggest an expectedly 
different performance and function upon drug treatments, in different 
cellular pathways such as the cell cycle, apoptosis, DNA damage 
response and on top of all, adhesion and metastasis findings.  
Thousands of genes may contribute to breast cancer 
pathophysiologies when deregulated by genomic or epigenomic events 
followed by chemotherapies. In a study (Neve et al., 2006), functional 
contributions of genes in 51 breast cancer cell lines were investigated, 
leading to a model system design. This system indicated that the 
Figure 10. Microarray analysis of the two genetically distinct MDA-MB-231 and 
MCF-7 breast cancer cells. Volcano plot exhibits 3171 genes (approximately 10% 
of the analyzed genes) which are differentially regulated among MDA-MB-231 and 
MCF-7 breast cancer cells. Blue clusters designate genes which are expressed 
diversely (P-Value 0.05; 1 way ANOVA). Black bold lines on the X axis signify fold 
change cut off of 2.  
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recurrent genomic and transcriptional characteristics of these breast 
cancer cell lines mirror 145 primary breast tumours. This facilitates the 
use of breast cancer cell types in culture, to simulate the real outcome 
of drug treatment in vivo. 
In a microarray investigation the gene expression signatures and 
biomarkers of MCF-7 and MDA-MB-231 cell types were compared by 
representational difference analysis, microarrays and proteomics. It has 
been stated that a set of nine genes including GPCR11, cadherin 11, 
annexin A1, vimentin, lactate dehydrogenase B (up-regulated in MDA-
MB-231) and GREB1, S100A8, amyloid b precursor protein, claudin 3 
and cadherin 1 (down-regulated in MDA-MB-231) were sufficient to 
distinguish MDA-MB-231 from MCF-7 cells (Nagaraja et al., 2006). 
Similar to the findings of this study, the number of altered transcripts was 
over 1000 based on a change of two-fold or greater. 
On the other hand, recently there was a comprehensive 
molecular study conducted on the main breast cancer subtypes and their 
different subsets of genetic and epigenetic abnormalities. It was stated 
that much of the clinically observable plasticity and heterogeneity occurs 
within, and not across, these major biological subtypes of breast cancer 
(Koboldt DC, 2012). 
In an earlier finding of our laboratory, multi-colour FISH was 
carried out to karyotype MDA-MB-231 and MCF-7 cells and also 
compare their chromosomal translocations at the basal level. It was 
revealed that some chromosomes were more frequently targeted for 
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aberrations, e.g. the frequency of aberrations on chromosome 8 of both 
breast cancer cell lines was consistently much higher than that of the 
other chromosomes. Chromosome 17 was also another highly targeted 
chromosome for aberrations (Poonepalli A., 2008, Ph.D. thesis, NUS) 
(Sameni et al., Manuscript in preparation). In previous studies, 
chromosome 8 was asserted to be most commonly targeted for 
aberrations in many breast cancer cell lines examined by comparative 
genome hybridization and spectral karyotyping assays (Bilal et al., 2012, 
Kytola et al., 2000). Acquisition of an oncogenic translocation can initiate 
a cycle of genomic instability that has the potential to create other 
mutations (Gasparini et al., 2007). Chromosomal translocations which 
are a consequence of chromosomal breakages and fusions (Mitelman 
et al., 2007) result in activation, inactivation or deletion of genes at the 
fusion or break sites.  
The gross chromosomal numerical instability and the complex 
translocations in the breast cancer cells, MCF-7 and MDA-MB-231 were 
reported significantly diverse, substantiating the findings of genetic 
differences between these two cell lines.  
After obtaining preliminary molecular signatures of MCF-7 and 
MDA-MB-231 cells by microarray findings, population doubling studies 
were used to expand the above analysis to identify the cell cycle duration 




Figure 11. (A) Gene clustering and (B) gene ontology of the differentially 
expressed genes in MCF-7 and MDA-MB-231 cells. Charts show the quality and 






3.2.1.2. Population doubling rates of different cell types 
To investigate the speed of cell responses with regards to cell 
proliferation, the optical density (OD) value of cells was measured for 3 
sequential days followed by crystal violet staining. All different cell types 
displayed different population doubling rates, as depicted in Figure 12. 
The invasive TNBC MDA-MB-231 cells were shown to have the fastest 
doubling rate at 24.45 hours, while the MCF-7 and MCF-10A cells 
presented 29.34 and 38.8 hours to duplicate their generations.  Based 
upon these findings all cell lines demonstrated an exponential growth 
resulting in elevated cell density after 72 hours.  
3.2.2. The drug vehicle, Dimethyl sulfoxide (DMSO), does not exert 
cell death and DNA damage at 0.1 % [v/v] concentration 
Plumbagin was dissolved in DMSO as a solvent and therefore, to 
study the cell response to the Plumbagin treatment, comparison of the 
normal media condition with the drug solvent is also necessary. Having 
known that the results have to be normalized by the DMSO treatment as 
the control, it is imperative to corroborate that DMSO does not induce 
significant changes in cell responses leading to false positive results. 
Hence in this section, cell viability, cell morphology and DNA damage 
analysis for all three cell types is assessed following DMSO treatment. 
In two independent studies, cells were treated with the drug vehicle 
DMSO at different concentrations ranging from 0.0 % [v/v] to 2.5 % [v/v] 
to study its toxicity in breast cancer cell types which are used in this 
investigation. As shown in Figure 13, a reduction of cell viability is 
70 
 
obvious in a dose-dependent manner. Based upon the findings, at 
DMSO 0.1 % [v/v], the cell death was insignificant, (P=0.75, P=078 and 
P=0.79, correspondingly for MCF-10A, MDA-MB-231 and MCF-7), 
therefore this concentration of DMSO was assumed non-cytotoxic. 
Consequently to achieve a final concentration of 0.1 % [v/v] in the total 
cell culture media volume in the total cell culture media volume, 
Plumbagin was dissolved in this concentration. To further substantiate 
the non-cytotoxicity of 0.1 % [v/v] of DMSO, cell morphology studies 
were performed, using light microscopy (Figure 13A). DMSO-treated 
cells did not change in cell density and morphology compared to the 
untreated controls. According to this data, 0.1 % [v/v] of DMSO did not 
affect the density and morphology of the cells used in this study. At this 
y = a.ebx 
a = amplitude 
b = exponent 
Doubling time = ln(2)/b  
 
Figure 12. Population doubling rates of all the cell types. MCF-10A, MDA-
MB-231 and MCF-7 grew at a doubling time of 38.8, 24.45 and 29.34 hours per 
doubling (hour/PD). Quantifications and the graph are prepared by Graphpad 
prism 4 software. 
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dose the population, size and the shape of the treated and untreated 
cells were almost same at the magnification of 200X, with no sign of 
cytotoxicity in treated cells, such as cell shrinking, nuclear fragmentation, 
or membrane blebbing. The comet assay was then performed, in two 
independent sets, to scrutinize the DMSO-induced-DNA damage 
induced at 0.1 % [v/v] concentration. As compared to untreated controls, 
DMSO at the vehicle concentration caused very low amounts of DNA 
damage with regards to difference of DNA mean tail moments lower than 
0.5 μm (Figure 14). None of the DMSO-treated cell types either showed 
significant increase in the percentage of DNA content (P=0.13, P=0.14 
and P=0.19, correspondingly for MCF-10A, MDA-MB-231 and MCF-7). 
Altogether, with no impact on cell morphology or viability and no 
significant increase in the DNA damage induction, this data suggests 
that the final concentration of 0.1 % [v/v] DMSO is appropriate as the 
solvent of the drugs. Later in the findings, wherever required to 








Figure 13. Cytotoxicity assay for DMSO. (A) Crystal violet cell viability assay 
of cells after 48 hours of DMSO treatment. (B) Morphological appearances of 
cells treated with 0.1 % [v/v] of DMSO, indicating no noticeable changes in cell 
morphology compared to untreated ones. Pictures of cell morphology captured 




Figure 14. DNA damage analysis using Comet assay. (A) Degree of DNA 
damage induced by DMSO is measured in Mean Tail Moment. (B) Percentage 





3.2.3. Plumbagin inflicts deleterious consequences of cell 
metabolism inactivation in breast cancer cells after 48 hours 
treatment 
To study the cytotoxic potential of Plumbagin on MDA-MB-231 
and MCF-7 breast cancer cells, the impact of this phytochemical on the 
cell metabolism was investigated. Therefore, the amount of 
metabolically active cells after 48-hour treatment was examined through 
both quantification of generated tetrazolium salt (MTT assay) and 
measurement of ATP content (CellTiter-Glo assay). The results 
indicated that Plumbagin inactivates cell metabolism as obvious by a 
dose dependent drop in both ATP content of cells and the formazan salt 
produced in the MTT assay (Figure 15). A low ATP measure does not 
always represent cell death, but could lead to metabolic inhibition in 
cells. In order to study how Plumbagin affects the cell survival, it was 
necessary to analyse the cell viability, colony formation ability and cell 
cycle to interpret this data fully.  
3.2.4. Plumbagin induces cell death in a dose dependent manner 
Growing cells of all three cell types were treated with a range of 0 to 4 
µM of Plumbagin for 48 hours. Thereafter, the crystal violet staining 
showed the cell density to decrease dose-dependently compared to 
DMSO. In terms of cell viability, the TNBC MDA-MB-231 cell line showed 
the most sensitivity to Plumbagin exposure. The yielded IC50 doses for 
MCF-10A, MDA-MB-231, and MCF-7 cells were 3, 1.5 and 3 µM, 
respectively (Figure 16A). For the rest of the study, IC50 doses or 
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otherwise stated two third of IC50 doses, would be used to conduct the 
experiments. MCF-10A cells as the relative normal control were treated 
with both 1.5 and 3 µM doses. IMR-90 cells were employed to evaluate 
the cell proliferation of primary human diploid fibroblasts upon treatment 
with aforementioned ranges of Plumbagin concentrations. None of these 
doses reached the IC50 level of this normal cell line, proving Plumbagin 
to be non-toxic to normal cells within the concentration range used in the 
present study (Figure 16B).   
Plumbagin exert anti-cancer and anti-proliferative activities in 
animal models and in cell culture in a  well-tolerated dose (Jackson et 
al., 2008, Tiwari et al., 2002, Padhye et al., 2012); plus the fact that 
doses of Plumbagin used in the current study are practicable in vivo as 
supported by others, reporting maximal plasma concentration of 
Plumbagin oral treatment in rat to be about 1.0 and 1.85 μM with related 
half-life of about 108 and 1,028 minutes, respectively (Hsieh et al., 2006, 









































































Figure 14. Plumbagin inactivates the metabolism of cells in breast cancer, 
after 48 hours treatment. This fact was exhibited through (A) quantification of 







Figure 15. Plumbagin induces cell death in breast cancer cells. Crystal violet 
assay on 48-hour-Plumbagin treated cells. The percentage of cell viability was 
standardized against the DMSO controls (0 μM) in (A) breast cancer cell lines MCF-
7 and MDA-MB-231 and (B) IMR-90 fibroblast cells and the relative normal MCF-
10A cell line 
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Cell morphology was evaluated by light microscopy with the 
magnifications of 100X and 200X (Figure 17). Cell shrinkage and nuclear 
fragmentation indicated a dose-dependent increase in apoptotic cell 
death upon Plumbagin treatment as indicated at the 200X (Figure 17B). 
The number of cells with vacuolated morphology has increased steadily 
for MDA-MB-231 cells, indicating pre-apoptotic autophagy cell death. 
The noticeable feature of flattened or enlarged cells during the treatment 
of all cell lines represents growth arrest of the cells. At the basal level, a 
more differentiated and tight cell-cell junction form in the luminal MCF-7 
cells was observed as compared to the TNBC MDA-MB-231 cells, 
harbouring a more mesenchymal-like appearance. This difference of the 
breast cancer cell types at the basal level was supportive of earlier 
findings (Neve et al., 2006). Again the morphology of the normal cells 
(IMR-90) was studied at the 9th cell passages, confirming the findings of 
cell viability study, that Plumbagin does not affect the normal cells 
morphology at the concentration series of 0 to 4 µM. 
3.2.5. Plumbagin diminishes the clonogenic ability of cells, induces 
cell cycle arrest and enhances apoptosis in breast cancer cell types  
To further investigate the cytotoxicity of Plumbagin on breast cancer 
cells, colony formation assay was carried out. Cells were treated with 





Figure 16. Morphology of cells following Plumbagin treatment. The 
morphology of cytotoxic effects of Plumbagin in the same cells result in cell 
death and lower cell density in breast cancer cell types as compared to the 
relative normal MCF-10A and IMR-90 cell lines. (A) Dose-dependent treatment 
of cells with Plumbagin at 100 X magnification (B) Cell morphology changes in 
the photomicrographs of MCF-10, MDA-MB-231 and MCF-7 cells, before and 





days to study their colony forming ability. A significant reduction in 
number of colonies was observed in both the cancer cell types with 
respect to their untreated ones and also to the non-cancerous MCF-10A 
cells (Figure 18). Consistent with crystal violet assay on cell survival, 
MDA-MB-231cells appeared very sensitive to Plumbagin treatment, as 
indicated by a drastic drop in the number of colonies, even after 14 days 
of recovery from the drug.  
Cell cycle analysis was performed to determine if the inhibitory 
activity of Plumbagin on the cell proliferation and clonogenic potential, 
engages the cell death or growth arrest. Therefore, treated cells were 
subjected to FACS analysis after staining them with PI. A remarkable 
increase in the sub-G1 population of cells was observed in the treated 
cancer cells, as compared to the non-cancerous MCF-10A cells (Figure 
19).   
There was an approximate two-fold increase in the accumulation 
of cells in the sub-G1 phase, (P= 0.00), a representative of apoptotic cell 
region, in the luminal MCF-7 breast cancer cells, indicating DNA 
fragmentation and hence cell death. While, in TNBC MDA-MD-231 cells, 
the percentage of sub-G1 population rose to more than two-fold after 
Plumbagin treatment (P= 0.00) and it was also accompanied with a slight 
non-significant rise (3.7%) in the G2/M population (P= 0.75), 
corroborating with both the cell viability and colony formation results 



























Figure 17. Plumbagin suppresses the clonogenicity of breast cancer cells. 
In the colony formation assay only Plumbagin-resistant cells are able to 
proliferate and form colonies after treatment. The rest are either arrested or 
undergoing apoptosis progressively within the recovery period. (*) indicates that 
the decreased number of colonies in cancer cell lines as compared to non-treated 
































Figure 18. Plumbagin enhances apoptosis in breast cancer cells. (A) 
The cell cycle profile of Plumbagin treated cells is measured by propidium 
iodide staining. (B) Increase in sub-G1 phase is greater in cancer cells. 
Accumulation of MDA-MB-231 cells at the G2/M phase is also observed 
after Plumbagin exposure. (*) indicates that the apoptotic population in 
cancer cells is statistically significant higher compared to non-treated cells 





3.2.6. Plumbagin down-regulates the expression of Cyclin B, 
activates caspase-8 and caspase-9 and up-regulates the 
expression of p53 in treated cells 
Having studied the cytotoxic and cytostatic potential of Plumbagin 
on MCF-7 and MDA-MB-231 cells, western blotting was carried out to 
investigate the expression of proteins involved in cell cycle regulation, 
such as p53 (53 kDa) and Cyclin B (55 kDa) and cell death pathways 
such as caspases 8 (18/55 kDa) and 9 (35/46 kDa) (Figure 20 and 21). 
More obviously in MCF-7 and MDA-MB-231 cells, the treatment with 
Plumbagin resulted in a non-significant down-regulation in the levels of 
Cyclin B which is required for G2/M transition, indicating a cell cycle 
arrest at this phase. It was shown previously that Cyclin D1 induction in 
breast cancer cells shortens G1 and is sufficient for cells arrested in G1 
to complete the cell cycle (Musgrove et al., 1994, Zhu et al., 2001). 
Consistently relatively shorter G1 stages were found, though non-
significant, upon Plumbagin treatment but was validated with negligible 
up-regulation or no change in levels of Cyclins D1 (35 kDa) and D3 (35 
kDa) protein expression (Figure 20). 
p53 mutations are mainly missense mutations inside the core 
domain, which will result in the expression of a full-length mutant p53 
protein. MCF-10A and MCF-7 cells produce basal expression of p53, 
while MDA-MB-231 cells are reported to have mutant p53 (Lim et al., 
2009). The proliferation inhibitory effect of Plumbagin on MCF-10A and 
MCF-7 cells was associated with an increase in the p53 protein where it 
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regulates the cell cycle and thus, functions as a tumour suppressor. 
However, the induction of apoptosis in MDA-MB-231 breast cancer cells 
is independent on p53 as the high level of endogenous p53 is mutated 
in these cell types (Figure 21).  
The apoptotic effect of Plumbagin in all the cell types and 
especially MDA-MB-231 cells was modulated by an increase in caspase-
9 and caspase-8 proteins, as the initiator caspases of the intrinsic and 
extrinsic pathways of apoptotic cell death, respectively (Figure 21). The 
uncleaved form of both caspases, in the form of procaspases, indicating 
the activated form was also shown; however, procaspase-8 was only 
detected in MDA-MB-231 and MCF-7 cells, specifying the caspase-8 
activity to breast cancer cells (Figure 21). It is worth mentioning that 
caspases are more regulated at that post-translational level, ensuring 



























































































Figure 19. Western blot analysis of Cyclin proteins regulating cell cycle 
in the breast cancer and normal cells after Plumbagin treatment. (A)  
Blots were probed with the Cyclin B, Cyclin-D1 and Cyclin-D3. (B) Fold 
changes of protein expressions against β-actin was calculated using 





























































































Figure 20.  Western blot analysis of cell cycle and cell death related 
proteins in the breast cancer and normal cells after Plumbagin treatment. 
(A)  Blots were probed with the p53, caspase-8 and caspase-9. β-actin was 
used as a loading control. (B) Fold changes of protein expressions against β-









3.2.7. Plumbagin-mediated apoptosis and cell cycle arrest 
contribute to significant DNA damage in cells  
To examine if the Plumbagin-induced cell cycle arrest and cell 
death are correlated to the levels of DNA damage, all the treated cells 
were subjected to single-cell gel electrophoresis, known as comet assay 
which measures DNA damage and recovery incurred in the cells. 
Following treatment with Plumbagin for 48 hours and a subsequent 48 
hours of recovery period, comet assay was conducted to detect total 
amount of different types of double-strand and single-strand breaks 
expressed as increases in the mean DNA tail moment in micrometer 
(µm) and the percentage of DNA damage. As shown in Figure 22, 
treatment with Plumbagin, yields in various degrees of DNA damage for 
all cells, compared to the respective controls. In accordance with 
previous findings of this study, MDA-MB-231 cells exhibited a sharp 
increase in mean DNA tail moment upon treatment, indicating high rate 
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Figure 21.  Plumbagin-induced apoptosis and cell cycle arrest are 
connected with increased DNA damage. (A) Representative images of DNA 
content and tail moment of an undamaged nucleus (at left) and a damaged 
nucleus (at right) after performing comet assay. (B) Breast tumour cells are 
more susceptible to Plumbagin induced DNA damage and they slightly show 
more increase in the mean DNA tail moment (µm), as an indicator of DNA 
damage, compared to the relatively normal MCF-10A. (C) In all cell lines 
Plumbagin induces significant DNA damage content in a dose dependent 






3.2.8. Double strand breaks form the main part of Plumbagin-
induced DNA damage 
 Exogenous agents such as DNA damaging drugs mostly trigger 
DSB, as compared to other types of DNA damage response pathways. 
Upon a DNA-DSB reaction, the H2AX gene gets phosphorylated at 
serine 139 and turns into gamma-H2AX. Worthy of mention, ATM and 
DNA-PKcs which belong to the PI3-kinases family are responsible for 
this phosphorylation. To specifically detect the DSB induced by 
Plumbagin, immunocytochemistry of phosphorylated histone H2AX, or 
γH2AX focus assay was performed, which exploits a one-to-one 
correspondence between DNA DSB and γH2AX foci. After 
immunofluorescent visualization, the number of γH2AX foci was 
calculated as a measure of the number of DNA DSB in IMR-90, MCF-
10A, MDA-MB-231 and MCF-7 cells. In 150 cells, the average number 
of γH2AX foci and number of cells with more than three foci (Figure 23) 
were found to be increased after 48-hours treatment; which were 
subsequently validated by the up-regulation in phosphorylation levels of 
H2AX protein (Figure 24). However, following another 48 hours of 
recovery, a moderate decrease in the foci formation was evident in MCF-
7 and MCF-10A cells, indicative of modest repair as compared to MDA-
MB-231, which proved a steep potential for DSB-DNA repair mechanism 
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Figure 22. Double strand breaks, which are indicated by the presence of 
γH2AX foci, are induced upon Plumbagin treatment. (A) Representation 
of Plumbagin-induced γ-H2AX foci in damaged nuclei (left) compared to the 
nontreated undamaged nuclei (right) after 48 hours. (B) Quantification of γ-
H2AX foci, as displayed by the average number of phosphorylated histone 
H2AX foci and (C) Number of cells with more than three foci in 150 cells after 






 MDA-MB-231 and MCF-10A cells were found to have the highest 
number of cells with more than 3 foci in 150 cells, respectively (Figure 
23C). Both MCF-7 and MDA-MB-231 cells displayed a higher expression 
of γH2AX protein upon Plumbagin treatment; whereas MCF-10A cells 
stabilized a relatively similar level of expression with regards to the 
respective control (Figure 24). Detection of phospho-H2AX protein and 
the average number of γH2AX foci substantiate that both cancer cells, 
particularly the TNBC MDA-MB-231 cells, are more sensitive to the DSB-
DNA-damaging effects of Plumbagin, compared to the relatively normal 
MCF-10A cells.  
3.2.9. Plumbagin inhibits the cell migration of breast cancer cells  
To visualize the involvement of Plumbagin in cell motility, wound-
healing assay was used in the presence of Plumbagin and drug-free 





























Figure 23. Up-regulation in phosphorylation levels of H2AX protein, after 
Plumbagin treatment. (A) γ-H2AX protein expression was verified by western blot. 
β-actin was used as a loading control. (B) Fold change of protein expressions against 






media. The results were recorded after the immediate scratch 24, and 
48 hours after treatment (Figure 25), showing gradual inhibition in cell 
migration ability at 24 and 48 hours. This migration might partially be due 
to cell proliferation, as depicted by the number of migrated untreated 
cells after 48 hours. However, compared to migration rate of treated 
cells, this number has decreased due to the decline in the migration and 
also the cell proliferation ability upon apoptosis. Both breast cancer cells 
migrate at slower rate under the influence of Plumbagin, keeping similar 
ratios to previous reports revealing that the invasiveness of MCF-7 is 
lower than MDA-MB-231 cells (Neve et al., 2006). As calculated from 
Figure 8B, the IC50 doses of Plumbagin produce around 13.3% and 
10.5% inhibition of cell migration as compared to the respected controls 
in MDA-MB-231 and MCF-7 cells, respectively.  
3.2.10. Chronic treatment with Plumbagin results in reduced 
population doubling capacity  
Growth kinetics of MCF-10A cell and the breast cancer cells 
MDA-MB-231 and MCF-7 were studied upon long term treatment with 
Plumbagin. Over the course of 28 days treatment with 2/3rd of IC50 doses 






Figure 24. Plumbagin inhibits the breast cancer cell migration in the wound 
healing assay. (A) Representative image of the reduction of cell migration by 
Plumbagin. Cells were wounded and then treated with or without Plumbagin. Original 
magnification of 100X Images was taken either immediately after scratching the cells 
or 48 hours later at three different locations. After which the migrated cells in the wound 
were counted. (B) Quantification of the number of migrating cells per field was 
performed by ImageJ software with respect to the experimental control. Columns 
signify average number of migrating cells in of three different experiments. 





























The results demonstrated that Plumbagin significantly abrogates 
the population doubling capacity of all cells as compared to their 
corresponding controls during the four weeks (Figure 26) following 
treatment. There was considerable slow proliferation of MDA-MB-231 
and MCF-7 breast cancer cells during the first week post treatment, while 
the same MCF-10A counterparts displayed PDN drop starting from 
second week. However, at the end of the study time point, MCF-10A 
cells at 2µM dose, exhibited highest sensitivity to chronic Plumbagin 
treatment. As evident from the growth kinetics data mentioned in this 
study, MCF-7 cells were the relatively resistant ones in the culture upon 
four weeks treatment with Plumbagin. Altogether these data suggest that 






Figure 25. Growth kinetics of cell types after chronic treatment with 
Plumbagin. Population doubling number (PDN) of (A) MCF-10A, (B) MDA-
MB-231 and (C) MCF-7 cells after 28 days of treatment with 2/3rd IC50 doses 
of Plumbagin. Data are obtained from intervals of 7 days. (*) indicates 

















3.2.11. Plumbagin reduces the telomerase activity after 32 days of 
treatment without altering the hTERT protein in breast cancer cells 
Telomerase activity is present in the majority of human cancers, 
providing the potential for the infinite cell proliferation. The value of the 
total product generated (TPG), as representations of telomerase activity, 
was measured after 32 days of chronic Plumbagin treatment with 2/3rd 
of IC50 doses. Most immortalized cells in culture develop the ability of 
unrestricted cellular proliferation and also exhibit escalated levels of 
telomerase activity, MCF-10A cells as expected, displayed up-regulation 
of telomerase activity and hTERT protein expression at basal level. 
Nevertheless, the basal telomerase activity was shown to be much 
higher in cancer cells compared to the immortalized normal MCF-10A 
cells. After 32 days of treatment MCF-7 cells exhibited a drastic fall of 
more than 50% reduction in telomerase activity compared to other cells 
(Figure 27A,B). Interestingly, the hTERT protein expression was shown 
to be of similar levels in the three cell types following 48-hour treatment 
when compared with respective controls (Figure 27C).  
Taken together, these data suggest that Plumbagin significantly 
reduces the telomerase activity in breast cancer cells, and more 
strikingly in MCF-7; while it does not alter the hTERT protein manifestly 
in all cell types, suggesting that Plumbagin may inhibit telomerase 
activity independent of hTERT or hTR mRNA expression levels, where 
the decrease in telomerase activity might be attributed to other factors 
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such as hTERT nuclear translocation, hTERT ubiquitination or 
inactivation of telomerase enzyme (Ulaner et al., 2000, Liu et al., 2001). 
3.2.12. Chronic treatment with Plumbagin shortens the telomere 
length in breast cancer cells 
As a logic follow up to the observations of decreased activity of 
telomerase and the alterations in the correspondent genes following 
treatment with Plumbagin, it was sought to investigate whether these 
fluctuations could also influence the telomere length in breast cancer 
cells. As presented in Figure 28, Plumbagin treatment exerts telomere 
attrition in breast cancer cells after 32 days of chronic treatment with 
2/3rd of IC50 doses. This data correlates to the telomerase activity of cells, 
depicted in Figure 27A, B, whereby MCF-7 cells exhibited the most 
marked basal telomerase activity, followed by the most considerable fall 
upon Plumbagin treatment. These findings suggest that prolonged 
Plumbagin treatment inhibits telomerase activity in breast cancer cells 
resulting in telomere shortening. The relative amount of these down-
regulating effects is directly dependant on the basal telomerase activity 








Figure 26. Plumbagin reduces telomerase activity in breast cancer cells. 
Following 32 days of treatment with 2/3rd of IC50 doses of Plumbagin, the 
telomerase activity was reduced in (A) total product generated (TPG) or (B) 
percentage of telomerase activity, by TRAP (telomere repeat amplification 
protocol) assay in breast cancer cells compared to the control. (*) indicates 
P<0.05 (C) hTERT as the catalytic unit of telomerase enzyme nearly maintains 
the same level of protein expression upon 48 hours treatment of Plumbagin.  
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Figure 27. Plumbagin treatment exerts telomere attrition in breast cancer 
cells after 32 days treatment. (A) Southern blot analysis of the normal MCF-
10A and breast cancer cells at their 2/3rd of IC50 doses after 32 days of Plumbagin 
treatment. Graphical presentation of the telomere length of samples compared 
to DIG marker (DM) and the high telomere control (HTC). (B) Fluctuation of 
telomere length is demonstrated as declined percentage in treated cells with 
respect to their controls. The change is statistically more significant in cancer 










Table 4. Drop in relative percentage of telomere length upon Plumbagin 
treatment. Measuring the telomere length in base pairs (bps) and percentage of 
relative telomere length by terminal restriction fragment (TRF) assay and Kodak 
imaging software analyzes. Cells were treated with 2/3rd of IC50 doses of Plumbagin 
for 32 days, resulting in considerable fall of telomere length in breast cancer treated 
cells. 
 
Table 3. Average number of chromosomes in MCF-10A, MDA-MB-231 and 
MCF-7 cell lines. Cells were treated with 2/3rd of IC50 doses of Plumbagin for 32 
days, and Q-FISH experiment was performed. 
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3.2.13. Telomeres erosion and aberration in breast cancer cells 
followed by Plumbagin treatment upon 32 days  
To corroborate the telomere attrition effects of Plumbagin on 
breast cancer cells, the impacts of this phythochemical on the telomere 
integrity and length of telomeric TTAGGG repeats were investigated, as 
analyzed by Q-FISH following 32 days treatment of cells with 2/3rd of IC50 
doses. 
Q-FISH analysis of telomeric length disruption was performed for 
metaphase chromosome spreads by quantitation of telomere repeat 
sequences of chromosome ends (Figure 29-A,B).  
The average number of chromosomes was lower in TNBC MDA-
MB-231 cells as compared to the luminal MCF-7 cells (Table 4). In line 
with TRF findings, Q-FISH data also revealed that MCF-7 cells, which 
possess enhanced basal telomere foci along with higher basal 
telomerase activity, will undergo more percentage of telomere length 
attrition associated with higher number of aberrant telomeres, when 
exposed to Plumbagin (Figure 30 A,B). These findings thus link the initial 
level of telomerase activity and telomere length of breast cancer cells and 
their susceptibility to Plumbagin, suggesting the fact that Plumbagin 
might accelerate the telomere shortening action and genome instability 




Figure 28. Q-FISH analysis of cells after 32 days of treatment Plumbagin. 
(A) Representative metaphase spreads stained for telomeres (red) and 
centromeres (green) (B) Telomere fluorescence intensity (TFI) values 
contributing to the telomere length are demonstrated decreasing for different 
cell lines as compared to respective untreated controls. Chronic Plumbagin 
treatment significantly reduces the average telomere florescent intensity. (*) 
indicates P < 0.05. 






















































Figure 29. Plumbagin increases the chromosomal instability in breast 
cancer cells followed by telomere dysfunction. (A) Representation of 
metaphase spreads stained for telomeres (red) and centromeres (green) 
displaying chromosomes with (1) different expression of telomere signal 
intensities on sister chromatids or (2) loss of telomere signals (B) Number of 
Plumbagin-induced aberrant telomeres per cell, as assessed for 15 
chromosomal spreads in breast cancer cells and the relative normal MCF-10 
cell line. Chronic Plumbagin treatment significantly increases the number of 






Neve and colleagues have demonstrated that genome-
aberration-induced transcriptional changes are conserved in the MDA-
MB-231 and MCF-7 cells (Neve et al., 2006). In light of the high genomic 
and transcriptional heterogeneity in these cells, they have also proposed 
the idea that assessment of responses to inhibitors of the dominant or 
dominant-negative genes will disclose different and probably predictable 
molecular responses among these two cells (Neve et al., 2006).  In line 
with their findings the genetic diversities between these two cell types 
were also substantiated in this study, which may lead to different 
molecular reactions against drug treatment. Therefore, it is expected to 
observe different levels of susceptibility and molecular actions between 
the TNBC MDA-MB-231 and the luminal breast cancer MCF-7 cells 
towards Plumbagin treatment. In other terms, Plumbagin efficacy might 
be influenced by different defective pathways of each breast cancer cell 
line.  
Based on the cell viability and colony formation findings, the 
present study demonstrates that at selective doses, Plumbagin causes 
cytotoxicity in cells, specifically MDA-MB-231 cell type. These findings 
suggest that Plumbagin inhibits cell growth and viability; the extent of 
which depends on the cell type used in the study. Plumbagin inactivates 
cell metabolism by diminishing ATP production as well, a trend which is 
similar to the decrease in cell survival. This is in agreement with the 
findings that dimeric naphthoquinones may selectively target breast 
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cancer cells that depend on oxygen consumption and ATP production 
(Emadi et al., 2011).   
Our data demonstrates that Plumbagin can induce DNA damage 
in all the cell types studied as evidenced by single cell gel electrophoresis. 
Severe DNA damage in cells may initiate compensatory and self-
destructive mechanisms such as cell cycle arrest and apoptosis. 
Increased sub-G1 population in cell cycle analysis and higher apoptotic 
cells support this notion in this study. Similarly some studies have also 
related this phenomenon to the induction of reactive oxygen species 
(ROS) (Powolny and Singh, 2008, Wang et al., 2008), which is known to 
activate AMPK, as one of the key mediators of Plumbagin’s anti-tumour 
activity (Chen et al., 2013).    
In concordance with other studies of Plumbagin on several cancer 
cell types (Li et al., 2012, Gomathinayagam et al., 2008, Kawiak et al., 
2012), in the current study the presence of higher percentage of cells in 
the sub-G1 cell cycle following Plumbagin treatment indicates apoptosis 
as a cause of cell death in these cells. However, Plumbagin treatment not 
only triggers cell death, but also leads to cell cycle arrest at the G2/M 
phase, consistent with a previous report (Kuo et al., 2006). 
Here is shown that induction of DNA damage, apoptosis and cell 
cycle arrest following Plumbagin treatment in breast cancer cells is 
substantiated by alterations in caspase 8, caspase 9, p53, Cyclin B and 
phosphorylation of γH2AX proteins. 
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TP53 is mutated at codon 280 in TNBC MDA-MB-231 cells and 
this is overexpressed in this study. TP53 mutation leads to DNA binding 
modification and induction of apoptosis through p53 response to DNA 
damage. The majority of cancer-specific p53 mutations result in nuclear 
accumulation of mutant p53 protein displaying properties such as long 
half-life and the ability to transcriptionally activate genes that are not 
activated by wild-type p53 (Mirzayans et al., 2012). 
These findings showed that Plumbagin reduces the breast cancer 
cell migration rate, which confirms the previous findings showing that 
Plumbagin down-regulates the expression of CXCR4 in breast cancer 
cells leading to decrease in the rate of cell migration and invasion (Manu 
et al., 2011). 
In this study, the telomerase activity was assessed after 48 hours 
and no changes in the activity was observed. Initially, the time duration of 
14 days was tested for long-term studies. At this time point the telomere 
length of the cancer cell types showed a gradual attrition, while there was 
no significant change in the trend of telomerase activity (data not shown). 
Thereafter, 32 days of treatment, was tested and based on the results, it 
was selected as the long-term period of study. 
It has been reported that β-rubromycin, a member of the 1,4 
naphthoquinone family exerts telomerase inhibitory activity (Wu et al., 
2007). To best of our knowledge, this is the first study to show that 
Plumbagin, as another member of the 1,4 naphthoquinons, inhibits 
telomerase in breast cancer cells and results in telomere shortening after 
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long term treatment. This novel observation might be contributed to the 
apoptosis and growth inhibitory functions of Plumbagin. MCF-7 cells, with 
their higher basal telomerase activity compared to other cell types, 
exhibited higher increase in apoptosis, down-regulation of telomerase 
activity and telomere shortening following Plumbagin treatment. In 
accordance to this data, an earlier study conducted in our laboratory has 
established that following Plumbagin treatment in brain tumour cells,  
ONS76 and KNS60, with the most remarkable rate of telomerase activity, 
had the highest rate of apoptosis, telomerase activity down-regulation 
and telomere length attrition among all the brain tumour cell types (Khaw 
et al., Manuscript in preparation). These observations are all in consistent 
with the scrutiny that telomerase down-regulation starts the pathway to 
induce apoptosis and cancer cell elimination (Rubis et al., 2013a) and 
might also suggest a telomerase-related  cytotoxicity of Plumbagin 
treatment to cancer cells.  
In spite of the reduction in telomerase activity no change was 
observed in the levels of hTERT protein expression following Plumbagin 
treatment. This contradicts with some earlier reports that hTERT exerts a 
direct antiapoptotic function in cancer cells (Hao et al., 2005); suggesting 
that Plumbagin may inhibit telomerase activity independent of hTERT or 
hTR mRNA expression levels. Here, the decrease in telomerase activity 
might be attributed to other factors such as hTERT nuclear translocation, 
hTERT ubiquitination or inactivation of telomerase enzyme. 
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According to Saito and colleagues, the terminal restriction 
fragments of non-cancerous tissues tend to be longer compared to breast 
cancer ones, albeit having no detectable telomerase activity. Similarly in 
this study, MCF-10A, as a relative normal cell type, harboured longer 
telomere lengths despite of expressing lower basal telomerase activity 
(Saito et al., 2002).  
In consistent with our findings, in a recent in vivo study, it is shown 
that Plumbagin inhibits the cell growth and induces apoptosis in human 


















CHAPTER 4  
4. Molecular mechanism of action of Plumbagin in suppressing 
human breast cancer, a microarray-based study 
4.1. Background  
According to the findings in the previous Chapter, and together 
with others, Plumbagin was shown to impact various cancer-related 
pathways, including proliferation, DNA damage, metastasis, apoptosis, 
cell cycle and telomere-telomerase dynamics (Hafeez et al., 2013, Lee et 
al., 2012, Lu et al., 2013a, Sinha et al., 2013, Wang et al., 2008, Khaw et 
al., Manuscript in preparation). 
In order to explore the effects of Plumbagin more 
comprehensively at gene levels, we and others (Kumar et al., 2013, Yang 
et al., 2004, Thasni et al., 2013) have used expression arrays to assess 
the effects of this compound on RNA expression. A previous study in our 
lab has demonstrated that in brain tumour cells, physiologically 
achievable concentrations of Plumbagin can induce DDR and alter cell 
cycle and cell death pathways by impacting transcription of several genes 
(Khaw et al., Manuscript in preparation). This study, along with other 
molecular studies, supports the idea that Plumbagin can impact multiple 
cellular pathways. However, its specificity and effects on tumour-related 
pathways in human breast cancer cells remain to be delineated. It is 
reasoned that consideration of cell type-specific effects would be critical 
for comparison of Plumbagin anti-cancer potentials. To address these 
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issues, a microarray gene profiling approach is utilized in this study to 
examine gene expression in the TNBC MDA-MB-231 and luminal MCF-
7 human breast cancer cells following exposure to Plumbagin as 
compared to the non-treated cells and the relatively normal MCF-10A cell 
type. Finally, in order to illustrate the anti-cancer potentials of Plumbagin-
induced gene expression changes in breast cancer cells, these findings 
are discussed in the context of cancer-related functions of the regulated 
genes. 
4.2. Microarray data analysis 
Gene expression profiles were generated using microarray after 
48 hours of treatment with Plumbagin at the IC50 doses in the cell types 
used in the study. Expression values of the 31,320 probes in the 
microarray were analyzed by 2-way ANOVA, after adjusting the raw data 
for background signals. Significantly expressed genes with significant 
differential expression patterns were selected based on a false discovery 
rate of 5% between the treated and non-treated samples for each cell 
type. Figure 31 depicts the number of differentially expressed genes (P< 
0.01) based on the initial criteria of cell type and treatment, according to 
the principal components analysis (PCA) mapping (Figure 32A). All the 
genes were analyzed using Partek Genomics SuiteTM, and as 
demonstrated in Figure 32B, the variety in the cell types was the main 
source of variation amongst the expressed genes. Selected groups of 
differentially regulated genes were then clustered using the DAVID 
Functional Annotation Tool (Huang da et al., 2009). Selected genes were 
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further classified into more cancer-specific categories including cell cycle, 
DNA damage, apoptosis, metastasis, and telomere-telomerase 
equilibrium.  
 
Figure 30. Microarray criteria. Cells were treated with Plumbagin in duplicates and 
the gene expression profile was studied by microarray analysis. The number of 
significantly expressed genes was detected for each criterion specific to cell type 





Figure 31. Sources of variation in the significance of gene expression 
upon Plumbagin treatment. (A) Microarray principal components analysis 
(PCA) mapping of criteria obtained from two biological replicates of Plumbagin-
treated cells. Eclipse drawn around the duplicate criterion for each cell type-
treatment represents area spanning two-fold standard deviation from the 
median expression levels. (B) Sources of variation in the gene analysis 





4.3. Expression analysis of genes related to cell cycle, apoptosis 
and DNA damage response in Plumbagin treated cells  
To identify the expression pattern of cell cycle-related genes, 
such as CCNE1, CDK2, TP53, CCNB1, E2F1 and PTEN in response to 
pharmacological treatment of Plumbagin, the changes in gene 
expression level between treated cancer cells and MCF-10A, and their 
respective untreated controls are determined. Pertinent to this, genes 
involved in DDR including PARP1, PRKDC and ATM, which respectively 
encode the PARP-1, catalytic subunit DNA-PK and the ATM proteins 
were also evaluated. Using microarray with the capacity to display 
transcripts level of known genes, the gene expression profile of 
apoptosis-related genes including BAK, CD40LG, XIAP, SIVA, APAF1, 
TP53INP1, BAD, BAK1, BID, CASP9, BCL2L1, FAS, BAG3, MCL1 and 
TNFRSF25 is also assessed (Figure 33).  
Interestingly differential gene expression patterns for the above-
mentioned pathways for each criterion was observed, in Plumbagin-
treated cells, which will all be discussed later. A number of these findings 








Figure 32. Gene expression profile of cell cycle, DNA damage response and 
apoptosis pathways after exposure to Plumbagin in cells. Cells were treated with 
Plumbagin and the gene expression study was performed by microarray analysis to 
determine the percentage of differentially regulated genes in breast cancer cell types 




4.4. Differential breast cancer metastasis-related gene 
expression in cells, following Plumbagin treatment 
Evaluation of metastasis-related genes expression pattern 
following Plumbagin treatment was also carried out in human breast 
cancer cells. Consistent with the previous report of this study on the cell 
migration inhibitory potential of Plumbagin in Chapter 3, Figure 34A 
shows list of genes involved in inhibiting metastasis which were mostly 
up-regulated upon Plumbagin treatment. On the other hand as 
demonstrated in Figure 34B, Plumbagin predominantly down-regulated 





Figure 33. Microarray analysis of metastatic genes expression profile upon 
Plumbagin treatment. Cells were treated with Plumbagin and the gene expression 
profile was carried out by microarray analysis. The percentage of differentially 
regulated genes in breast cancer cell types MCF-7 and MDA-MB-231 was 
compared to the non-cancerous MCF-10A and the non-treated form of each cell. 
Both MCF-7 and MDA-MB-231 breast cancer cells exert invasion inhibitory 
activities by overall up-regulation of (A) breast cancer metastasis-inhibitor genes; 
and down-regulation of (B) breast cancer metastasis-promoter genes expression 
level after Plumbagin treatment. The modality of changes is represented by 






4.5. Plumbagin treatment alters the telomere homeostasis genes 
expression in breast cancer cells 
In the previous Chapter, long term anti-cancer efficiency of 
Plumbagin was shown to be attributed to the telomerase inhibitory 
potential of Plumbagin leading to telomere attrition. Hence, in the next 
step it is sought to examine the alteration of genes which enrol in the 
telomere-telomerase equilibrium. As seen in Figure 35, the expression 
of a number of these genes was shown to change significantly, upon 
Plumbagin treatment. The majority of these genes are essential for 
telomere maintenance and telomerase activity in breast cancer cells.  
Figure 34. Microarray analysis of differentially expressed telomere homeostasis 
genes in Plumbagin-treated cells. Cells were treated with IC50 doses of Plumbagin 
for 48 hours and the fluctuation of genes expression related to telomere-telomerase 
dynamic was expressed as percentage with regards to respected controls. 
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4.6. “Transcription regulatory activity” was the most triggered 
phenotype after Plumbagin treatment in both MCF-7 and MDA-MB-
231 cells  
The gene expression profile of MCF-7 and MDA-MB-231 breast 
cancer cells treated with Plumbagin was assessed further by specifically 
using Venn diagram analysis of differential expressed genes. A total 
number of 438 genes showed more than 2 fold changes after 48 hours 
of Plumbagin treatment (Figure 36A). The number of genes were 
narrowed down by ruling out those, whose regulation were also altered 
in the normal epithelial MCF-10A cells.  The remaining 308 genes were 
regulated only in Plumbagin-treated breast cancer cell types MCF-7 and 
MDA-MB-231 cells (Figure 36B).  
Thereafter, genes were clustered based on gene ontology (GO) 
groups into three categories: cellular components, biological process 
and molecular functions. In each cluster down-regulation and up-
regulation of several genes were found, which were related to different 
pathways, such as cellular synapses, cell growth and adhesion, immune 
system process, cellular response to stimuli and above all, transcription 
regulatory activity (Figure 37). The controlling genes in the transcription 
activity were evaluated and the results showed that two of the most 
important transcription regulatory genes, NACC1 and TAF8, were 
significantly altered following Plumbagin treatment in both MDA-MB-231 




Figure 35. Venn diagram showing the number of statistically significantly 
expressed genes upon Plumbagin treatment at IC50 doses. (A) Number of 
significantly expressed genes which are common between MDA-MB-231 and 
MCF-7 treated cancer cell types is 434. (B) While from this number, 308 genes 
were common between the treated cancer cells and were not significantly 
expressed in the normal non-cancerous MCF-10A cells.  The genes were 
selected based on a false discovery rate (FDR) of 5% (equivalent to P≤ 0.05). 







Figure 36. Gene ontology classification of the highly modulated common genes 
between the breast cancer cells upon Plumbagin treatment. Within the 308 
selected genes, their gene ontology were examined for (A) Cellular components (B) 
Biological process and (C) Molecular functions. 







NACC1 was down-regulated with a fall by 41.6% and 52.9% and 
TAF8 was up-regulated with an increase of 45.6% and 60.4% over 48 
hours treatment with Plumbagin, in MDA-MB-231 and MCF-7 cells, 
respectively. The modality of gene expression of TNKS1BP1 as a breast 
cancer associated gene was also remarkable, with a drop by 117.2% 
and 24.6% in MDA-MB-231 and MCF-7 cells, correspondingly.  
In the next step, with no clustering restriction, differential 
Plumbagin-related alteration of genes involved in transcription regulatory 
activity amongst MCF-7 and MDA-MB-231 cells were checked (Figure 
39).  
 
4.7. OSGIN1, ARFL2, BSG and FOS were the most regulated 
genes in MDA-MB-231 cells; and CYP1B1, NUMBL and CYP17A1 
were the most altered genes in MCF-7 cells after Plumbagin 
treatment 
Furthermore, the most up-regulated and down-regulated genes 
due to Plumbagin exposure were scrutinized for each cell type. Oxidative 
stress induced growth inhibitor 1 (OSGIN1) with 78.8% and ADP-
ribosylation factor-like 2 (ARFL2) with 74.2% increase were the most up-
regulated genes in MDA-MB-231 cell type. While Basigin (Ok blood 
group) (BSG), or CD147, by 154.5%; and FBJ murine osteosarcoma 
viral oncogene homolog (FOS) by 158.5% fall were the most down-
regulated genes in MDA-MB-231. As for MCF-7, Cytochrome  P450-1B1  
(CYP1B1)  with  88.3%  increase;  and   numb   
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 Figure 38. Gene expression profile of NACC1, TAF8 and TNKS1BP1 in 
Plumbagin treated MDA-MB-231 and MCF-7 cells. The common significantly 
expressed genes between the cancer cells were checked for the most altered 
transcription regulatory genes, NACC1 and TAF8 were extracted. The modality of 
gene expression of TNKS1BP1 as a breast cancer associated gene is also worthy 
of mention.                                                                          
 
 
Figure 37. Percentage change in the expression of genes involved in 
transcription regulation in MDA-MB-231 and MCF-7 cells treated with 
Plumbagin. Cells were treated with IC50 doses of Plumbagin for 48 hours and the 
percentage change of genes involved in transcription regulatory activity is as 




homolog (Drosophila)-like (NUMBL) with 79.3%; and cytochrome P450, 
family 17, subfamily A, polypeptide 1 (CYP17A1) with 91.0% decrease 
were the most altered genes in MCF-7 cells (Figure 40). All these genes 
are known to control in tumour progression or suppression, and their 




Figure 39. The most regulated genes in MDA-MB-231 and MCF-7 cells after 
exposure to Plumbagin. Cells were treated with IC50 doses of Plumbagin for 48 
hours. Thereafter, the percentage change of the most up-regulated and down-
regulated genes, due to Plumbagin treatment was calculated for MCF-7 and MDA-





Numerous genes were significantly altered by Plumbagin. 
However, as the first step, we chose to consider those transcripts that 
were notably modulated in cancer-related pathways. In the present 
study, it is showed that Plumbagin elicits a significant effect on growth 
inhibition and induction of apoptotic processes in MDA-MB-231 and 
MCF-7 breast cancer cells mediated by alterations in the gene 
expression of cell cycle, DNA damage response, metastasis, and 
apoptosis regulatory genes as shown by microarray analysis.  
Among the altered cell cycle related genes, down-regulation of 
some, such as CCNE1 and TP53 and up-regulation of E2F1 in both 
cancer cells were observed. TP53 was found to be up-regulated in 
normal cells. The accumulated amounts of this gene is known to be 
mutant in MDA-MB-231 cells (Ercan et al., 2012), as was observed in 
the immunoblottings in Chapter 3. Gene expression of TP53 was shown 
to be down-regulated in MCF-7 cells as well, which is in contrast to the 
earlier findings of high levels of p53 protein expression upon Plumbagin 
treatment.  
Deregulation of E2F1 transcription factor, which constitutes an 
oncogenic stress inducing apoptosis, triggers entry into S phase. When 
DNA damage occurs, it activates ATM, which subsequently activates the 
tumour suppressor p53, a key player in the control of cell growth and 
viability. Subsequently, CDK2 down-regulates and E2F1 elevates the 
ATM promoter activity and induces an increase in ATM mRNA and 
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protein levels. This is accompanied by an E2F-induced increase in p53 
phosphorylation (Berkovich and Ginsberg, 2003).  However, mutant p53 
is also known to operate by interfering with and/or modifying the function 
of other proteins. Mutant TP53 can prevent the ATM-dependent DNA 
repair in TNBC cells (Muller et al., 2011). That might reason how genes 
implicated in DDR showed different patterns of alterations in the cells. 
Plumbagin treatment resulted in up-regulation of PRKDC, ATM and 
PARP1 in MCF-7 cells, but down-regulation in MDA-MB-231 cell type, 
suggesting a p53 independent apoptosis in these cells. 
Cell division cycle (CDC)s genes control the molecules related to 
the cell cycle, and they are vital and important for the initiation and 
progression of the consecutive phase of the cell cycle (Spruck et al., 
2003). It has been found that cyclins bind to cyclin-dependent protein 
kinase (CDK) and CDCs to control the cell cycle process (Urbanowicz-
Kachnowicz et al., 1999). The results of this study also showed that 
cyclins (CCNE1 and CCNB1) and CDK2 were mostly down-regulated in 
Plumbagin-treated breast cancer cells, except CCNB1 in MDA-MB-231 
cell type. In consistent with the findings of Chapter 3, this might suggest 
that Plumbagin inhibited the growth of breast cancer cells through the 
arrest of cell cycle and inhibition of proliferation. Similar effects on the 
cell cycle and apoptosis were observed previously in Plumbagin-treated 




Inhibition of cell growth by Plumbagin could also be due to the 
induction of apoptosis in addition to cell cycle arrest; therefore, the 
effects of Plumbagin on expression of genes belonging to proapoptotic 
and antiapoptotic proteins were also examined. There was overall down-
regulation in APAF1, BAD, BCL2L1, FAS, and MCL1 genes and up-
regulation of several genes, such as BAX, CD40LG, XIAPSIV and BAK1 
in Plumbagin-treated cancer cells that are related to the inhibition of cell 
growth and induction of apoptosis.  
Apoptosis regulatory gene, CASP9 was overexpressed in breast 
cancer cells, as was demonstrated in Chapter 3 and similar to past report 
(Xu et al., 2013), whereas SIVA, TNFRSF25, BAK1 and MCL1  were 
differentially expressed. Death receptor FAS, which activates apoptosis 
through recruitment of caspase-8 (Suda et al., 1993), was slightly up-
regulated in Plumbagin-treated cancer cells. This immunosuppressive 
property of Plumbagin is in line with previous findings (McKallip et al., 
2010). In agreement with the report by Xu et al, it was shown that 
Plumbagin treatment results in the down-regulation of the expression of 
BCL2L1 and up-regulation of Bax and BAK1 in at least one of the cancer 
cell types (Xu et al., 2013). The BCL2L1 gene, which encodes an anti-
apoptotic protein (Papadopoulos, 2006), was significantly inhibited by 
Plumbagin in MDA-MB-231 cells. BAK1 and MCL1, which both encode 
proteins belonging to the BCL2 protein family interact with the tumour 
suppressor p53 after exposure to DNA damaging agents, to induce 
apoptosis (Leu et al., 2004, Moll et al., 2005). Similar to TP53, these 
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genes also show a substantial down-regulation in the TNBC MDA-MB-
231 cell type after treatment with Plumbagin. Collectively, microarray 
gene expression profile of the treated cells, suggest the probable role of 
both intrinsic and extrinsic pathways of apoptotic cell death in 
Plumbagin-treated breast cancer cells. 
Moreover, this study focused on determining whether Plumbagin 
could impact on the breast cancer-specific metastasis related genes, 
which is also critically important for breast cancer cell invasion.  
ZEB1 expression triggers the breast cancer invasiveness, and is 
shown to be regulated by the NFκB transcription factor. Inactivation of 
NFκB in breast cancer cells leads to reduced ZEB1 levels, resulting in 
loss of invasion potential (Teng et al., 2013). Plumbagin treatment has 
lead to down-regulation of ZEB1 in both MCF-7 and MDA-MB-231 cell 
types. This might be contributed to our findings together with others who 
have revealed inhibitory effects of Plumbagin on the NFκB expression 
(Xu et al., 2013, Sandur et al., 2006, Li et al., 2012). On the other hand, 
it has been elicited that miR-130b is a negative regulator of ZEB1 and 
mutant TP53 exerts oncogenic functions by directly binding to the 
promoter of this gene and inhibiting its transcription (Dong et al., 2013). 
Plumbagin has shown to efficiently up-regulate miR-130b in the MDA-
MB-231 cells, despite of harbouring TP53 mutant gene. Transforming 
growth factor-β (TGF-β) is a strong growth inhibitor and furthermore, acts 
as an oncogenic factor. Of particular mention, TGF-β signalling plays an 
important role during metastasis of breast cancer (Imamura et al., 2012). 
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Plumbagin treatment elevated the levels of this gene in MCF-7 cells. 
Recent studies have discovered that microRNAs (miRNA) have 
important roles in regulating cancer cell invasion and metastasis. 
Expression analyses have verified that miR-34A expression is drastically 
decreased in metastatic breast cancer cells and human primary breast 
tumours with lymph node metastases. Overexpression of this gene could 
inhibit breast cancer cell migration and invasion in vitro (Yang et al., 
2012), which Plumbagin showed to effectively up-regulate this gene in 
both cancer cells and more significantly in MDA-MB-231 cell type. 
Recent studies have reported that miR-182 enhances breast cancer cell 
motility and invasiveness. miR-182 induction is linked to down-regulation 
of MIM (Missing in Metastasis), RhoA activation and poor prognosis (Lei 
et al., 2013). Plumbagin down-regulated the gene expression levels of 
RHOA in both cells, and miR-182 in MCF-7 cell type, while it up-
regulated the expression levels of MIMT1 in MDA-MB-231 cells.  miR-
98 inhibits breast cancer cell proliferation, survival, tumour growth, 
invasion, and angiogenesis by targeting and reducing the expression of 
activin receptor-like kinase-4 (ALK4) and matrix metalloproteinase-
11(MMP11), both of which are potential targets of this gene (Siragam et 
al., 2012).  This metastasis inhibitor gene was up-regulated in 
Plumbagin-treated MDA-MB-231 cells, leading to more significant 
suppression of MMP11 and ALK4 genes in this cell type. MicroRNA-155 
(miR-155) is commonly up-regulated in various types of human cancer 
and its expression inversely contributes to VHL tumour suppressor 
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expression level in breast cancer cells. miR-155 is associated with late-
stage, lymph node metastasis and poor prognosis, as well as triple-
negative tumour in breast cancer. It was reported earlier that miR-155 
has a pivotal role in tumour angiogenesis by down-regulating the VHL 
(Kong et al., 2013, Zia et al., 2007, McCarthy, 2013). In this study 
Plumbagin was shown to adversely increase the expression levels of 
miR-155 in both cancer cells and decrease the VHL level in MDA-MB-
231 cells, despite of the slight increase of that in MCF-7 cell type. This 
might be due to the irreversible gain-of-function mutant TP53 genes in 
MDA-MB-231 cells, as it was revealed that mutant TP53 drives invasion 
in breast tumours through up-regulation of miR-155 (Neilsen et al., 
2013). It is established that miR-155 exerts its oncogenic role by 
negatively regulating SOCS1 tumour suppressor gene (Jiang et al., 
2010). SOCS1 is shown to be up-regulated in Plumbagin-treated MDA-
MB-231 cells. miR-340 is known to inhibit breast cancer cell migration 
and invasion through targeting oncoprotein c-Met (Wu et al., 2011), and 
was up-regulated in Plumbagin-treated MDA-MB-231 cells. Mutant TP53 
was shown to bind to the miR-223 promoter and reduce the 
transcriptional activity of this cell invasion inhibitor. On the basis of 
previous findings, it was proposed that one of the pathways affected by 
mutant TP53 to increase cellular resistance to chemotherapeutic agents 
in breast cancer, involves down-regulation of miR-223 (Masciarelli et al., 
2013). However, Plumbagin treatment was shown to successfully up-
regulate the expression of this gene in the TP53 mutant MDA-MB-231 
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cell type. miR-506 is a novel miRNA found to be significantly related to 
breast cancer patient survival in meta-analyses. NFκB binds to the 
upstream promoter region of miR-506 to suppress transcription. 
Moreover, it has been shown that overexpression of miR-506 
suppresses adhesion, invasion, and migration of MDA-MB-231 cells 
(Arora et al., 2013). Plumbagin treatment could up-regulate this gene in 
both cancer cells and specifically in MCF-7 cell type. miR-221 is known 
to function as an oncogene, which is essential in regulating 
tumourigenesis and metastasis in TNBCs (Nassirpour et al., 2013). The 
findings of this study have revealed the fact that Plumbagin significantly 
down-regulated this oncogene in the TNBC MDA-MB-231 cells. CXCR4 
is expressed by various types of tumour cells, including breast cancer 
(Andre et al., 2006) and leads to angiogenesis and metastasis (Epstein, 
2004). Plumbagin could successfully down-regulate the gene expression 
levels of CXCR4, which is in line with earlier reports (Manu et al., 2011). 
As shown in Chapter 3, Plumbagin suppressed cancer cell 
migration. The microarray data generated strongly confirmed and 
validated this fact and proved that to be more significantly observed in 
the invasive TNBC MDA-MB-231 cell type.  
As explained in Chapter 3, the telomere shortening and 
telomerase activity inhibition was observed in the chronic long term study 
of Plumbagin-treated cells. Telomere length, as an important factor in 
tumor cells, might be exploited as a prognostic and/or risk marker for 
breast cancer (Heaphy et al., 2011). Telomere dysfunction might be of 
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value as a marker of aggressiveness of the tumour in breast cancer 
patients. A link has been made for telomere-mediated genomic instability 
and clinico-pathological parameters in breast cancer (Poonepalli et al., 
2008). This connection might be modified by hormone receptor status 
and genetic diversity (Pellatt et al., 2013). Here, the expression level of 
genes involved in the telomere-telomerase dynamics was studied 
following treatment of cells with Plumbagin. This plant compound 
revealed to alter these genes in different ways.  
It has been observed that overexpression of the tumour 
suppressor BRCA1 causes inhibition of telomerase activity and telomere 
shortening in breast cancer cells (Xiong et al., 2003). Moreover, BRCA1 
was found to have roles in maintaining telomeres as well (McPherson et 
al., 2006). This study reports overexpression of this gene in both the 
cancer cell types after Plumbagin treatment. Elevated expression of the 
MYC  gene is found in almost one-third of breast carcinomas (Escot et 
al., 1986). Depletion of this gene was reported to be correlated with 
reduced expression levels of BRCA1 , therefore breast cancer cells with 
reduced BRCA1 expression due to reduction of MYC exhibit impaired 
DNA repair activity (Chen et al., 2011). In breast tumour cells, MYC 
activates the telomerase TERT (Hines et al., 2005, Xu et al., 2010). In 
the current study, this might be the reason for their synchronized up-
regulation and down-regulation in MCF-7 and MDA-MB-231 cells, 
respectively, following Plumbagin treatment. Both MCF-7 and MDA-MB-
231 cells harbour wild type for BRCA1 gene, however, Plumbagin has 
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shown to induce multiple pathways of apoptosis and cell cycle arrest in 
BRCA1 blocked cells compared to unblocked cells (Thasni et al., 2013). 
BRCA2, is required for telomere homeostasis and may be particularly 
important for the replication of G-rich telomeric lagging strands (Min et 
al., 2012). BRCA2 mediates HR and down-regulation of this gene, which 
is thought to result from defective HR (Min et al., 2012), was seen in both 
Plumbagin-treated breast cancer cells. ESR1 was observed to be up-
regulated in breast cancer cells and not in MCF-10A. In agreement with 
our findings, Plumbagin was shown previously to bind to the active site 
of ER-a (encoded by ESR1) with higher affinity as compared to estradiol 
(Thasni et al., 2008) and therefore up-regulate the ER-a 46 kDa protein 
expression, without regulating the ER-b (encoded by ESR2) expression. 
Activation of this isoform, which inhibits classical ER-a signalling 
pathway, may lead to induction of apoptosis (Figtree et al., 2003). ER is 
also reported to activate MYC and telomerase through direct and indirect 
stimulation of hTERT promoter in MCF-7 cells (Kyo et al., 1999). This 
might explain the slight up-regulation of TERT and TERC expression at 
the genetic level followed by increase in ESR1 and MYC, without 
affecting the hTERT protein expression of MCF-7 cells upon Plumbagin 
treatment. Nevertheless, MDA-MB-231 cells exhibited a decrease in 
MYC, TERT and TERC gene expressions followed by a sharp increase 
in ESR1.  
Genetic inhibition of telomerase resulted in sensitization and 
recovery of breast tumour cells (Poynter et al., 2009). Plumbagin 
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treatment has led to MDM2 overexpression with no change in the levels 
of TERC gene expression in MDA-MB-231 cell type. This could be due 
to the fact that MDM2 specifically binds to TERC promoter in vivo and 
TERC activity is inhibited by overexpression of MDM2 (Zhao et al., 
2005). TERT down-regulation significantly contributes to increased 
levels of apoptosis in MDA-MB-231 and MCF-7 cells (Rubis et al., 
2013b). This might explain the stronger efficacy of Plumbagin-induced 
cell death in MDA-MB-231 cells to the slight inhibitory effect of this phyto-
compound on TERT, in this cell type. Montanaro and colleagues 
speculate that very low level of DKC1, contribute to noticeably reduced 
telomerase activity in breast cancer cells, independently of the 
expression of other imperative components of the telomerase complex 
such as TERT. It has been displayed that this reduction is mediated 
through the decrease of TERC (Montanaro et al., 2008). Plumbagin 
treatment was shown to exert similar pattern of expression in TERC and 
DKC1 in each of the MCF-7 and MDA-MB-231 cells. However, despite 
the more significantly reduced expression of these genes in MCA-MB-
231 cell type, more telomerase inactivation for MCF-7 cells is observed 
(described in Chapter 3). 
Butler and colleagues have demonstrated that the levels of 
TERF2, TERF1, TINF2, and POT1 mRNA, but not TERT RNA, are 
inversely correlated with telomere length and content in breast tumours 
(Butler et al., 2012). TRF2 is a telomere-binding protein with roles in 
telomere protection and telomere length regulation and is up-regulated 
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in some human tumours. It has been illustrated that TERF2 increased 
expression is a potent oncogenic event that along with telomerase 
deficiency accelerates carcinogenesis (Blanco et al., 2007). Tankyrase 
promotes telomere elongation by interaction with the telomeric protein 
binding factor TRF1, a negative regulator of telomere extension. This 
positive regulator of telomere elongation is elicited to be over expressed 
in human breast cancer cells (Gelmini et al., 2004). In this study, 
Plumbagin unfavourably up-regulated the TANK gene in the breast 
cancer cells. Telomere-associated protein TIN2 is encoded by TINF2, 
which is essential for development of a variety of human malignancies. 
Various known chemical inhibitors of NFκB could also strongly inhibit 
TINF2 transcriptional activity (Xin et al., 2011). Similar to TERF1 and 
TERF2, TINF2 is also a negative regulator of telomere length and its 
down-regulation was shown to be important to maintain telomeric DNA 
in cancer (Yamada et al., 2002). TINF2 was shown to be significantly up-
regulated in this study, implying that Plumbagin induces TINF2 activity 
in both the breast cancer cell types. For breast cancer cells to maintain 
sufficient telomere length to confront cell death, it is established that not 
only they need reactivation of telomerase activity, but also they must 
break out of negative regulation of telomerase activity (Saito et al., 
2002). In this regard, it was observed that Plumbagin has disturbed the 
crucial balance between accelerator (DKC1) and suppressor genes 
(TERF1, TERF2, TINF2) of telomerase activity in the breast cancer cells.  
POT1 is a negative regulator of telomerase activity and it was thought 
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that it might act as a tumour suppressor gene (Salhab et al., 2008). 
POT1 was up-regulated in both cancer cells upon Plumbagin treatment.  
Transcription regulatory activity was shown to be the most 
triggered gene ontology phenotype after Plumbagin treatment in the 
cancer cells. This finding is strongly supported by the previous evidences 
as follows. Plumbagin is shown to interfere with a number of transcription 
regulatory factors in favour of cancer suppression. This phytochemical 
has shown to suppress STAT3 activation pathway through induction of 
protein tyrosine phosphatise (SHP-1) in cancer cells (Sandur et al., 
2010). It also reduces binding activities of NFκB and AP-1 via ERK 
signalling pathway in human lung cancer cells (Shieh et al., 2010). This 
phyto-compound is also able to repress NFκB activation and NFκB -
regulated gene products by altering p65 and IkappaBalpha kinase 
activation (Sandur et al., 2006). Collectively, earlier findings and the data 
of this study show that Plumbagin inhibits both telomerase and NFκB 
transcription. This might indirectly suggest that that telomerase directly 
regulates NFκB-dependent transcription (Ghosh et al., 2012). 
In the next step, the gene expression profile of the most 
outstanding transcription regulatory genes was examined. NACC1 and 
TAF8 were identified to be commonly and significantly expressed in both 
Plumbagin-treated MDA-MB-231 and MCF-7 cells.  
TAF8, which is a transcription initiation factor, was shown to be 
significantly up-regulated. This gene encodes one of the TATA-binding 
protein (TBP)-associated factors (TAFs), which are fundamental 
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subunits of the universal transcription factor complex TFIID (Purrello et 
al., 1998). Both TBP and TFIID stimulate p53 in binding to DNA (Chen 
et al., 1993). In contrast, NACC1 transcription repressor was markedly 
down-regulated in MCF-7 and MDA-MB-231 cells upon Plumbagin 
treatment. NACC1 or nucleus accumbens-associated protein 1 (NAC1) 
might be a potential oncogene. Expression of this gene may be related 
to tumour progression, and tumour cell proliferation and survival. This 
may be arbitrated, at least to some extent, through inhibiting 
transcriptional activity of GADD45GIP1 (Okazaki et al., 2012).  
Among the common significantly expressed genes between 
MCF-7 and MDA-MB-231 cells, TNKS1BP1 (tankyrase 1 binding 
protein), as a striking tumour associated gene, was significantly down-
regulated after Plumbagin treatment. Recently, it was shown that 
TNKS1BP1 is one of the targets of miR-26b, and its high expression 
in cancer stroma is significantly related to breast cancer recurrence 
(Verghese et al., 2013). 
Gene expression is regulated and harmonized at multiple levels. 
Regulation of transcription controls the time and quantity of the 
transcription. A gene transcription can be regulated by at least five main 
transcriptional regulatory elements: specific factors, general 
transcription factors, enhancers, silencers, insulators, and locus control 
regions (LCRs) (Noonan and McCallion, 2010). Enhancers are specific 
DNA sequences, which activate transcription apart from the element's 
location or orientation (Bulger and Groudine, 2011). NFκB is an 
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enhancer transcription factor and has been shown that certain breast 
cancer cells rely on that for aberrant cell proliferation and concurrently 
avoid apoptosis. Activated  NFκB  may be a  therapeutic target for 
distinctive subclasses of ER_ breast cancers (Biswas et al., 2004). The 
NFκB  transcription factor family in mammals comprises of different 
members (Oeckinghaus and Ghosh, 2009), which this study revealed 
them to acquire different regulations in breast cancer cells after 
Plumbagin treatment. However, NFKB2 gene expression showed 
significant decrease, which is in line with previous studies reporting that 
Plumbagin inactivates NFκB in cancer cells (Xu et al., 2013, Sandur et 
al., 2006, Li et al., 2012). 
On the other hand, silencers are sequence-specific elements that 
exert a negative (silencing or repressing) consequence on target gene 
transcription (Ogbourne and Antalis, 1998). Silencers are binding sites 
for negative transcription factors (TF)s called repressors. Insulators help 
in protecting genes from inappropriate signals originating from their 
surrounding environment (Bushey et al., 2008). Finally, LCRs consist of 
multiple cis-acting elements that function together to confer tissue-
specific and developmentally timed expression to genes (Li et al., 2002). 
Given the fact that many of these distal-acting regulatory elements or 
regions are situated more than 1 kb from their target genes, regulation 
of transcription often involves long-range DNA interactions, which are 
mediated by the formation of chromatin loops (Sexton et al., 2009). The 
long-range regulatory elements forms one of the most important 
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mechanisms for gene regulation in breast cancer (Betts et al., 2013). 
The effects of Plumbagin on number of genes implicated in long-range 
transcriptional regulation of breast cancer, including  ESR1 (Pan et al., 
2008, Fullwood et al., 2009) were studied; AP-1 or JUN (Wang et al., 
2011); AP2-γ or TFAP2C (Tan et al., 2011); FoxA1 (Lupien et al., 2008); 
GATA-3 (Spilianakis and Flavell, 2004);  and  PGR (Magklara and 
Smith, 2009). The demonstrated results exhibit that these genes in 
TNBC MDA-MB-231 were more affected upon treatment with 
Plumbagin. 
Specific factors act as disease-specific transcription factors. In 
this study the gene expression level of transcription factors, which were 
shown to significantly contribute to breast cancer was investigated. 
These results showed their alteration upon Plumbagin treatment. 
Breast cancer estrogen-inducible protein (pS2) gene, also known 
as TFF1, is a human breast cancer prognostic marker. This gene is a 
target of estrogen-receptor-related receptors (ERRs) and is shown to 
protect cells from induced apoptosis (Lu et al., 2001). This gene was 
down-regulated in MCF-7 cells, but up-regulated in MDA-MB-231 cells 
upon Plumbagin treatment. ATP-binding cassette, subfamily B 
(MDR/TAP), member 1 (ABCB1) or MDR1, encodes a protein that is 
responsible for resistance to anti-cancer drugs in breast tumour cells 
(Fang et al., 2013, Rubis et al., 2012). Multidrug resistance (MDR) is the 
expansion of cross-resistance to many natural product anti-cancer 
drugs, which is one of the major reasons of cancer chemotherapy failure. 
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This type of MDR is often connected to overexpression of the MDR1 
gene product, P-glycoprotein (Pgp). The expression of MDR in breast 
tumours is related to their origination from a tissue, which mainly 
expresses Pgp, and to the development of resistance during successive 
courses of chemotherapy (Glazer and Rohlff, 1994). This study shows 
that Plumbagin treatment up-regulated this gene in MCF-7 and down-
regulated it in MDA-MB-231 cell types. 
Cofactor of BRCA1 (COBRA1) was initially acknowledged as a 
protein that binds to the gene product BRCA1. COBRA1 modulates 
estrogen-dependent and independent transcription and suppresses the 
growth of breast cancer cells. Its expression is extensively reduced in 
metastatic and recurrent breast cancer, pointing to a tumour suppressor 
function in breast cancer progression. COBRA1 and BRCA1 are shown 
to engage in common gene regulatory pathways to repress breast 
cancer development (Aiyar et al., 2007). In our study upon Plumbagin 
treatment, both genes were up-regulated in MCF-7 cells, as same as the 
BRCA1 expression in MDA-MB-231 cells, however, COBRA1 was 
significantly decreased in MDA-MB-231 cell type, which might be due to 
the invasive nature of these cells (Sun et al., 2008). Polo-like kinase 1 
(PLK1) is overexpressed in many types of human cancers playing role 
in the transcription regulation of cell division. PLK1 mediates ER -
regulated gene transcription in human breast cancer cells (Wierer et al., 
2013), and was established to be significantly overexpressed in TNBC 
compared to the other breast cancer subtypes (Maire et al., 
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2013). Plumbagin treatment seemed to increase the overexpressed 
PLK1 in breast cancer cells. Emerging evidence has demonstrated that 
up-regulated expression of KIAA1199 in human breast cancer, 
contributes to poor survival (Michishita et al., 2006).  Plumbagin 
decreased the level of this gene in MCF-7 cells, but increased that in 
MDA-MB-231 cell type. Grainyhead-like 2 (GRHL2) transcription factor 
is a recent identified protooncogene, demonstrated to have an essential 
role in breast carcinogenesis. The protein encoded by this gene is a 
transcription factor that can act as a homodimer or as a heterodimer with 
either GRHL1 or GRHL3 (Werner et al., 2013). Exposure to Plumbagin 
showed an adverse increase in the expression level of this gene in both 
cancer cells.  
Coming to the most regulated genes of this microarray study, 
OSGIN1, ARFL2, BSG, and FOS appeared to be the most altered genes 
in MDA-MB-231; and CYP1B1, NUMBL, and CYP17A1 were extracted 
as the most regulated genes in MCF-7 cells after Plumbagin treatment. 
OSGIN1 also known as OKL38 or BDG1, was one the mostly up-
regulated genes in MDA-MB-231 cells, after exposure to Plumbagin. 
This human tumour growth inhibitor gene encodes an oxidative stress 
response protein that regulates cell death. Expression of the gene is 
regulated by p53 and is induced by DNA damage. The loss of this protein 
correlates with uncontrolled cell growth and tumour formation. OSGIN1 
was shown to inhibit growth and migration of breast cancer cells via 
induction of cell cycle arrest and apoptosis. The protein regulates 
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apoptosis by inducing cytochrome c release from mitochondria 
(Mukherjee et al., 2009, Wang et al., 2005).  
ARFL2 gene expression is known to associate with p53 
localization and chemo-sensitivity in breast cancer cells (Beghin et al., 
2008). The protein product of this gene has shown to affect microtubule 
dynamics in breast cancer cells and have exerted a major impact on 
reducing breast tumour cell aggressiveness (Beghin et al., 2007, Beghin 
et al., 2009). Following treatment with Plumbagin, ARFL2 gene was also 
one of the most up-regulated genes in the invasive TNBC MDA-MB-231 
cell type. 
The other anti-cancer effect of Plumbagin in favour of treating the 
invasive MDA-MB-231 was to down-regulate the BSG or CD-147 gene 
in this cell type, to one of the most significant levels in this microarray 
study.  BSG was shown to promote breast cancer progression by its 
involvement in every facet of malignancy, including invasion, metastasis 
(Yang and Chen, 2013). High expression of this gene is shown to 
contribute to the poor prognosis of TNBC patients (Zhao et al., 2013).  
AP-1 or FOS protein has been implicated as the regulator of cell 
proliferation, differentiation, and transformation, to the extent that Fos 
has been established to be critical for MCF-7 breast cancer cell growth 
(Lu et al., 2005).  In some cases, expression of this gene has also been 
associated with apoptotic cell death. FOS gene is regarded as an 
oncogenic transformation and tumour progression, whose 
overexpression in breast tumours produces an invasive and hormone 
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resistant phenotype (Smith et al., 1999). This oncogene has been shown 
to significantly decline in the invasive MDA-MB-231 cells upon 
Plumbagin treatment. 
CYP1B1, also known as cytochrome P450 is a major enzyme 
catalyzing the formation of genotoxic 4-hydroxyestradiol, and its gene is 
over expressed in tumour cells (McFadyen et al., 2004). CYP1B1 is 
genetically polymorphic, and the variations in this gene have shown to 
potentially be related to the risk of breast cancer (Zheng et al., 2000). 
Our study has revealed that Plumbagin adversely increases the gene 
expression of this enzyme in MCF-7 cells to significant levels. 
Previous studies have shown that NUMBL signalling is critical to 
maintain multiple nodes of metastatic progression, including persistence 
of cancer-initiating cells (Vaira et al., 2013). Our results revealed a 
significant down-regulation of this gene in Plumbagin-treated MCF-7 
cells. 
The CYP17A1 gene was shown to be protective for breast cancer 
(Tuzuner et al., 2010). This gene acts upon progesterone to add 
a hydroxyl (-OH) group at carbon 17 of the steroid D ring (the 
hydroxylase activity) (Porubek, 2013). The close genotype of this gene, 
named CYP17A2/A2, was only observed in women with ER+ 
positive breast cancer and not in ER- breast cancer patients (Cribb et al., 
2011). However, this study disclosed that Plumbagin provokes the most 
significant decrease in the levels of CYP17A1 in the Plumbagin treated 
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ER+ MCF-7 breast cancer cells, denoting another remarkable anti-
cancer impact for this phyto-compound. 
The findings of this Chapter revealed that Plumbagin 
dysregulates multiple cancer-related pathways at genetic level and plays 
a crucial role in suppressing breast cancer cell proliferation, survival, 





















CHAPTER 5  
5. Inhibition of telomerase or DNA repair factors modulate the 
sensitivity of breast cancer cells towards the anti-cancer effects of 
Plumbagin 
5.1. Short term kinetic studies of Plumbagin 
5.1.1. Background 
 
A variety of anti-cancer effects of Plumbagin on breast cancer cells 
were observed, and thereafter proceeded to explore how to increase this 
efficiency by a more targeted therapy through combining Plumbagin and 
another appropriate drug. Therefore, experiments were conducted to 
elucidate the short-term kinetics of Plumbagin on different molecular 
pathways as to better know the time-dependant effects of Plumbagin on 
the cells and consequently decide upon the proper combination 
therapeutics. 
Subsequently, based on the results, the anti-cancer effects of 
Plumbagin were investigated through three different studies, exploring 
the combinatorial effects of Plumbagin along with three signalling 
pathway specific inhibitors for PARP-1, DNA-PKcs and telomerase. In 




5.1.2. Plumbagin alters the DNA damage response pathways 
significantly in time-dependent studies 
The kinetics of Plumbagin on the DNA damage response 
pathways were studied by treating MDA-MB-231 and MCF-7 breast 
cancer cells and MCF-10A cells with the IC50 doses of Plumbagin for 48 
hours followed by 24-hour recovery in the drug-free media, all designed 
in a 72-hour study. The resultant findings were investigated by means of 
western blot analysis for appropriate proteins. 
The specific DSB indicator, γH2AX (17kDa), was examined, and 
subsequently we probed for ATM/ pATM (370 kDa) and DNA-PKcs/ 
pDNA-PKcs (460 kDa) as the two biomarkers of homologous 
recombination (HR) and non-homologous end-joining (NHEJ) repair 
pathways, respectively. To study the effects of Plumbagin on base 
excision repair (BER) of SSB, the expression level of PARP-1 was 
detected. 
The protein expression levels in MCF-10A cells remained 
unchanged for ATM, pATM, and PARP-1 (97/113 kDa) at all the time 
points (Figure 41), signifying lack of activation of HR and BER repair 
pathways after Plumbagin treatment. While there was a slight fluctuation 
in the γH2AX expression level and a significant increase in the pDNA-
PKcs protein level (from 24 hours), validating the microarray data in 
Chapter 4, and indicating that Plumbagin triggers DSB signalling 
pathways with specific regards to NHEJ repair pathway in MCF-10A cells.  
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Plumbagin induced-DSB was present in both MDA-MB-231 and 
MCF-7 cells. In consistent with the earlier findings in the section 3.2.8, 
the γH2AX protein was also up-regulated in these cells upon Plumbagin 
treatment. As for MDA-MB-231 cells, an early activation of HR (marked 
up-regulation of phosphorylated (activated) ATM starting from 9 hours) 
was detected. However, similar to the microarray findings in Chapter 4, a 
slight down-regulation in the NHEJ repair pathway (decrease in 
phosphorylated DNA-PKcs from  
Figure 40. Plumbagin alters the DNA damage response pathways significantly 
in time dependant studies. Plumbagin treated cells were harvested for 
immunoblotting after 0, 3,6,9,12,24 and 48 hours of treatment followed by another 
24 hours for recovery. (A) The blots were probed with different DNA damage 
response proteins and compared to understand the molecular kinetics in Plumbagin 




Figure 41. Plumbagin alters the DNA damage response pathways significantly 
in time dependant studies. Plumbagin treated cells were harvested for 
immunoblotting after 0,3,6,9,12,24 and 48 hours of treatment followed by another 
24 hours for recovery. (B) Densitometry of some of the obtained blots were done 
using the ImageJ software. Data is shown by the fold change of the proteins 
expression. 
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12 hours) was observed upon Plumbagin treatment (Figure 41). 
Plumbagin-induced changes in both pathways were reversible as shown 
by the recovery of DNA repair proteins to basal level after 24 hours. 
Impact of Plumbagin on SSB-response pathway showed to be 
inert in MDA-MB-231 cells, as exhibited by the relative steady expression 
levels of PARP-1 in this cell type. However, a slight irreversible increase 
was observed starting from 24 hours treatment in MCF-7 cells, validating 
the microarray data in Chapter 4. 
In spite of the findings in MDA-MB-231 cells, both SSB and DSB 
pathways were gradually modulated in MCF-7 cells by Plumbagin 
treatment (Figure 41). Interestingly, for all the biomarkers, pATM, pDNA-
PKcs, γH2AX and PARP-1, the peak of significant expression levels 
seemed to be at 48 hours of treatment compared to previous time points, 
suggesting a slight delay in the activity of repair pathways as compared 
to that in MDA-MB-231 cells. The up-regulation of all four markers was 
detected neutralized following the 24 hours of recovery at 72 hours for 
MCF-7 cells. 
The observation that both ATM and DNA-PKcs repair proteins 
were constant at all time points in all the three cell types is indicative of 
no sensitivity of these proteins towards Plumbagin treatment at the basal 
level.  
Taken together, this study showed that Plumbagin induces the 
DSB signalling pathways as shown by up-regulated γH2AX and mainly 
through alteration of HR, in breast cancer cells. ATM was shown to be 
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the main kinase that phosphorylates H2AX protein to γH2AX, upon 
Plumbagin treatment.   
In contrast, the single strand break or double strand break 
response pathways (especially NHEJ) either were not modulated or 
depicted low variation upon kinetic studies of Plumbagin in both cell 
types. These findings suggest that combined with Plumbagin treatment, 
targeting SSB and NHEJ signalling pathways, correspondingly through 
PARP-1 and DNA-PKcs kinase inhibition could be a proper therapeutic 
modality. 
5.1.3. Plumbagin alters the telomere dynamics slightly, but does 
not affect the hTERT protein level in kinetics studies 
To inspect the kinetics of Plumbagin on telomere/telomerase 
equilibrium, expression levels of POT1, TRF2 and hTERT were 
calculated upon short-term treatment.  
Figure 42 seemed to suggest a slight or no effect on protein 
expression for hTERT (122 kDa), TRF2 (66kDa) and POT1 (71 kDa) 
throughout 48 hours treatment with Plumbagin in all the cell types 
compared to their respective actin controls. However, for POT1 level, 
despite there being no apparent change in MDA-MB-231 cells, a slim up-
regulation was seen in MCF-7 and MCF-10A cells during 48-hour 
treatment with Plumbagin, validating the microarray data in Chapter 4. 
This suggests that Plumbagin might not modulate the telomere dynamics 
effectively following short term treatment.  
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Based on the findings and in light of telomerase being the hallmark 
of cancer, this idea arises that its inhibition could lead to synergistic 
effects along with Plumbagin treatment resulting in a more targeted and 
efficient combination therapy. It is worth of mention that this selection 
appears more crucial with respect to the fact that telomerase activity is 
mainly specific to cancer cells but not detected in the normal cell 
counterparts. 
The absence of DNA-PKcs, PARP-1 and telomerase in cells 
treated with Plumbagin might result in an increased susceptibility towards 
a co-treatment of Plumbagin with any of these enzymes. 
Accordingly, the next investigations aim to study the effects of dual 
treatments of Plumbagin with inhibition of either of the factors PARP-1, 
DNA-PKcs and telomerase. 
 
Figure 42. Plumbagin modifies the telomere dynamics slightly, but does not 
affect the hTERT activity in kinetic studies. Cells were treated with Plumbagin at 
IC50 doses for different time points within 72-hours study and the proteins were 





5.2. PARP-1 inhibition by PJ-34 induces cell resistance towards 
cytotoxic effects of Plumbagin 
5.2.1. Background 
PARP inhibitors are being investigated as a mono-therapy for the 
treatment of patients with BRCA1/2 mutations and in the treatment of 
triple-negative breast cancer, because of its molecular similarities 
to BRCA1-mutated malignancies; and as a strategy to potentiate the 
DNA-damaging effects of chemotherapeutic drugs (Foulkes et al., 2003, 
Jacinto and Esteller, 2007, Turner and Reis-Filho, 2006).  
PARP-1 is responsible for the repair of DNA single strand breaks 
and PARP-1 inhibition causes an increase in persistent SSBs. When 
SSBs are encountered by replication fork, a fork collapse will happen 
followed by the formation of DSBs, which are repaired by HR. In the case 
of excessive SSBs, resultant collapsed replication forks and 
accumulation of DSBs, the HR-deficient cells exposed to PARP inhibitors 
are unable to maintain the integrity of their genome and become non-
viable (Underhill et al., 2011). 
PJ-34 is a potent PARP-1 inhibitor which was reported to enhance 
chemotherapeutic effects in certain types of tumours including breast 
cancer cells (Huang et al., 2008, Hastak et al., 2010, Michels et al., 2013, 
Lavarone et al., 2013, Magan et al., 2012, Chevanne et al., 2010).   
According to the findings in Chapter 3, showing that Plumbagin is 
a DNA-damaging phytochemical to breast cancer cells, we hypothesised 
that combined treatment of Plumbagin and PARP-1 inhibitors might be a 
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promising approach for breast cancer and specifically the TNBC 
treatment (Figure 43). 
 
5.2.2. PARP-1 inhibitor reduces breast cancer cell proliferation 
To examine the impact of PJ-34 on cell survival, cells were treated 
with series of PJ-34 concentrations (0, 10, 20, 30, 40 µM) for 24 hours. 
TNBC MDA-MB-231 cells exhibited the highest rate of sensitivity towards 
PJ-34 treatment (Figure 44), to the extent that at 20 µM cells reached 
about 40% of the inhibitory dose after 24 hours. Even so, correspondingly 
MCF-7 and MCF-10A cells were sensitized by PJ-34 cytotoxicity less than 
MDA-MB-231 cells. Therefore, similar to previous findings, the 10 µM 
inhibitory dose was selected for the subsequent experiments (Mayor, 
2004, Inbar-Rozensal et al., 2009).                                        
 
5.2.3. Dose-dependent decrease in the levels of PARP-1 cleavage 
upon treatment with PJ-34 
To find out the protein expression level of PARP upon treatment 
with PJ-34, cells were subjected to PJ-34 at 0, 10 and 20 µM doses for 
24 hours and western blotting was performed. As illustrated in Figure 45, 
PJ-34 treatment leads to down-regulation in the levels of PARP cleavage 




Figure 44. Hypothesis for co-treatment of Plumbagin and PARP-1 inhibition in 
breast cancer cells.  According to the data shown in this study, Plumbagin is a 
DNA-damaging phytochemical to cancer cells and specially TNBC and therefore we 
hypothesize that PARP-1 inhibition might specifically amplify the DNA damaging 
effects of Plumbagin in breast cancer cells. 
Figure 43. PJ-34 reduces the cell viability of breast cancer cells in a dose 
dependant manner. Crystal violet cell viability assay was carried out on cells, 








5.2.4. PARP-1 inhibition exerts antagonistic effects on Plumbagin 
cytotoxicity in breast cancer cells 
 Next, breast cancer cells were pre-incubated with PJ-34 at the 
PARP-1 inhibitory dose of 10 µM for 24 hours, followed by 48 hours of 
treatment with Plumbagin at doses ranging from 0-10 µM. As 
demonstrated by the crystal violet (Figure 46) and cell morphology 
findings (Figure 47), It was observed that combination treatment with PJ-
34 increases the survival of all cell types, when compared to Plumbagin 
treatment alone (Figures 16 and 17),  
TNBC MDA-MB-231 cells are more sensitive to Plumbagin, 
(Figure 16), and PJ-34 (Figure 44) than the luminal breast cancer cell 
type MCF-7 cells because TNBC cells are defective in BER. Nonetheless, 
in case of PJ-34 and Plumbagin combination, the half inhibitory dose of 
Plumbagin, rose to higher doses of 7 and 7.5 µM for MDA-MB-231 and 
MCF-7 cells, respectively. As for MCF-10A, after the combination 
Figure 45. PARP inhibitor PJ-34 reduces the PARP cleavage activity in 
breast cancer cells. Cells were treated with PJ-34 at at 0, 10 and 20 µM 
doses and immunoblotting was carried out for PARP and its respective β-actin 
protein after 24 hours treatment. 
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treatment, the viability of cells did not display any reduction within the 
range of 0-10 µM of Plumbagin (Figures 46 and 47). Though compared 
with the findings of Inbar-Rozensal and colleagues (Inbar-Rozensal et al., 
2009), who showed that PJ-34 cause cell death in MCF-7 and MDA-MB-
231 human breast cancer cells, without impairing normal proliferating 
human epithelial MCF-10A, these data appeared to be contradictory. 
These findings suggest that the synergistic effect of PJ-34 and 
Plumbagin reflect inefficient nucleotide excision repair to result in cell 
death; to the extent that PJ-34 may exert antagonistic effects on 
Plumbagin sensitivity.  
Figure 46. PJ-34 exerts antagonistic effects on Plumbagin cytotoxicity 
through cell viability. Cells were pre-treated with 10 µM P-34 for 24 hours and 
then exposed to a range of Plumbagin concentrations. Subsequently, after 48 




Figure 47. Cell morphology representation of combined treatment of 
Plumbagin and PJ-34. After 24 hours incubation with PJ-34 at 10 µM dose, cells 
were treated with Plumbagin for 48 hours at doses 0, 1, 2,4,6,8 and 10 µM. 
Thereafter, cell morphology assay was conducted to study the morphology of 
combination results at 100 X magnification. 
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5.3. Cytotoxicity of Plumbagin in breast cancer cells is 
synergistically increased by NU7026-mediated inhibition of DNA-
PKcs  
5.3.1. Background 
In Chapter 3 it was shown that Plumbagin induces DSBs, leading 
to apoptosis. Plumbagin, due to the presence of a quinone moiety, has 
been reported to generate ROS (Inbaraj and Chignell, 2004) and ROS 
has been implicated to play a role in the apoptotic process (Srinivas et 
al., 2004). It has been revealed that apoptosis-inducing properties of 
Plumbagin contribute to the ROS-mediated inhibition of topoisomerase II 
(Topo II) (Kawiak et al., 2007, Fujii et al., 1992). The mode of Topo II 
inhibition by Plumbagin has been reported to be through the stabilization 
of the Topo II–DNA cleavable complex (Fujii et al., 1992). 
NU7026, as a novel DNA-PKcs inhibitor, is proved to potentiate 
the cytotoxicity of Topo II poisons used in the cancer chemotherapeutics 
(Willmore et al., 2004). It is speculated that DNA-PKcs is required by cells 
to repair the DNA damage caused by Plumbagin and therefore, the 
chemical inhibition of DNA-PKcs by NU7026 in cells renders higher 
sensitivity to Plumbagin induced DSBs and subsequent genomic 





5.3.2. DNA-PKcs inhibitor limits cancer cells proliferation 
To explore the effect of NU7026 on growth of breast tumour cells, 
initially cell viability assay was applied following treatment with increasing 
doses of NU7026 (0-20 µM) for 24 hours. Increasing doses of NU7026 
treatment resulted in a dose-dependent decrease in cell proliferation as 
compared to the control (Figure 48). In general, at 10 µM, there was 20-
45% reduction in the cell survival of all cell types. MDA-MB-231 cells 
again demonstrated the greatest sensitivity towards NU7026 treatment. 
Based on the findings of this study and together with previous reports 
(Amrein et al., 2007, Toulany et al., 2008, Willmore et al., 2004), the dose 
of 10 µM NU7026 was selected for subsequent studies. 
 
Figure 48. Inhibition of DNA-PKcs in breast cancer cells result in lower cell 
survival. Cells were treated with a range of NU7026 concentrations for 24 hours to 
study the cytotoxicity DNA-PKcs inhibition in breast cancer cells. Thereafter, they 
were subjected to crystal violet cell viability assay. 
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5.3.3. Inhibition of DNA-PKcs together with Plumbagin treatment 
induces cell cycle arrest, cell death and suppresses the 
clonogenicity of cells 
To determine the generated cytotoxicity obtained from combined 
treatment of Plumbagin and DNA-PKcs inhibition, after 24 hours pre 
incubation of cells with 10 µM NU7026, cells were treated with Plumbagin 
at their IC50 doses for 48 hours and subsequently were stained with PI 
and subjected to FACS analysis. For dual treatment, increase in the sub-
G1 population was significantly higher in MCF-7 and and MCF-10A cells 
(Figure 49A), representative of DNA fragmentation and thus cell death. 
However, MDA-MB-231 cells were more resistant to the combination-
induced cell death as low levels of sub-G1 population were detected as 
the same level as NU7026 treatment alone. From the cell cycle profiles, 
it can be seen that the dual treatment also induced an increase in the 
G2/M population in the relative normal MCF-10 cells, corresponding to 
cell cycle arrest accompanied by a consequent decrease in the G1 
population. MDA-MB-231 and MCF-7 cells on the other hand displayed a 
considerable decrease in G2/M population with a related increase in G1 
population. This observation shows that Inhibition of DNA-PKcs together 
with Plumbagin treatment not only triggers cell death, but even more 
induces cell cycle arrest predominantly at the G1 phase of the breast 
cancer cell cycle. 
As a follow-up to cell cycle analysis, all the cell types underwent 
the dual treatment and 2 X 103 cells were reseeded in drug-free media 
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for 14 days to study colony formation ability after drug treatment. As 
shown in Figure 50, the numbers of colonies formed by all the cell types 
were reduced in combination treatment as compared to NU7026 and 
Plumbagin treatments alone. The cytotoxic effects of NU7026 as 
represented by the number of colonies seem to be less than Plumbagin 
after 14 days recovery. 
Overall, this data suggests that the cell cycle arrest triggered by 
Plumbagin induced-damage in cells with inhibited DNA-PKcs, prevents 
further proliferation. Interestingly, the results obtained from this 
clonogenic assay showed MCF-7 cells to be most affected in terms of 
colony forming ability after drug treatment, consistent with the higher 
population at sub-G1 phase of cell cycle. 
Western blotting was performed to validate the observations of the 
cell cycle arrest as reported earlier, by protein expression analysis of 
Cyclin B1 in breast cancer cells, MCF-7 and MDA-MB-231. Furthermore, 
the protein expression level of pro-apototic protein caspase-3 was 
evaluated. In both cells, Plumbagin and NU7026 exhibited synergistic 
effects on promoting G2/M arrest by the down-regulation of Cyclin B1 
protein level after the dual treatment as compared to Plumbagin alone. 
Although MCF-7 cells do not express caspase-3 (Liang et al., 2001), 
NU7026 seemed to maintain the promoted effects of Plumbagin on 
apoptosis through caspase-3 in MDA-MB-231 cells, as there was 
continues enhanced expression of this protein upon dual treatment 
(Figure 49B). This is suggestive of the fact that NU7026 might exert its 
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apoptotic effects through caspase-dependent pathways in MDA-MB-231 
breast cancer cells.  
 
Figure 49. Dual treatment with Plumbagin and DNA-PKcs inhibition triggers 
the cell death of human breast cancer cells more effectively than non-
cancerous cells. Cells were pre-treated with 10 µM NU7026 for 24 hours and then 
exposed to a range of IC50 doses of Plumbagin. After an overall of 72 hours 
treatment (A) cell cycle assay was performed following (B) protein expression 
analysis of Caspase 3 and CyclinB1 in breast cancer cell lines. Blots were probed 

























Figure 50. The density of cells colonies following dual treatment with 
Plumbagin and DNA-PKcs inhibition. Cells were pre-treated with 10 µM 
NU7026 for 24 hours and then exposed to IC50 dose of Plumbagin for 48 hours. 
Subsequently, cells were allowed to grow for 14 days in fresh medium. The 
different densities following single or combined treatment with NU7026 revealed 




5.4. Telomerase inhibition by MST-312 sensitises breast cancer 
cells to Plumbagin treatment 
5.4.1. Background 
The current approaches towards cancer drug design are to 
develop ones, which will target cancer cells and eliminate them more 
precisely, while leaving adjacent normal cells unaffected. Telomerase is 
broadly expressed in most of human cancers, yet undetectable in somatic 
cells, suggesting an exciting target. Recently, number of 
pharmacogenomic strategies such as antisense oligonucleotides, RNA 
interference, ribozymes, mutant expression, and the exploitation of 
differential telomerase expression have focused on telomerase inhibition 
modalities in breast cancer treatment (White et al., 2001, Melana et al., 
1998, Multani et al., 1998). However, their most significant role is more 
evident not as stand-alone pharmaceuticals but as part of a coordinated 
treatment plan in conjunction with different chemotherapeutic agents. 
Telomerase inhibition has been shown to boost the response to anti-
cancer therapeutics in human breast cancer cells (Cerone et al., 2006).  
In Chapter 3 telomerase inhibitory effects of Plumbagin were 
demonstrated upon long term chronic treatment of 32 days. We here 
hypothesise that Plumbagin may exert a more effective targeted therapy 
in combination with telomerase inhibition, by implementing its DNA 
damaging potential, after a shorter period of time in breast cancer cells.  
MST-312, which is a synthetic derivative of tea-catechin, was 
reported to inhibit the telomerase enzyme activity (Seimiya et al., 2002). 
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It blocks the cell cycle at the G2/M phase, increases pH2AX protein level, 
and induces apoptosis in lung cancer cells. MST-312 also provokes 
G2/M cell cycle arrest and acute ATM-pathway-dependent DNA damage 
in astrocytoma cells (Wong et al., 2009). 
In this section, it is sought to investigate the anti-cancer effects of 
combinatorial approach on targeting telomerase by MST-312 and 
Plumbagin treatment, in TNBC MDA-MB-231 and luminal MCF-7 breast 
cancer cells as compared to the relative normal MCF-10A cell type. 
These combinatorial experiments were set for short-term (48 hours) and 
long-term (14 days) studies to inspect the cell viability, DNA damage, 
telomere/telomerase equilibrium, cell morphology, clonogenicity, cell 
cycle, immunofluorescence, genome stability and protein expression 
levels of these cells, upon dual treatments. 
5.4.2. MST-312 treatment slightly reduces the cell proliferation 
capacity  
The crystal violet cell viability assay is exploited to assess the 
toxicity of MST-312 to cells after 24 hours. Figure 51 shows a 
concentration dependant drop in cell intensity of breast cancer and 
normal cells, signifying dose dependant toxicity, which was more 
observed in the MCF-10A cells. Nevertheless, in breast cancer cells, the 
overall cell survival rate was not significantly affected in the presence of 
MST-312 for the range of 0-5 µM after 24 hours. 
Earlier studies have shown that 1 μM MST-312 effectively reduces 
telomere length in cancer cells (Wong et al., 2010, Qazi et al., 2010, 
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Serrano et al., 2011). According to the data of this study, demonstrating 
the relative non-toxicity for 1 µM dose of MST-312 and together with other 
studies, this dose was considered as the main dose of MST-312 in most 
of the subsequent studies. 
 
5.4.3. Telomerase inhibition sensitizes the breast cancer cells to 
Plumbagin-induced cell death  
To examine the effect of Plumbagin, combined with the telomerase 
inhibitor MST-312 on the survival of breast cancer cells, morphological 
observation and crystal violet assays were conducted (Figure 52). Cells 





















Figure 51. Cytotoxicity of MST-312 in breast cancer cells and MCF-10A. After 
24 hours of treatment with MST-312, cells were subjected to crystal violet cell viability 
assay. The Y-Axis represents the percentage of reduction in cell survival compared 
to control.  
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were pre-incubated with MST-312 (1μM) for 24 hours prior to Plumbagin 
(IC50 doses) exposure to ensure that telomerase inhibitor has exerted its 
effects before Plumbagin becomes effective.  The percentage of cell 
viability was normalized to results from non-exposed cells (control). With 
Plumbagin treatment alone, the viability of cells reduced to about 53% for 
respective IC50 doses of each cell type, validating the IC50 doses selected 
in previous section. MST-312 treatment of 1 μM reduced the viability of 
the cells by 13 % in MCF10-A, 40 % in MDA-MB-231 and 25 % in MCF-
7. In combination treatment, there was about 50% reduction in MCF-7 
and MCF-10A, and 67% reduction in MDA-MB-231 cells, with more 
floating and rounded features, as the manifestations of dying cells. The 
cytotoxic effect of dual treatment of MCF-7 and MCF-10A cells was 
similar to that of Plumbagin single treatment. Interestingly, reduction in 
MDA-MB-231 cell viability was 20% greater in dual treatment; compared 
to Plumbagin single treatment. 
To explore the clonogenic ability of telomerase inhibited cells after 
Plumbagin treatment, colony formation essay was conducted in MDA-
MB-231 and MCF-7 breast cancer cells. After 24 hours of pre-treatment 
with MST (1μM) and a subsequent 48 hours treatment with Plumbagin 
(IC50), the cells were allowed to recuperate in drug-free medium for 14 
days. Only the cells which survived the treatment were able to form 
colonies. Decrease in cell proliferation in colonies could be due to either 
cell cycle arrest or apoptosis caused by the treatment. As shown in Figure 
53, the Plumbagin reduced the colony formation ability in both cancer cell 
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types by 41 %, and 18% in MDA-MB-231 and MCF-7, respectively when 
compared to DMSO. However, to our surprise, MST-312 treatment 
decreased the number of colonies by 70 % and 72 % in MDA-MB-231 
and MCF-7 cells, respectively, in comparison to DMSO. A decrease of 
72 % in MDA-MB-231 and 86% in MCF-7 cells colonies over the 
combination treatment, suggested that MST-312 treatment impaired the 






Figure 52. Telomerase inhibition limits cell proliferation in Plumbagin 
treated cancer cells. Cells were pre-treated with MST-312 (1 μM) for 24 hours 
followed by Plumbagin (IC50) treatment for another 48 hours. Thereafter, they 
were subjected to: (A) cell morphology by light microscopy with the 
magnification of 100X showing cell death and lower cell density after dual 
treatment, and (B) crystal violet assay on the same cells indicated more 
reduction in cell survival upon co-treatment of Plumbagin and MST-312 in MDA-
MB-231 cells. The percentage of cell viability was standardized against DMSO 






































Figure 53. Plumbagin-MST-312 co-treatment decreased the clonogenic ability 
of cells. (A) In the colony formation assay, only drug-resistant cells are able to 
proliferate and form colonies after treatment. The rest of the cells are either arrested 
or underwent apoptosis progressively within the 14 days recovery period following 
the 48 hours treatment with Plumbagin (IC50) and MST-312 (1μM). (B) 
Representative image of colony formation capacity of breast cancer cells treated 





5.4.4. Telomerase inhibition produces significant synergistic 
apoptosis in breast cancer cells, when combined with Plumbagin  
Microscopic observation of cells treated with both telomerase 
inhibitor and Plumbagin showed indication of massive cell death as 
compared to mono-treatments. Presence of large number of floating cells 
after combined incubation period together with lower clonogenicity and 
survival rate in breast cancer cells implies a potential for cell apoptosis. 
Hence to evaluate the cell growth situation of combined treatments cell 
cycle studies were conducted using FACS methodology. Cell cycle assay 
was done after 14 days of treatment with Plumbagin (2/3rd of IC50) and 
MST-312 (MDA-MB-231: 0.5μM, MCF-7: 1μM). The results confirmed 
breast cancer cell apoptosis through the observed increase in the sub-
G1 population (Figure 54A). These observations also led to the other 
inference that MST-312 promotes both cells towards G2/M arrest. 
Interestingly, in MDA-MB-231, both Plumbagin and MST-312 exerted 
apoptotic effects and hence the combination treatment resulted in a huge 
synergistic level. While, mono-treatment with MST-312 in MCF-7 cells 
potentiated the G2/M arrest more, than Plumbagin treatment. However, 
after combination both sub-G1 and G2/M levels were up-regulated. 
To validate the cell cycle data, immunoblotting of respected 
proteins was performed (Figure 54B). The protein expression of Cyclin 
B1, as the indicative of G2/M arrest was reduced in both cells, and 
substantially in MCF-7, after dual treatment with MST-312 and 
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Plumbagin. To determine the possible involvement of p53 in inducing 
growth arrest, the expression of p53 and p21 was evaluated after all types 
of treatments. The level of p21 was reduced in MCF-7 cells after MST-
312 and subsequently more after the combination treatment; showing 
greater sensitivity towards MST-312 and Plumbagin combined treatment. 
Although, the overexpressed p53 is mutant in MDA-MB-231, but the level 
was decreased in MCF-7 cells. 
Taking these findings together, cell cycle analysis illustrated that 
MST-312 treatment arrested the cells mainly at G2/M as compared to 
Plumbagin, and the combined treatment of these two drugs led to 










Figure 54. Co-treatment of Plumbagin and MST-312 induces growth arrest 
and apoptosis in breast cancer cells. (A) Cell cycle profile of 14 days 
treatment with Plumbagin (2/3rd of IC50) and MST-312 (MDA-MB-231: 0.5μM and 
MCF-7: 1μM) in breast cancer cells, using propidium iodide staining and flow 
cytometry detection. Though MST-312 potentiates cell cycle arrest at G2/M 
phase, population of apoptotic cells is greater in combined treatment than in 
individual treatments. (*) indicates P <0.05 when compared to DMSO. (B) 
Changes in level of cell cycle regulatory proteins were also tested. Whole cells 
were lysed and equal amounts of proteins were separated using 10-12% SDS-
PAGE, transferred to PVDF membrane and immunoreacted with antibodies 
against p53, p21 and Cyclin B. β-actin was used as loading control. 
“Plum” denotes Plumbagin, “MST” signifies MST-312. D: DMSO control; P: 




5.4.5. MST-312 reduces the telomerase activity and shortens 
telomere length in Plumbagin-treated breast cancer cells, without 
impairing the hTERT protein expression 
To evaluate the effectiveness of telomerase inhibitor MST-312 on 
telomerase activity, TRAP assay was performed. The percentage of 
telomerase activity was shown to be interrupted by both mono-treatment 
and combined treatments of Plumbagin and MST-312 (Figure 55). In 
MDA-MB-231 cells, there was a reduction in telomerase activity by 21 %, 
24 %, and 44 % in comparison to DMSO control, correspondingly in 
Plumbagin, MST-312 and combination treatments. It can be interpreted 
that reduction in telomerase activity in combination is contributed to both 
telomerase inhibitor MST-312 and Plumbagin. In MCF-7 cells, 
telomerase activity decreased by 26 % (Plumbagin), 77 % (MST-312), 
and 84 % (combination) compared to DMSO control, which deduce that 
reduction in telomerase activity in combination treatment is mainly 
contributed to telomerase inhibitor MST-312. 
Decrease in telomerase activity can be due to interruption of the 
function of telomerase enzyme and/or down-regulation of the expression 
of telomerase enzyme. Even though there was a decrease in telomerase 
activity as seen in TRAP results, hTERT expression which is the catalytic 
subunit of telomerase enzyme, was not down-regulated (Figure 56). 
hTERT expression level in MDA-MB-231 and MCF-7 cells had no change 
or a slight increase in Plumbagin and combination treatment. This result 
i n d i c a t e s  t h a t  t e l o m e r a s e  a c t i v i t y  
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inhibition by MST-312 did not involve the down-regulation of hTERT 
expression level. This small inhibitor molecule specifically decreases the 
































Figure 56. MST-312 efficiently reduces the telomerase activity in breast 
cancer cells. Following 14 days of treatment with Plumbagin (2/3rd of IC50) and 
MST-312 (0.5 μM for MDA-MB-231 and 1 μM for MCF-7), the telomerase 
activity was detected by TRAP (telomeric repeat amplification protocol) assay. 
In MCF-7 combination treatment, more reduction in the percentage of 
telomerase activity was detected. (*) indicates P <0.05 when compared to 
DMSO control. 
Figure 55. MST-312 does not decrease the expression level of hTERT, the 
catalytic subunit of telomerase. hTERT expression level was determined 
compared to β-actin as the loading control, after 14 days of treatment with 
Plumbagin (2/3rd of IC50) and MST-312 (MDA-MB-231- 0.5μM and MCF-7- 




To investigate if the inhibition of telomerase activity was translated 
into reduction of telomere length, terminal restriction fragment analysis 
was done. The cells were treated for 14 days with Plumbagin (2/3rd of 
IC50) and MST-312 (MDA-MB-213: 0.5 μM and MCF-7: 1μM). As seen in 
Figure 57A and B, telomere reduction is observed across both breast 
cancer cell types following telomerase inhibition. In MDA-MB-231 cells, 
the telomere length of control cells, treated with DMSO, was observed as 
2444 bp and this length was further reduced by 112 bp in Plumbagin 
treated cells and 438 bp in co-treated cells after 14 days. In MCF-7 
telomere length decreased by 309 bp in Plumbagin treated cells and 1164 
bp in combination treatment compared to DMSO treated controls. 
Reduction in telomere length was 3 fold greater in MCF-7 combination 
treatment in comparison to control cells.  
TRF1 and TRF2 combat the telomerase activity, thereby restrict 
or inhibit telomere elongation (Smogorzewska et al., 2000, van Steensel 
et al., 1998). POT1 also regulates telomeric length acting as an activator 
or inhibitor of telomerase depending on the position of POT1 in the 3' 
overhang  (Baumann and Price, 2010). Therefore, the expression levels 
of these proteins were investigated in the same treated cell. 
Reduction in telomere length of MST-312-treated cells was 
corroborated by decreased protein expression levels of POT1, TRF1 and 
TRF2 through western blot in MCF-7 cells (Figure 57C). However, similar 
to Figure 42, TRF2 was up-regulated upon Plumbagin treatment, even 
after 14 days; hence the Plumbagin treatment results might interpret the 
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difference in the pattern of expression of POT1, TRF1 and TRF2 in 
combined treatment. 
As for MDA-MB-231 cells, Figure 57C did not show any 
considerable changes for POT1 and TRF1, but a slight up-regulation in 
the expression level of TRF2 was observed in the order of mono- and co-
treatments, as compared to the control cells. The reduction in telomere 
length could most probably be due to telomerase inhibition by MST-312 
in combination treatments rather than Plumbagin’s effects after 14 days.  
Taken together, these data highlighted that dual treatment with 
telomerase inhibition and Plumbagin induces the telomere attrition in 





































Figure 57. Co-treatment of Plumbagin and MST-312 induces more 
telomere shortening in cancer cells. Terminal Restriction Fragment (TRF) 
measuring telomere length after 14 days of treatment with Plumbagin (2/3rd of 
IC50) and MST-312 (MDA-MB-213: 0.5 μM and MCF-7: 1μM). (A) Southern 
blot analysis of telomeric regions. Analysis was done using Kodak imaging 
software. (B) Graphical presentation of the telomere length of samples 
compared to DIG marker (DM) and the high telomere control (HTC). (C) 
Western blot analysis on TRF1, TRF2 and POT1 proteins upon treatment. β-
actin was used as loading control. D: DMSO control; P: Plumbagin; M: MST-




5.4.6. Inhibition of telomerase in breast cancer cells results in 
elevated Plumbagin-induced DNA damage and telomere 
dysfunction  
To investigate the extent of DSB caused by Plumbagin (IC50) and 
MST-312 (1μM) treatment across DNA, as well as its specificity to 
telomere region after 48 hours of treatment, telomere dysfunction induced 
foci (TIF) analysis was performed (Figure 58). Presence of DSB was 
further validated through western blot analysis of γH2AX, with β-actin as 
reference. In TIF, DSB was represented by green γH2AX foci, telomere 
regions were denoted by red telomere probe and co-localisation (TIF) of 
both signals resulted in yellow dots.  
To detect the frequency of DSB occurring at telomeric regions, 
number of co-localized foci was counted. As shown in Figure 58B, 
average number of TIFs per cell in MDA-MB-231 upon Plumbagin 
treatment was 0.5 fold greater than untreated DMSO control cells, 
whereas in MCF-7, it was 1.3 times greater than DMSO. Upon MST-312 
treatment the number of TIFs in MDA-MB-231 cells was not considerable, 
though it increased by 0.8 fold in MCF-7 cells. In combination treatment, 
number of TIFs was 1.4 and 1.8 fold higher than in control cells in MDA-
MB-231 and MCF-7, respectively; inferring that telomerase inhibition 
enhances the probability of DSB incidences at the telomeres.  
Similar trend was observed for treatment-induced DBS, as shown 
in Figure 59A, indicating the average number of γH2AX foci in Plumbagin 
and combination treatment for both cell types. In MDA-MB- 231 cells 
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there was an insignificant increase in the average DNA damage upon 
MST-312, while there was about 5 fold increases in the average number 
of γH2AX foci for MCF7 cells. With respect to Plumbagin treatment, in 
MDA-MB-231 cells, the increase of γH2AX foci in combination treatment 
was 4-fold higher while interestingly, in MCF-7 cells this number declined 
by one. The findings of this study indicated that the DNA damage 
observed in combination treatment mostly contributes to Plumbagin in 
short term treatment.  
To validate the observations in TIF assay, western blot analysis 
was performed for γH2AX protein expression level. As compared to the 
corresponding β-Actin, in both cancer cell types the trend of γH2AX 
protein expression levels soar from Plumbagin to the combination 
treatment (Figure 59B). This was in line with the trends observed in TIF 
assay as seen previously. In consistent with the TIF findings and the trend 
of γH2AX foci, the phosphorylation level of γH2AX protein was less upon 
MST-312 and combined treatments in MCF-10A cells, suggestive of the 
fact that MST-312 might attenuate the DNA damaging potential of 
Plumbagin in normal cells. 
Once again, the observations of TIF together with the telomere 
attrition and telomerase inhibition were more altered in response to MST-
312 and accordingly in MST-312 and Plumbagin combined treatments in 
both cells highlighting that the mechanism of action of Plumbagin is more 


































Figure 58. Induction of telomere dysfunction following telomerase inhibition 
in Plumbagin treated cells. Colocalization of ɤH2AX and telomeres represents 
telomere dysfunction induced foci (TIF) after being treated for 48 hours with 
Plumbagin (IC50) and MST-312 (1μM). (A) Immunofluorescence image of TIF in 
control and treated cells. Bright yellow dots are visible in treated cells with 
colocalization. (B) Average number of TIFs per cells.  
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cells, while MST-312 affects the telomere dynamics mechanisms. 
To further examine the effects of telomerase inhibition on DNA 
damaging abilities of Plumbagin in breast cancer cells, immunoblotting 
was carried out for other key proteins involved in DDR pathways. 
The enhanced DNA damaging potential of Plumbagin in combined 
treatments was corroborated by higher expression levels of 
phosphorylated DNA-PKcs and phosphorylated ATM (Figure 60).  
In MCF-7 cells, PARP-1 expression level was increased in either 
of MST-312 and Plumbagin treatments, but when combined the protein 
expression seemed to be attenuated. Whereas expression level of pDNA-
PKcs increased in MST-312 and combination treatments compared to 
single exposure to Plumbagin. On the other hand, the expression levels 
of PARP-1 and pDNA-PKcs were relatively constant in MDA-MB-231 
control, Plumbagin, MST-312, and combination treatments. For the pATM 
protein expressions, data presented in Figure 60 seemed to suggest a 
slight up-regulation in the expression levels of this protein for both breast 
cancer cells, after 48 hours of single and co-treatment with MST-312, 



































Figure 59. MST-312 promotes the extent of Plumbagin-induced double 
strand breaks in human breast cancer cells. Cells were treated with 
Plumbagin (IC50) for 48 hours, followed by 24-hours pre-incubation with MST-
312 (1μM). Thereafter immunoblotting and immunocytochemistry detection of 
γH2AX was employed to measure the protein expression and average number 
of γH2AX foci, as a representative of double strand breaks. (A) Average number 
of γH2AX foci per cell, indicating presence of double strand breaks across the 
genome. (B) Western blot analysis of γH2AX protein expression level as 
compared to the β-Actin standard control. D: DMSO control; P: Plumbagin; M: 






Together the findings of this study confirm the earlier reports 
establishing the fact that MST-312 acts through activation of the 
ATM/pH2AX DNA damage pathway in short-term treatments of cancer 
cells (Serrano et al., 2011).  
Figure 60. MST-312 modulates the DNA damage response pathway 
proteins in breast cancer Plumbagin-treated cells. Representative blots for 
PARP, pATM and pDNA-PKcs proteins following 24-hours pre-incubation with 
MST-312 (1μM) and 48 hours treatment with Plumbagin (IC50). β-actin was 
used as loading control. Protein level alterations upon dual treatments were 
more evident in MCF-7 cells, compared to MDA-MB-231 cells. 




5.4.7. Telomerase inhibition of human breast cancer cells 
promotes the amount of Plumbagin induced chromosomal 
instability  
As demonstrated in Chapter 3, Plumbagin exposure resulted in 
telomere dysfunction after 32 days. It is speculated that the inhibition of 
telomerase in breast cancer cells may lead to enhanced Plumbagin-
induced chromosomal instability within 14 days; therefore PNA-FISH was 
performed to investigate genomic instability and chromosomal 
aberrations. Following 14 days of chemical inhibition of telomerase by 
MST-312 (MDA-MB-231: 0.5μM and MCF-7: 1μM) and Plumbagin 
treatment (2/3rd of IC50) in breast cancer cells, telomere associated 
aberrations were detected such as telomere signal loss, chromosome 
fusion without telomere signals (dicentric and tricentric chromosomes), 
multiple telomere signals, and also chromosome or chromatid breaks. As 
shown in Figure 61, there were about 12 %, 16 %, 17 % and 22 % total 
chromosomal aberrations observed in control, Plumbagin, MST-312, and 
combination treatments, respectively in MCF-7 cells. Whereas, in MDA-
MB-231 cells, correspondingly the total aberrations were 3 %, 5 %, 6 % 
and 8 % in control, Plumbagin, MST-312, and combination treatments. In 
both the cell types, the percentages of chromosomal aberrations were 
larger in combined exposures than in Plumbagin (single treatment group) 




Figure 61. Effects of combined treatment with MST-312 (telomerase inhibition) 
and Plumbagin on the chromosome stability. Peptide Nucleic Acid- Fluorescence 
in-Situ Hybridisation (PNA-FISH) was performed on breast cancer cells treated with 
Plumbagin (2/3rd of IC50) followed by pre-incubation with MST-312 (MDA-MB-231: 
0.5μM and MCF-7: 1μM). The findings are evidence of increase in chromosomal 




5.5. Discussion  
Plumbagin was shown to modify the DNA damage response 
pathways and telomere dynamics differently, one moderately and the 
other one significantly and displayed no effect on the hTERT protein 
expression in time dependant studies.  
The mechanism through which Plumbagin induces DNA damage 
is still not fully elucidated. Various proteins are involved in orchestrating 
DNA repair pathways: PARP is involved in repairing SSB, ATM in HR 
DSB repair and DNA-PKcs in NHEJ DSB repair. Upon sensing DNA 
damage induced by genotoxic agents, ATM, which is an inactive dimer or 
trimer undergoes autophosphorylation at serine 1981 and gets activated 
(Bakkenist and Kastan, 2003), whereas DNA-PKcs undergoes 
phosphorylations at several sites (Mi et al., 2009). Consequently, histone 
protein H2AX that is downstream of phosphorylated ATM and 
phosphorylated DNA-PKcs signalling pathways gets activated. Once 
ATM and/or DNA-PKcs is activated, H2AX translocates to nucleus and 
phosphorylates on Serine 139 to γH2AX which then localizes at DSB 
damage in DNA to allow repair mechanisms acting on the breaks 
(Rogakou et al., 1998). H2AX is part of the H2A histone family that is 
found in the nucleosomes of eukaryotic cells (Kuo and Yang, 2008). 
Upon Plumbagin treatment, expression levels of DNA repair 
proteins involved in DSB repair pathways, such as pATM and pDNA-
PKcs were shown to be up-regulated. This indicates that the type of DNA 
damage caused by Plumbagin is mostly DSB. The extent of DSB caused 
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by Plumbagin treatment was great as evident by the average number of 
γH2AX foci in treated cells. According to the findings of PNA-FISH and 
TIF studies, a major portion of this damage might be collocated with the 
impaired telomeres. In MDA-MB-231 cells, the repair mechanism for DSB 
may mainly involve HR, as pATM is up-regulated while pDNAPKcs does 
not show considerable changes. In MCF-7, both HR and NHEJ repair 
pathways were employed in repairing the DSB induced by Plumbagin. 
DNA damage induction upon treatment with Plumbagin, as a 
naphthoquinone, could be due to the generation of ROS (Srinivas et al., 
2004). ROS is known to induce DNA damage leading to cell cycle arrest 
and apoptosis (Inbaraj and Chignell, 2004). Hence, upon Plumbagin 
treatment, DNA repair proteins were recruited to higher levels in response 
to the induced damage. Nevertheless, this recruitment was not constant 
and in the absence of Plumbagin at the recovery period of 24 hours of 
kinetic studies, the expression level of these proteins declined. By the 
indication that Plumbagin-induced damage subsides and in order to 
potentiate the exogenous impacts of this phythochemical, further need 
for a combination treatment along with Plumbagin was emphasized.  
In consistent with earlier findings in the microarray gene 
expression studies, after 48 hours of Plumbagin treatment, the protein 
expression profile of PARP-1 and pDNA-PKcs decreased in MDA-MB-
231 and increased or did not change in MCF-7 cell lines. This might 
suggest that DNA DSBs formed by Plumbagin treatment can present a 
barrier to DNA replication, leading to persistent DNA DSBs in MDA-MB-
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231 breast cancer cells, while it triggers the DNA repair molecules in the 
MCF-7 cell line. 
Given the importance of DNA-PK in DNA DSB response, a 
specific, small molecule inhibitor of DNA-PKcs, NU7026, was used as a 
probe to examine the interplay among DNA-PKcs, cell cycle results and 
cell growth in Plumbagin-induced DNA DSB repair and apoptosis. The 
findings underscored a synergistic role of DNA-PKcs in regulating 
pathways involved in cell cycle progression, irreversible clonogenicity and 
apoptosis in DNA DSB response to Plumbagin. As indicated before, 
Plumbagin-induced DSB was characterized by the rapid formation of 
phosphorylated γ-H2AX foci and recruitment of the catalytic subunit, 
DNA-PKcs at DSB sites. Activated DNA-PKcs initiates NHEJ for DNA 
DSB repair. Inhibition of DNA-PKcs markedly increased Plumbagin 
induced-apoptotic cell death, along with irreversible diminishing the 
colony forming ability of cells. This data supported a critical role of DNA-
PKcs in the inhibition of Plumbagin-induced NHEJ repair in both breast 
cancer cells and specifically MCF-7. 
Our data revealed that NU7026 arrested the normal MCF-10A 
cells at the G2/M phase, by increases in the percentage of this stage as 
22.76%, 29.62%, 36.02% and 36.75% for the control, Plumbagin, 
NU7026 and Plumbagin-NU7026 treatments, respectively. While, it holds 
the breast cancer cell types more obviously at the G1 phase, blocking the 
replication of damaged DNA. For the control, Plumbagin, NU7026 and 
Plumbagin-NU7026 treatments, this trend was obvious for the MDA-MB-
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231 cell line as 54.57%, 61.89%, 69.24% and 71.63%, respectively and 
for MCF-7 cells as 62.86%, 62.39%, 76.50% and 69.31%, 
correspondingly.  
This impact was elicited to enhance the similar results of 
Plumbagin on the cells. 
It has been shown that inhibition of DNA-PKcs by NU7026 results 
in an increased expression of pro-apoptotic protein Bax and decreased 
expression of anti-apoptotic protein Bcl-2 in the presence of 
hydroquinone (You et al., 2013). We posit that activated DNA-PKcs 
affects the pro-apoptotic caspase-3 protein balance indirectly by 
promoting the repair of DSB, whereas NU7026 reverses the process to 
boost the expression of this protein. This study also revealed that 
Plumbagin induces the protein expression of caspase-3, in line with past 
reports (Seshadri et al., 2011, Khaw et al., Manuscript in preparation), 
and its combination with NU7026 maintains the induction of this protein. 
Given the role of caspase-3 in mediating apoptosis, induction of this 
protein promotes apoptosis and, thereby, contributes to the potentiation 
of cell killing by NU7026.  
Inhibition of PARP-1, by PJ-34, in combination treatments led to 
antagonistic effects on Plumbagin cytotoxicity in breast cancer cells. The 
results are in contrast to Hastak and colleagues, revealing that PARP-1 
inhibition by PJ-34 synergizes with gemcitabine and cisplatin in TNBC 
cells but not in luminal cancer cells (Hastak et al., 2010).  
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However, the manifested results might be the consequence of 
combination with Plumbagin, as a DNA-damaging agent which produces 
superoxide and hydrogen peroxide as products of its redox-cycling 
activity (Patridge et al., 2012). In light of this fact, these findings are 
comparable to the findings that combination treatment of PJ-34 and 
H2O2 was antagonistic in HCC1806 TNBC cell line (Sandvick et al., 
2010). On the other hand, it was established that PJ-34 induced growth 
arrest and cellular lethality is influenced by genetic background of the 
cells, dose and exposure time (Madison et al., 2011). In conclusion, PJ-
34 did not seem to potentiate Plumbagin’s cytotoxicity in breast cancer 
MCF-7 and MDA-MB-231 cells. 
Anticancer activity of Plumbagin against human breast cancer 
cells, including inhibition of cell growth and apoptosis induction, was 
shown to be partly due to inhibition of NF-kB/Bcl-2 pathway (Padhye et 
al., 2012). Throughout the combination studies on MST-312 and 
Plumbagin treatment, interestingly, it was found that Plumbagin exerts 
efficient anti-cancer effects on the highly resistant and metastatic MDA-
MB-231 breast cancer cells. In MDA-MB-231 cells, the combination 
treatment of Plumbagin with MST-312 had noteworthy effects in both 
short term and long term studies. Treatment with MST-312, a telomerase 
inhibitor, sensitized the MDA-MB-231cells to Plumbagin treatment 
following both short term and long term exposure. This could probably be 
due to the shorter basal telomere length in MDA-MB-231 cells compared 
to MCF-7 as observed in control results. It was reported by Hemann and 
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colleagues that it is not the average telomere length, but rather the 
critically short telomeres, which trigger cellular responses to the loss of 
telomere function (Hemann et al., 2001). The lag phase, which is required 
to critically shorten the telomere length, would be less for shorter 
telomeres. Furthermore, based on the immunocytochemistry 
observations, Plumbagin treatment showed greater genotoxic 
consequences in MDA-MB-231 cells. Plumbagin possibly affects cell 
density by inhibiting cell growth or inducing cell death as observed in cell 
cycle assay. In long term treatment, Plumbagin and MST-312 single 
treatments caused G2/M phase arrest while Plumbagin and MST-312 
combination treatment more obviously led to increased apoptosis.  
In MCF-7 cells, the combination treatment with MST-312 yielded 
almost equal cytotoxic effects as Plumbagin single treatment in short 
term. This was observed in both cell viability and TIF experiments, where 
the observed cytotoxic and genotoxic effects in the combination treatment 
could also be contributed to the presence of Plumbagin. In these short 
term studies the less sensitization of MCF-7 cells towards MST-312 
treatment could be due to longer lag phase which MCF-7 requires 
because of its longer telomere length. Noteworthy, after 14 days of 
treatment, MCF-7 cells were more affected in combination treatment than 
single treatments with Plumbagin. This indicates that MST-312 has 
begun to show its effects along with Plumbagin in combination treatments 
after 14 days. It was reported by Seimiya and colleagues  that when cells 
are treated with telomerase inhibitor, those with longer telomeres would 
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require more doubling time to exhaust telomeric sequence compared with 
cells with shorter telomeres (Seimiya et al., 2002). It was monitored in 
Chapter 3 that MCF-7 cells have longer population doubling time. 
Furthermore, TRF findings also showed longer basal telomere length for 
MCF-7 cells, which collectively might point to one of the main reasons for 
the difference of cellular responses of MDA-MB-231 and MCF-7 cells to 
combination treatments in short term and long term studies. Furthermore, 
both cell types are known to be genetically distinct in many ways, as 
explained in the previous Chapters. Therefore, the response to 
combination treatment varies between the cell types and it is time 
dependent. MCF-7 cells require longer time than MDA-MB-231 cells to 
respond in combination treatment compared to Plumbagin treatment 
alone. Though there is longer lag phase observed in MCF-7 cells due to 
longer telomere length, Plumbagin continue to induce DNA damage, 
making the combination treatment more efficient.  
The cytotoxic effects of Plumbagin and MST-312 combination 
treatments appeared to be irreversible, unlike that of Plumbagin single 
treatments as discussed earlier. Only cells that were resistant to the 
Plumbagin and MST-312 treatments during short term exposure were 
able to form colonies. Other cells were either arrested or underwent 
apoptosis. However the results indicated that very few cells were able to 
form colonies in combination treatment in both cell types, even though 
the treatment was terminated after 48 hours and the cells were allowed 
to recuperate in drug-free medium for 14 days. This shows that the 
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inflicted damage by combination treatments were too extensive that the 
cells were not able to repair or overcome the cell cycle arrest. Such 
deleterious damages could not only have targeted DNA but also caused 
damage to other cellular components (Roos and Kaina, 2006). 
Reduction in telomerase activity was mostly contributed to 
telomerase inhibition in both cells. In MCF-7, the reduction in telomerase 
activity has led to telomere attrition. Depletion in the telomerase activity 
rate of MCF-7 cells was 5 folds from the control cells to combined treated 
ones with Plumbagin and MST-312, though the rate of telomere 
shortening was slower. When telomerase activity is inhibited, cancer cells 
would face the end replication problem similar to normal cells due to 
absence of telomerase activity. In such case, the end replication problem 
still exists because of the dependence of DNA polymerases on primers. 
Therefore, the unidirectional 5' to 3' DNA replication will again face 
problem to complete the replication of eukaryotic chromosome ends and 
hence telomere length will again reduce in every round of cell division 
(Harley et al., 1990, Levy et al., 1992, Rodier et al., 2005).  
As manifested by the results, when cells were treated with 
Plumbagin and MST-312 single treatments, they were arrested at G1 
phase in MCF-7 cells, which ensured that damaged DNA would not 
replicate. This infers why the number of cells undergoing cell division in 
Plumbagin and MST-312 co-treated cells was much lower than that of 
controls. This might also explain how the rate of telomere length attrition 
was not commensurate with rate of telomerase activity reduction in MCF-
194 
 
7 cells. In long term treatments of MCF-7 cells, the reduction in telomere 
length, though slow, but together with the relevant cytotoxic effects were 
significant enough as evident by the increase in TRF1 and POT1 protein 
expression levels in combination treatments. POT1 is 
a negative regulator of telomerase activity (Kelleher et al., 2005). TRF1 
negatively regulates telomere length and it was reported that 
overexpression in TRF1 (Munoz et al., 2009) or overproduction of wild 
type TRF1 induces telomere shortening (Iwano et al., 2004, van Steensel 
and de Lange, 1997). POT1 binds the 3’-overhang, whereas, TRF2 
directly binds the double-stranded telomeric DNA; and both protect 
telomeres from DDR by representing the ATM and ATR kinase signalling 
pathways, respectively.  
In both MCF-7 and MDA-MB-231 cells, single treatment with 
Plumbagin showed up-regulation in the expression levels of TRF2. This 
may be due to DNA damaging properties of Plumbagin proving the 
information that upon DNA damage, telosome reacts by up-regulating the 
TRF2 expression and telomerase activity in malignant cells. It was shown 
that this up-regulation of TRF2 protein expression might act as 
antiapoptotic mechanisms in the DDR of malignant cells (Klapper et al., 
2003). Telomerase inhibition by MST-312 single treatment did not modify 
the TRF2 expression level in MCF-7 cells; though in MDA-MB-231 cell 
type, it resulted in the increased trend of TRF2, both at the single 
exposure or as combined with Plumbagin treatment. This might be due 
to the pure epithelial nature of MDA-MB-231 breast cancer cell types 
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(Cailleau et al., 1974), since it was verified that telomerase abrogation 
accelerates TRF2-induced epithelial carcinogenesis (Blanco et al., 2007). 
Furthermore, it has been illustrated that telomerase inhibition might not 
be effective to cease the growth of TRF2-overexpressing tumours 
(Blanco et al., 2007). Both TRF1 and TRF2 were reported as negative 
regulators of telomere length and their down-regulation was shown to be 
important to maintain telomeric DNA in cancer (Yamada et al., 2002). 
Therefore, their up-regulation might disturb the telomere dynamics. 
Regarding the genotoxicity and cytotoxicity of each drug, MCF-7 
cells were mainly prone to Plumbagin, especially in short term studies, as 
it was evident in TIF and cell cycle sub-G1 population number, 
respectively. In these findings apoptosis was more observed in 
Plumbagin single treatments than MST-312 ones. However, synergistic 
effects of MST-312 and Plumbagin treatments after 14 days were 
noticeable; and might have also been more effective if the duration of 
studies was longer.  
On the contrary, as for MDA-MB-231 cells, the genotoxicity and 
cytotoxicity of treatments were synergistically exerted by genotoxic 
effects of Plumbagin and telomere dysfunction through telomerase 
inhibition of MST-312. Telomerase involvement in long term maintenance 
of telomere length and chromatin structure might potentiate its response 
to genotoxic stimuli. It was reported by Tamakawa and colleagues that 
telomerase positive breast cancer cells, respond to genotoxic agents in a 
cell cycle stage–specific manner: telomerase activity can increase cell 
196 
 
survival by alleviating the toxic effect of genotoxic agents that are 
predominantly active in G2 phase of the cell cycle (Tamakawa et al., 
2010). Hence when DNA damage is induced in S/G2 phase of the cell 
cycle, telomerase inhibition increases the cytotoxicity of a genotoxic 
stimulus (Tamakawa et al., 2010). Furthermore, it has been reported 
earlier that telomerase inhibition increased the susceptibility of malignant 
glioblastoma cells to Cisplatin-induced apoptosis (Kondo et al., 1998, 
Seimiya et al., 2002). The findings of this study are consistent with above 
reports (Kondo et al.1998 and Seimiya et al 2002), were Plumbagin and 
telomerase inhibitor MST-312 treatments impacted greatly and 
synergistically on the telomerase activity inhibition, apoptosis rate and 
cell viability of MDA-MB-231 cells. Cell cycle assay showed that 
Plumbagin-induced DNA damage occurs at G2 phase. Accordingly, 
combining the telomerase inhibitory effects of MST-312 with Plumbagin 
increased the cytotoxicity and genotoxicity of the MDA-MB-231 cells in 
both short and long term studies.  
Similar to the earlier findings and the microarray results in Chapter 
4, PARP-1 response was up-regulated in Plumbagin-treated MCF-7 cells, 
but inert in MDA-MB-231 cells. However, the cellular reaction of PARP-1 
towards MST-312 treatments was ruled out in both the cell types, as 
evidenced by the steady level of protein expression throughout the 
exposure. However, it was presented that the protein levels of both pATM 
and pH2AX were elevated upon combined treatment of Plumbagin and 
MST-312 in MDA-MB-231 and MCF-7 cells. The higher levels of these 
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two proteins could be believed to be due to MST-312 impact to large 
extents, as it was evident in immunoblotting findings of this telomerase 
inhibitor single treatment. These observations substantiate the report that 
MST-312 performs through activation of the ATM/pH2AX DNA damage 
pathway in short term-treated cancer cells (Serrano et al., 2011). 
The total number of aberrations which was mainly due to telomere 
signal loss was corroborated by TIF assay. This association advocated 
that upon combination treatment with Plumbagin and MST-312, the DSB 
DNA damages were colocalized at the telomere sites leading to more 
critical cancer cell genome instability. Genotoxic effects of Plumbagin 
treatment led to DSBs across genome and specifically at telomeric 
regions. Moreover, with MST-312 combination, it was observed more 
telomere instability such as telomere signal loss, chromosomes with 
multiple telomere signals, and chromosome fusions without telomere 
signals resulting in dicentric and tricentric chromosomes. Telomere 
attrition followed by telomerase inhibition and DSBs at telomeric regions 
resulted in deprotection of chromosome ends and eventually 
chromosomal fusion. This could most likely be due to the fact that the 
dysfunctional telomere repeats were too short for the efficient binding of 
telomere associated proteins such as TRF2 (Broccoli et al., 1997). Short 
telomeres would then evoke DNA repair activities that would result in 
chromosome fusions, most likely to be mediated by NHEJ repair 
mechanism (Smogorzewska et al., 2002). 
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 It was reported by Hemann and colleagues that the chromosome 
fusion junction sequence contains microhomology characteristic of NHEJ 
events, which is in agreement with a model in which telomere dysfunction 
results in transient chromosome end degradation followed by NHEJ-
mediated fusion of broken chromosome ends (Hemann et al., 2001). 
Increase in phosphorylated DNA-PKcs expression level in MCF-7 cells 
and constant expression level in MDA-MB-231 cells was also observed. 
Phospho-DNA-PKcs is involved in NHEJ repair mechanism as mentioned 
previously. Hence, more telomere related chromosome dysfunctions in 
MCF-7 cells was observed than in MDA-MB-231 cells.  
The presence of dicentric or tricentric chromosomes, produced by 
telomeric fusions, poses problem to the cell for subsequent cell division 
(Londono-Vallejo, 2008). Multiple centromeres might be brought to 
opposite poles during anaphase and the resulting bridges would be 
broken, leaving DSB at one end. The broken ends would then be fused 
to another chromosome with uncapped telomere, which would reinitiate 
a cycle of breakage-fuse-bridge (BFB) (Gisselsson et al., 2000). As there 
are many chromosomes with dysfunctional telomeres, different 
chromosomes fuse together randomly. Repetition of BFB in pre-crisis 
state would lead to widespread genome disintegration with fusion of 
different chromosome regions, resulting in chromosome ploidy changes. 
Further replication would lead to greater number of unstable 
chromosomes, thus the cells can no longer divide without losing vital 
genetic material. Cells then enter mitotic catastrophe and die (Macera-
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Bloch et al., 2002). The two main sources of telomere fusion and telomere 
dysfunctions observed in PNA-FISH results were due to telomere erosion 
by MST-312 treatment, and DSB caused by Plumbagin specifically at 
telomere region as seen in TIF results. According to TIF, the average 
number of TIF per cell was much higher in combination treatment in both 
MDA-MB-231 and MCF-7 cells, which might have promoted the genome 
instability of breast cancer cells.  
Decrease in telomerase activity can be due to interruption of the 
function of telomerase enzyme and/or down-regulation of the expression 
of telomerase enzyme. Though the telomerase activity was down-
regulated by telomerase inhibitor MST-312, the expression level of 
hTERT continue to increase in both cell types. As described earlier, the 
ribonucleoprotein telomerase consist of telomerase reverse transcriptase 
subunit (TERT), as the catalytic subunit, and telomerase RNA (hTR) that 
provides template for synthesis of telomere. These two components need 
to be assembled in order to form the fully functional telomerase. However, 
the molecular mechanism by which hTERT and hTR are assembled into 
a functional ribonucleoprotein is unknown (Bachand et al., 2000). 
Moreover, the mechanism of action of MST-312 is not yet elucidated 
(Seimiya et al., 2002). Hence, it is postulated that decrease in telomerase 
activity by MST-312 could be due to interruption of the function of 
telomerase enzyme or the assembly of the telomerase. MST-312 was not 
shown to cause telomere damage, rather inhibited the telomerase activity 
as observed in short term TIF. 
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MCF-10A cells are relatively ‘‘normal’’ breast epithelial cells, 
though, certain caveats should be recognized. Even though the karyotype 
is stable and near diploid, these cells are cytogenetically abnormal (Soule 
et al., 1990). Moreover, MCF-10A cells harbour genetic abnormalities 
such as deletion of p14ARF, p16, and MYC amplification (Elenbaas et 
al., 2001). This immortalized cell type expresses hTERT which is 
normally not found in normal epithelial cells. Consequently, its viability 
was affected by the combination treatment. The level of its telomerase 
activity along with its telomere length was disrupted by the telomerase 
inhibitor MST-312 throughout the treatments. It would have been better if 
a more normal breast epithelial cell was utilized as the control cell type 















CHAPTER 6  
6. CONCLUSION 
6.1. Final remarks  
To treat all types of breast cancer, finding pleiotropic agents that 
are multi-targeted drugs would be of great interest. Phytochemicals are 
the naturally occurring plant chemicals, which their potential function in 
cancer therapeutics is increasingly being studied. They are generally 
found in fruits and vegetables, and number of such agents are known to 
exert the anti-cancer effects irrespective of receptor-status (Russo, 
2007). Phytochemicals have played an imperative role in the discovery 
and development of drugs encompassing the advantage of being less 
toxic to normal cells as compared to most of chemotherapeutic drugs. A 
previous study from our laboratory has characterized the natural 
compound Plumbagin and it was found to have pleiotropic anti-cancer 
activities in human brain tumour cells (Khaw et al., Manuscript in 
preparation). In the current study, it was established that Plumbagin 
induces cytotoxic and genotoxic effects as well in breast cancer cells of 
different origins, either through a single treatment or as combined with 
telomerase inhibition or DNA-PKcs inhibition.  
Firstly, it was demonstrated that Plumbagin has much anti-cancer 
potential in both TNBC MDA-MB-231 and luminal MCF-7 breast cancer 
cells. Figure 62 exhibits part of the findings of this study regarding the 
molecular actions occurring in MCF-7, MDA-MB-231 breast cancer cells 
and the relatively normal MCF-10A cell type upon Plumbagin treatment.  
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The current study also showed that Plumbagin induces significant 
impacts on growth and metastasis inhibition and initiation of apoptotic 
processes. These consequences were mediated by alterations in the 
expression of several key-role player genes involved in cell cycle, DNA 
damage response, apoptosis , metastasis, telomere and telomerase 
dynamics, signal transduction and transcription regulatory genes. The 
cytotoxic effects of Plumbagin were more selective to MDA-MB-231 and 
MCF-7 breast cancer cells, as revealed by its insignificant effect on cell 
viability of IMR-90 normal epithelial cells. Furthermore, Plumbagin has 
shown to exert less effects on the MCF-10A immortalized normal 
epithelial breast cell in many assays including cell cycle, DNA damage 
studies, clonogenicity and cell migration. The gene expression 
alterations revealed that Plumbagin elicits its tumour suppressive 
activities differently in luminal and triple negative breast cancer cells. It 
is realized that Plumbagin strongly inhibits metastasis and cell growth, 
leading to apoptosis in the invasive MDA-MB-231 cells, even in short 
term studies. While in favour of cancer treatment, further to early 
activating the DNA damage response systems through gene expression 
and kinetic studies, Plumbagin is also able to significantly modify the 







Figure 62.  A number of demonstrated findings of this study at a single glance. 




Nonetheless, Plumbagin’s consequences were reversible in the 
presence of DNA repair mechanism. Hence, to provide a potent anti-
cancer treatment, Plumbagin was combined with inhibition of either of the 
enzymes telomerase, PARP-1, and DNA-PKcs by using the respective 
chemicals MST-312, PJ-34 and NU7026, respectively.  
PARP-1 inhibition by PJ-34 induced cell resistance towards 
Plumbagin’s cytotoxic effects. However, NU7026, showed to stabilize and 
enhance the cytotoxic effects of Plumbagin. The findings of this study 
revealed a synergistic role of DNA-PKcs inhibition in Plumbagin-NU7026 
combination treatments, through which it promotes cell cycle progression, 
cell death and irreversible clonogenicity of breast cancer cells in response 
to Plumbagin-induced DNA damage. 
Telomerase is present in the majority of cancer cells and not in 
normal cells, except for stem cells and germ lines. Hence, a dual 
treatment comprising telomerase inhibitor would more specifically target 
towards breast cancer cells to elicit genome instability and affect the 
telomere dynamics of the breast tumour cells. The combination treatment 
of two natural products, Plumbagin and MST-312, was observed to be 
highly effective in long term and short term studies in TNBC cells MDA-
MB-231. Whereas, the cytotoxic effects of combination treatment was 
more apparent in MCF-7 cells following long term treatment. The required 
longer period and its efficacy upon Plumbagin single treatment in MCF-7 
cells was due to the difference in lag phases between these two cell 
types, contributed to the difference in initial telomere length. 
205 
 
Moreover, in MDA-MB-231, Plumbagin and MST-312 combination 
yielded synergistic effects in terms of DNA damage and impairment at 
the telomeres and telomere dynamics. The cytotoxic effects of dual 
treatment with Plumbagin and MST-312 are not recoverable, unlike that 
of Plumbagin single treatment. In conclusion, the combination treatment 
of MST-312 and Plumbagin was more effective than Plumbagin single 
treatment in terms of DNA damage and telomere dysfunction, which 
might lead to greater genome instability and cell cycle arrest, and 
eventually cell death in cancer cells. 
6.2. Limitations and future directions 
Although MCF-10A is a relatively normal breast epithelial cell type, 
certain points are required to be considered. Due to its immortal nature, 
this cell type expresses hTERT and telomerase activity, which is normally 
not found in normal epithelial cells. It would have been better if a more 
normal breast epithelial cell was utilized as the control cell type for the 
Plumbagin and MST-312 combination treatment.  
Different profiles were observed between the cell types at the gene 
expression level; however more validation of this data requires PCR 
studies along with more immunoblotting analyses to investigate if 
Plumbagin also has post translational modifications on breast cancer 
cells.  
Overall findings of this study revealed the fact that cell-
suppressing effects of Plumbagin influence the breast cancer cells more 
than MCF-10A. Nevertheless, due to restricted space, in the molecular-
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based approaches of microarray, the mechanism of action of Plumbagin 
on the relatively normal MCF-10A cells was discussed less than the 
breast tumour cells.  
In future experiments, it is recommended to employ a telomerase-
negative normal breast epithelial cell type as well as a control besides the 
immortalised telomerase positive MCF-10A cells. This crucial application 
will improve the comparison of telomere dynamics studies in breast 
cancer and normal cells. It is anticipated that combined treatment of 
Plumbagin and MST-312 may elicit lesser effect on normal cells because 
Plumbagin selectively affects cancer cells, and MST-312 may not affect 
normal somatic cells which lack telomerase activity. However this 
assumption should strongly be validated by using normal somatic breast 
cell types.  
To observe more significant difference between single treatment 
with Plumbagin and/ or combined with telomerase inhibitor MST-312, it is 
necessary to continue the course of treatment for longer period of time 
especially for MCF-7 cells that showed to have longer telomere length 
than MDA-MB-231. This would ensure the lag phase that is usually 
observed is overcome and the combination effect of both chemicals on 
the breast cancer cells would be more prominent.  
Furthermore, given the fact that the natural plant chemical, 
Plumbagin, is pleiotropic, its mechanism of action involves multiple 
functional pathways. Therefore, it would also be relevant to further 
understand the interaction or relative importance of the key pathways by 
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using overexpression of RNA interference and inhibiting the expression 
of certain genes. 
To validate the tumour suppressing effect of Plumbagin in breast 
cancer, application of primary cells and in vivo studies are of great priority 























AHMAD, A., BANERJEE, S., WANG, Z., KONG, D. & SARKAR, F. H. 2008. Plumbagin-
induced apoptosis of human breast cancer cells is mediated by inactivation of 
NF-kappaB and Bcl-2. J Cell Biochem, 105, 1461-71. 
AISNER, D. L., WRIGHT, W. E. & SHAY, J. W. 2002. Telomerase regulation: not just 
flipping the switch. Curr Opin Genet Dev, 12, 80-5. 
AIYAR, S. E., CHO, H., LEE, J. & LI, R. 2007. Concerted transcriptional regulation by 
BRCA1 and COBRA1 in breast cancer cells. Int J Biol Sci, 3, 486-92. 
AKIYAMA, M., HIDESHIMA, T., HAYASHI, T., TAI, Y. T., MITSIADES, C. S., MITSIADES, N., 
CHAUHAN, D., RICHARDSON, P., MUNSHI, N. C. & ANDERSON, K. C. 2003. 
Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced 
nuclear translocation of telomerase reverse transcriptase protein. Cancer Res, 
63, 18-21. 
AKIYOSHI, T., MATZNO, S., SAKAI, M., OKAMURA, N. & MATSUYAMA, K. 2009. The 
potential of vitamin K3 as an anticancer agent against breast cancer that acts 
via the mitochondria-related apoptotic pathway. Cancer Chemother 
Pharmacol, 65, 143-50. 
AMERICAN-CANCER-SOCIETY 2013. Cancer Facts & Figures 2013. Atlanta. 
AMREIN, L., LOIGNON, M., GOULET, A. C., DUNN, M., JEAN-CLAUDE, B., ALOYZ, R. & 
PANASCI, L. 2007. Chlorambucil cytotoxicity in malignant B lymphocytes is 
synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one 
(NU7026)-mediated inhibition of DNA double-strand break repair via 
inhibition of DNA-dependent protein kinase. J Pharmacol Exp Ther, 321, 848-
55. 
ANDERS, C. K., WINER, E. P., FORD, J. M., DENT, R., SILVER, D. P., SLEDGE, G. W. & 
CAREY, L. A. 2010. Poly(ADP-Ribose) polymerase inhibition: "targeted" 
therapy for triple-negative breast cancer. Clin Cancer Res, 16, 4702-10. 
ANDRE, F., CABIOGLU, N., ASSI, H., SABOURIN, J. C., DELALOGE, S., SAHIN, A., 
BROGLIO, K., SPANO, J. P., COMBADIERE, C., BUCANA, C., SORIA, J. C. & 
CRISTOFANILLI, M. 2006. Expression of chemokine receptors predicts the site 
of metastatic relapse in patients with axillary node positive primary breast 
cancer. Ann Oncol, 17, 945-51. 
ARORA, H., QURESHI, R. & PARK, W. Y. 2013. miR-506 regulates epithelial 
mesenchymal transition in breast cancer cell lines. PLoS One, 8, e64273. 
ASHTON, N. W., BOLDERSON, E., CUBEDDU, L., O'BYRNE, K. J. & RICHARD, D. J. 2013. 
Human single-stranded DNA binding proteins are essential for maintaining 
genomic stability. BMC Mol Biol, 14, 9. 
BACHAND, F., KUKOLJ, G. & AUTEXIER, C. 2000. Expression of hTERT and hTR in cis 
reconstitutes and active human telomerase ribonucleoprotein. RNA, 6, 778-
84. 
BAILEY, S. M. & CORNFORTH, M. N. 2007. Telomeres and DNA double-strand breaks: 
ever the twain shall meet? Cell Mol Life Sci, 64, 2956-64. 
BAILEY, S. M., CORNFORTH, M. N., ULLRICH, R. L. & GOODWIN, E. H. 2004. 
Dysfunctional mammalian telomeres join with DNA double-strand breaks. 
DNA Repair (Amst), 3, 349-57. 
BAILEY, S. M., MEYNE, J., CHEN, D. J., KURIMASA, A., LI, G. C., LEHNERT, B. E. & 
GOODWIN, E. H. 1999. DNA double-strand break repair proteins are required 
209 
 
to cap the ends of mammalian chromosomes. Proc Natl Acad Sci U S A, 96, 
14899-904. 
BAKKENIST, C. J. & KASTAN, M. B. 2003. DNA damage activates ATM through 
intermolecular autophosphorylation and dimer dissociation. Nature, 421, 
499-506. 
BARTEK, J. & LUKAS, J. 2007. DNA damage checkpoints: from initiation to recovery or 
adaptation. Curr Opin Cell Biol, 19, 238-45. 
BARTEK, J. & LUKAS, J. 2010. The DNA damage response in tumorigenesis and cancer 
treatment. Nature Reviews Cancer, 10. 
BAUMANN, P. & PRICE, C. 2010. Pot1 and telomere maintenance. FEBS Lett, 584, 
3779-84. 
BEALL, H. D., MURPHY, A. M., SIEGEL, D., HARGREAVES, R. H., BUTLER, J. & ROSS, D. 
1995. Nicotinamide adenine dinucleotide (phosphate): quinone 
oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor 
quinones: quinone cytotoxicity and selectivity in human lung and breast 
cancer cell lines. Mol Pharmacol, 48, 499-504. 
BEDNAREK, A., BUDUNOVA, I., SLAGA, T. J. & ALDAZ, C. M. 1995. Increased telomerase 
activity in mouse skin premalignant progression. Cancer Res, 55, 4566-9. 
BEGHIN, A., BELIN, S., HAGE-SLEIMAN, R., BRUNET MANQUAT, S., GODDARD, S., 
TABONE, E., JORDHEIM, L. P., TREILLEUX, I., POUPON, M. F., DIAZ, J. J. & 
DUMONTET, C. 2009. ADP ribosylation factor like 2 (Arl2) regulates breast 
tumor aggressivity in immunodeficient mice. PLoS One, 4, e7478. 
BEGHIN, A., HONORE, S., MESSANA, C., MATERA, E. L., AIM, J., BURLINCHON, S., 
BRAGUER, D. & DUMONTET, C. 2007. ADP ribosylation factor like 2 (Arl2) 
protein influences microtubule dynamics in breast cancer cells. Exp Cell Res, 
313, 473-85. 
BEGHIN, A., MATERA, E. L., BRUNET-MANQUAT, S. & DUMONTET, C. 2008. Expression 
of Arl2 is associated with p53 localization and chemosensitivity in a breast 
cancer cell line. Cell Cycle, 7, 3074-82. 
BELINSKY, M. & JAISWAL, A. K. 1993. NAD(P)H:quinone oxidoreductase1 (DT-
diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev, 
12, 103-17. 
BENSON, J. R. & JATOI, I. 2012. The global breast cancer burden. Future Oncol, 8, 697-
702. 
BERKOVICH, E. & GINSBERG, D. 2003. ATM is a target for positive regulation by E2F-1. 
Oncogene, 22, 161-7. 
BETTS, J. A., FRENCH, J. D., BROWN, M. A. & EDWARDS, S. L. 2013. Long-range 
transcriptional regulation of breast cancer genes. Genes Chromosomes 
Cancer, 52, 113-25. 
BIALEK, A. & TOKARZ, A. 2013. [Conjugated linoleic acid as a potential protective 
factor in prevention of breast cancer]. Postepy Hig Med Dosw (Online), 67, 6-
14. 
BIECHE, I., DE MURCIA, G. & LIDEREAU, R. 1996. Poly(ADP-ribose) polymerase gene 
expression status and genomic instability in human breast cancer. Clin Cancer 
Res, 2, 1163-7. 
BILAL, E., VASSALLO, K., TOPPMEYER, D., BARNARD, N., RYE, I. H., ALMENDRO, V., 
RUSSNES, H., BORRESEN-DALE, A. L., LEVINE, A. J., BHANOT, G. & GANESAN, 
S. 2012. Amplified loci on chromosomes 8 and 17 predict early relapse in ER-
positive breast cancers. PLoS One, 7, e38575. 
210 
 
BISWAS, D. K., SHI, Q., BAILY, S., STRICKLAND, I., GHOSH, S., PARDEE, A. B. & IGLEHART, 
J. D. 2004. NF-kappa B activation in human breast cancer specimens and its 
role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A, 101, 10137-
42. 
BLACKBURN, E. H. 1991. Telomeres. Trends Biochem Sci, 16, 378-81. 
BLACKBURN, E. H., GREIDER, C. W. & SZOSTAK, J. W. 2006. Telomeres and telomerase: 
the path from maize, Tetrahymena and yeast to human cancer and aging. Nat 
Med, 12, 1133-8. 
BLANCO, R., MUNOZ, P., FLORES, J. M., KLATT, P. & BLASCO, M. A. 2007. Telomerase 
abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis. 
Genes Dev, 21, 206-20. 
BOON, H. S., OLATUNDE, F. & ZICK, S. M. 2007. Trends in complementary/alternative 
medicine use by breast cancer survivors: comparing survey data from 1998 
and 2005. BMC Womens Health, 7, 4. 
BOULTON, S., KYLE, S., YALCINTEPE, L. & DURKACZ, B. W. 1996. Wortmannin is a 
potent inhibitor of DNA double strand break but not single strand break repair 
in Chinese hamster ovary cells. Carcinogenesis, 17, 2285-90. 
BROCCOLI, D., GODLEY, L. A., DONEHOWER, L. A., VARMUS, H. E. & DE LANGE, T. 1996. 
Telomerase activation in mouse mammary tumors: lack of detectable 
telomere shortening and evidence for regulation of telomerase RNA with cell 
proliferation. Mol Cell Biol, 16, 3765-72. 
BROCCOLI, D., SMOGORZEWSKA, A., CHONG, L. & DE LANGE, T. 1997. Human 
telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. Nat 
Genet, 17, 231-5. 
BULGER, M. & GROUDINE, M. 2011. Functional and mechanistic diversity of distal 
transcription enhancers. Cell, 144, 327-39. 
BUSHEY, A. M., DORMAN, E. R. & CORCES, V. G. 2008. Chromatin insulators: regulatory 
mechanisms and epigenetic inheritance. Mol Cell, 32, 1-9. 
BUTLER, K. S., HINES, W. C., HEAPHY, C. M. & GRIFFITH, J. K. 2012. Coordinate 
regulation between expression levels of telomere-binding proteins and 
telomere length in breast carcinomas. Cancer Med, 1, 165-75. 
CAILLEAU, R., YOUNG, R., OLIVE, M. & REEVES, W. J., JR. 1974. Breast tumor cell lines 
from pleural effusions. J Natl Cancer Inst, 53, 661-74. 
CAIRNEY, C. J. & KEITH, W. N. 2008. Telomerase redefined: integrated regulation of 
hTR and hTERT for telomere maintenance and telomerase activity. Biochimie, 
90, 13-23. 
CANELA, A., VERA, E., KLATT, P. & BLASCO, M. A. 2007. High-throughput telomere 
length quantification by FISH and its application to human population studies. 
Proc Natl Acad Sci U S A, 104, 5300-5. 
CARMINATI, P. O., DONAIRES, F. S., GODOY, A. P., MONTALDI, J. A., MEADOR, A. S., 
BALAJEE, G. A. & PASSOS 2013. DNA-PK is a Potential Molecular Therapeutic 
Target for Glioblastoma, Evolution of the Molecular Biology of Brain Tumors 
and the Therapeutic Implications, . 
CERONE, M. A., LONDONO-VALLEJO, J. A. & AUTEXIER, C. 2006. Telomerase inhibition 
enhances the response to anticancer drug treatment in human breast cancer 
cells. Mol Cancer Ther, 5, 1669-75. 
CESARI, I., HOERLE, M., SIMOES-PIRES, C., GRISOLI, P., QUEIROZ, E. F., DACARRO, C., 
MARCOURT, L., MOUNDIPA, P. F., CARRUPT, P. A., CUENDET, M., 
CACCIALANZA, G., WOLFENDER, J. L. & BRUSOTTI, G. 2013. Anti-
211 
 
inflammatory, antimicrobial and antioxidant activities of Diospyros 
bipindensis (Gurke) extracts and its main constituents. J Ethnopharmacol, 
146, 264-70. 
CHADENEAU, C., SIEGEL, P., HARLEY, C. B., MULLER, W. J. & BACCHETTI, S. 1995. 
Telomerase activity in normal and malignant murine tissues. Oncogene, 11, 
893-8. 
CHALMERS, A. J. 2009. The potential role and application of PARP inhibitors in cancer 
treatment. Br Med Bull, 89, 23-40. 
CHEN, C. H. & CHEN, R. J. 2011. Prevalence of telomerase activity in human cancer. J 
Formos Med Assoc, 110, 275-89. 
CHEN, M. B., ZHANG, Y., WEI, M. X., SHEN, W., WU, X. Y., YAO, C. & LU, P. H. 2013. 
Activation of AMP-activated protein kinase (AMPK) mediates plumbagin-
induced apoptosis and growth inhibition in cultured human colon cancer cells. 
Cell Signal. 
CHEN, X., FARMER, G., ZHU, H., PRYWES, R. & PRIVES, C. 1993. Cooperative DNA 
binding of p53 with TFIID (TBP): a possible mechanism for transcriptional 
activation. Genes Dev, 7, 1837-49. 
CHEN, Y., XU, J., BOROWICZ, S., COLLINS, C., HUO, D. & OLOPADE, O. I. 2011. c-Myc 
activates BRCA1 gene expression through distal promoter elements in breast 
cancer cells. BMC Cancer, 11, 246. 
CHEUNG, A. L. & DENG, W. 2008. Telomere dysfunction, genome instability and 
cancer. Front Biosci, 13, 2075-90. 
CHEVANNE, M., ZAMPIERI, M., CALDINI, R., RIZZO, A., CICCARONE, F., CATIZONE, A., 
D'ANGELO, C., GUASTAFIERRO, T., BIROCCIO, A., REALE, A., ZUPI, G. & CAIAFA, 
P. 2010. Inhibition of PARP activity by PJ-34 leads to growth impairment and 
cell death associated with aberrant mitotic pattern and nucleolar actin 
accumulation in M14 melanoma cell line. J Cell Physiol, 222, 401-10. 
CIMPRICH, K. A. & CORTEZ, D. 2008. ATR: an essential regulator of genome integrity. 
Nat Rev Mol Cell Biol, 9, 616-27. 
COHN, E. P., WU, K. L., PETTUS, T. R. & REICH, N. O. 2012. A new strategy for detection 
and development of tractable telomerase inhibitors. J Med Chem, 55, 3678-
86. 
COLUCCI, M. A., MOODY, C. J. & COUCH, G. D. 2008. Natural and synthetic quinones 
and their reduction by the quinone reductase enzyme NQO1: from synthetic 
organic chemistry to compounds with anticancer potential. Org Biomol Chem, 
6, 637-56. 
COOK, P. J., JU, B. G., TELESE, F., WANG, X., GLASS, C. K. & ROSENFELD, M. G. 2009. 
Tyrosine dephosphorylation of H2AX modulates apoptosis and survival 
decisions. Nature, 458, 591-6. 
CRAGG, G. M. & NEWMAN, D. J. 2005. Plants as a source of anti-cancer agents. Journal 
of Ethnopharmacology, 100, 72-79. 
CRIBB, A. E., JOY KNIGHT, M., GUERNSEY, J., DRYER, D., HENDER, K., SHAWWA, A., 
TESCH, M. & SALEH, T. M. 2011. CYP17, catechol-o-methyltransferase, and 
glutathione transferase M1 genetic polymorphisms, lifestyle factors, and 
breast cancer risk in women on Prince Edward Island. Breast J, 17, 24-31. 
CROWN, J., O'SHAUGHNESSY, J. & GULLO, G. 2012. Emerging targeted therapies in 
triple-negative breast cancer. Ann Oncol, 23 Suppl 6, vi56-65. 
212 
 
CUNNINGHAM, A. P., LOVE, W. K., ZHANG, R. W., ANDREWS, L. G. & TOLLEFSBOL, T. 
O. 2006. Telomerase inhibition in cancer therapeutics: molecular-based 
approaches. Curr Med Chem, 13, 2875-88. 
D'ADDA DI FAGAGNA, F. 2008. Living on a break: cellular senescence as a DNA-damage 
response. Nat Rev Cancer, 8, 512-22. 
D'ADDA DI FAGAGNA, F., HANDE, M. P., TONG, W. M., LANSDORP, P. M., WANG, Z. Q. 
& JACKSON, S. P. 1999. Functions of poly(ADP-ribose) polymerase in 
controlling telomere length and chromosomal stability. Nat Genet, 23, 76-80. 
D'ADDA DI FAGAGNA, F., HANDE, M. P., TONG, W. M., ROTH, D., LANSDORP, P. M., 
WANG, Z. Q. & JACKSON, S. P. 2001. Effects of DNA nonhomologous end-
joining factors on telomere length and chromosomal stability in mammalian 
cells. Curr Biol, 11, 1192-6. 
DAVID, S. S., O'SHEA, V. L. & KUNDU, S. 2007. Base-excision repair of oxidative DNA 
damage. Nature, 447, 941-50. 
DEMMA, J., HALLBERG, K. & HELLMAN, B. 2009. Genotoxicity of plumbagin and its 
effects on catechol and NQNO-induced DNA damage in mouse lymphoma 
cells. Toxicol In Vitro, 23, 266-71. 
DENT, R., TRUDEAU, M., PRITCHARD, K. I., HANNA, W. M., KAHN, H. K., SAWKA, C. A., 
LICKLEY, L. A., RAWLINSON, E., SUN, P. & NAROD, S. A. 2007. Triple-negative 
breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 
13, 4429-34. 
DOMCHEK, S. M., RECIO, A., MICK, R., CLARK, C. E., CARPENTER, E. L., FOX, K. R., 
DEMICHELE, A., SCHUCHTER, L. M., LEIBOWITZ, M. S., WEXLER, M. H., VANCE, 
B. A., BEATTY, G. L., VELOSO, E., FELDMAN, M. D. & VONDERHEIDE, R. H. 2007. 
Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on 
tumor immunosurveillance. Cancer Res, 67, 10546-55. 
DONG, P., KARAAYVAZ, M., JIA, N., KANEUCHI, M., HAMADA, J., WATARI, H., SUDO, S., 
JU, J. & SAKURAGI, N. 2013. Mutant p53 gain-of-function induces epithelial-
mesenchymal transition through modulation of the miR-130b-ZEB1 axis. 
Oncogene, 32, 3286-95. 
DREW, Y. & CALVERT, H. 2008. The potential of PARP inhibitors in genetic breast and 
ovarian cancers. Ann N Y Acad Sci, 1138, 136-45. 
DUROCHER, D. & JACKSON, S. P. 2001. DNA-PK, ATM and ATR as sensors of DNA 
damage: variations on a theme? Curr Opin Cell Biol, 13, 225-31. 
EA BEY, C. K., E BLANCO, R BACHOO, N WILLIAMS AND DA BOOTHMAN 2009. 
Synergisitic inhibition of DNA repair by combining ß-lapachone with Nu7026 
as a strategy for killing primary and metastatic breast cancers. Cancer 
Research, 69. 
ELENBAAS, B., SPIRIO, L., KOERNER, F., FLEMING, M. D., ZIMONJIC, D. B., DONAHER, J. 
L., POPESCU, N. C., HAHN, W. C. & WEINBERG, R. A. 2001. Human breast 
cancer cells generated by oncogenic transformation of primary mammary 
epithelial cells. Genes Dev, 15, 50-65. 
EMADI, A., LE, A., HARWOOD, C. J., STAGLIANO, K. W., KAMANGAR, F., ROSS, A. E., 
COOPER, C. R., DANG, C. V., KARP, J. E. & VUICA-ROSS, M. 2011. Metabolic 
and electrochemical mechanisms of dimeric naphthoquinones cytotoxicity in 
breast cancer cells. Bioorg Med Chem, 19, 7057-62. 
EPSTEIN, R. J. 2004. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant 
breast cancer therapies. Nat Rev Cancer, 4, 901-9. 
213 
 
ERCAN, C., VAN DIEST, P. J., VAN DER ENDE, B., HINRICHS, J., BULT, P., BUERGER, H., 
VAN DER WALL, E. & DERKSEN, P. W. 2012. p53 mutations in classic and 
pleomorphic invasive lobular carcinoma of the breast. Cell Oncol (Dordr), 35, 
111-8. 
ERIKSSON, A., LEWENSOH, R., LARSSON, R. & NILSSON, A. 2002. DNA-dependent 
protein kinase in leukaemia cells and correlation with drug sensitivity. 
Anticancer Res, 22, 1787-93. 
ESCOT, C., THEILLET, C., LIDEREAU, R., SPYRATOS, F., CHAMPEME, M. H., GEST, J. & 
CALLAHAN, R. 1986. Genetic alteration of the c-myc protooncogene (MYC) in 
human primary breast carcinomas. Proc Natl Acad Sci U S A, 83, 4834-8. 
FAGERHOLM, R., HOFSTETTER, B., TOMMISKA, J., AALTONEN, K., VRTEL, R., 
SYRJAKOSKI, K., KALLIONIEMI, A., KILPIVAARA, O., MANNERMAA, A., KOSMA, 
V. M., UUSITUPA, M., ESKELINEN, M., KATAJA, V., AITTOMAKI, K., VON 
SMITTEN, K., HEIKKILA, P., LUKAS, J., HOLLI, K., BARTKOVA, J., BLOMQVIST, C., 
BARTEK, J. & NEVANLINNA, H. 2008. NAD(P)H:quinone oxidoreductase 1 
NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in 
breast cancer. Nat Genet, 40, 844-53. 
FALCK, J., COATES, J. & JACKSON, S. P. 2005. Conserved modes of recruitment of ATM, 
ATR and DNA-PKcs to sites of DNA damage. Nature, 434, 605-11. 
FANG, Y., ZHAO, Q., MA, G., HAN, Y. & LOU, N. 2013. Investigation on MDR1 gene 
polymorphisms and its relationship with breast cancer risk factors in Chinese 
women. Med Oncol, 30, 375. 
FENG, J., FUNK, W. D., WANG, S. S., WEINRICH, S. L., AVILION, A. A., CHIU, C. P., 
ADAMS, R. R., CHANG, E., ALLSOPP, R. C., YU, J. & ET AL. 1995. The RNA 
component of human telomerase. Science, 269, 1236-41. 
FIGTREE, G. A., MCDONALD, D., WATKINS, H. & CHANNON, K. M. 2003. Truncated 
estrogen receptor alpha 46-kDa isoform in human endothelial cells: 
relationship to acute activation of nitric oxide synthase. Circulation, 107, 120-
6. 
FIRN, R. D. & JONES, C. G. 2003. Natural products--a simple model to explain chemical 
diversity. Nat Prod Rep, 20, 382-91. 
FONG, P. C., BOSS, D. S., YAP, T. A., TUTT, A., WU, P., MERGUI-ROELVINK, M., 
MORTIMER, P., SWAISLAND, H., LAU, A., O'CONNOR, M. J., ASHWORTH, A., 
CARMICHAEL, J., KAYE, S. B., SCHELLENS, J. H. & DE BONO, J. S. 2009. Inhibition 
of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N 
Engl J Med, 361, 123-34. 
FOULKES, W. D., STEFANSSON, I. M., CHAPPUIS, P. O., BEGIN, L. R., GOFFIN, J. R., 
WONG, N., TRUDEL, M. & AKSLEN, L. A. 2003. Germline BRCA1 mutations and 
a basal epithelial phenotype in breast cancer. J Natl Cancer Inst, 95, 1482-5. 
FRENKEL, M., BEN-ARYE, E. & COHEN, L. 2010. Communication in cancer care: 
discussing complementary and alternative medicine. Integr Cancer Ther, 9, 
177-85. 
FRIAS, C., PAMPALONA, J., GENESCA, A. & TUSELL, L. 2012. Telomere dysfunction and 
genome instability. Front Biosci, 17, 2181-96. 
FUJII, N., YAMASHITA, Y., ARIMA, Y., NAGASHIMA, M. & NAKANO, H. 1992. Induction 
of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones 
plumbagin and shikonin. Antimicrob Agents Chemother, 36, 2589-94. 
FULLWOOD, M. J., LIU, M. H., PAN, Y. F., LIU, J., XU, H., MOHAMED, Y. B., ORLOV, Y. 
L., VELKOV, S., HO, A., MEI, P. H., CHEW, E. G., HUANG, P. Y., WELBOREN, W. 
214 
 
J., HAN, Y., OOI, H. S., ARIYARATNE, P. N., VEGA, V. B., LUO, Y., TAN, P. Y., 
CHOY, P. Y., WANSA, K. D., ZHAO, B., LIM, K. S., LEOW, S. C., YOW, J. S., 
JOSEPH, R., LI, H., DESAI, K. V., THOMSEN, J. S., LEE, Y. K., KARUTURI, R. K., 
HERVE, T., BOURQUE, G., STUNNENBERG, H. G., RUAN, X., CACHEUX-
RATABOUL, V., SUNG, W. K., LIU, E. T., WEI, C. L., CHEUNG, E. & RUAN, Y. 2009. 
An oestrogen-receptor-alpha-bound human chromatin interactome. Nature, 
462, 58-64. 
GASPARINI, P., SOZZI, G. & PIEROTTI, M. A. 2007. The role of chromosomal alterations 
in human cancer development. J Cell Biochem, 102, 320-31. 
GELMINI, S., POGGESI, M., DISTANTE, V., BIANCHI, S., SIMI, L., LUCONI, M., RAGGI, C. 
C., CATALIOTTI, L., PAZZAGLI, M. & ORLANDO, C. 2004. Tankyrase, a positive 
regulator of telomere elongation, is over expressed in human breast cancer. 
Cancer Lett, 216, 81-7. 
GENESCA, A., PAMPALONA, J., FRIAS, C., DOMINGUEZ, D. & TUSELL, L. 2011. Role of 
telomere dysfunction in genetic intratumor diversity. Adv Cancer Res, 112, 11-
41. 
GHOSH, A., SAGINC, G., LEOW, S. C., KHATTAR, E., SHIN, E. M., YAN, T. D., WONG, M., 
ZHANG, Z., LI, G., SUNG, W. K., ZHOU, J., CHNG, W. J., LI, S., LIU, E. & 
TERGAONKAR, V. 2012. Telomerase directly regulates NF-kappaB-dependent 
transcription. Nat Cell Biol, 14, 1270-81. 
GILLEY, D., TANAKA, H., HANDE, M. P., KURIMASA, A., LI, G. C., OSHIMURA, M. & 
CHEN, D. J. 2001. DNA-PKcs is critical for telomere capping. Proc Natl Acad Sci 
U S A, 98, 15084-8. 
GISSELSSON, D., PETTERSSON, L., HOGLUND, M., HEIDENBLAD, M., GORUNOVA, L., 
WIEGANT, J., MERTENS, F., DAL CIN, P., MITELMAN, F. & MANDAHL, N. 2000. 
Chromosomal breakage-fusion-bridge events cause genetic intratumor 
heterogeneity. Proc Natl Acad Sci U S A, 97, 5357-62. 
GLAZER, R. I. & ROHLFF, C. 1994. Transcriptional regulation of multidrug resistance in 
breast cancer. Breast Cancer Res Treat, 31, 263-71. 
GOMATHINAYAGAM, R., SOWMYALAKSHMI, S., MARDHATILLAH, F., KUMAR, R., 
AKBARSHA, M. A. & DAMODARAN, C. 2008. Anticancer mechanism of 
plumbagin, a natural compound, on non-small cell lung cancer cells. 
Anticancer Res, 28, 785-92. 
GOMEZ-RAPOSO, C., ZAMBRANA TEVAR, F., SERENO MOYANO, M., LOPEZ GOMEZ, M. 
& CASADO, E. 2010. Male breast cancer. Cancer Treat Rev, 36, 451-7. 
GOMEZ, D. E., ARMANDO, R. G., FARINA, H. G., MENNA, P. L., CERRUDO, C. S., 
GHIRINGHELLI, P. D. & ALONSO, D. F. 2012. Telomere structure and 
telomerase in health and disease (review). Int J Oncol, 41, 1561-9. 
GONG, Y. & DE LANGE, T. 2010. A Shld1-controlled POT1a provides support for 
repression of ATR signaling at telomeres through RPA exclusion. Mol Cell, 40, 
377-87. 
GOUELI, B. S. & JANKNECHT, R. 2004. Upregulation of the Catalytic Telomerase 
Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or 
Raf. Mol Cell Biol, 24, 25-35. 
GREIDER, C. W. & BLACKBURN, E. H. 1985. Identification of a specific telomere 
terminal transferase activity in Tetrahymena extracts. Cell, 43, 405-13. 
GREIDER, C. W. & BLACKBURN, E. H. 1987. The telomere terminal transferase of 
Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer 
specificity. Cell, 51, 887-98. 
215 
 
GREIDER, C. W. & BLACKBURN, E. H. 1989. A telomeric sequence in the RNA of 
Tetrahymena telomerase required for telomere repeat synthesis. Nature, 
337, 331-7. 
GROMPE, M. & D'ANDREA, A. 2001. Fanconi anemia and DNA repair. Hum Mol Genet, 
10, 2253-9. 
GURUNG, R. L., LIM, S. N., KHAW, A. K., SOON, J. F., SHENOY, K., MOHAMED ALI, S., 
JAYAPAL, M., SETHU, S., BASKAR, R. & HANDE, M. P. 2010. Thymoquinone 
induces telomere shortening, DNA damage and apoptosis in human 
glioblastoma cells. PLoS One, 5, e12124. 
HAFEEZ, B. B., JAMAL, M. S., FISCHER, J. W., MUSTAFA, A. & VERMA, A. K. 2012. 
Plumbagin, a plant derived natural agent inhibits the growth of pancreatic 
cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-kappaB 
signaling pathways. Int J Cancer, 131, 2175-86. 
HAFEEZ, B. B., ZHONG, W., FISCHER, J. W., MUSTAFA, A., SHI, X., MESKE, L., HONG, H., 
CAI, W., HAVIGHURST, T., KIM, K. & VERMA, A. K. 2013. Plumbagin, a 
medicinal plant (Plumbago zeylanica)-derived 1,4-naphthoquinone, inhibits 
growth and metastasis of human prostate cancer PC-3M-luciferase cells in an 
orthotopic xenograft mouse model. Mol Oncol, 7, 428-39. 
HALAZONETIS, T. D., GORGOULIS, V. G. & BARTEK, J. 2008. An oncogene-induced DNA 
damage model for cancer development. Science, 319, 1352-5. 
HANAHAN, D. & WEINBERG, R. A. 2000. The hallmarks of cancer. Cell, 100, 57-70. 
HANAHAN, D. & WEINBERG, R. A. 2011. Hallmarks of cancer: the next generation. Cell, 
144, 646-74. 
HANDE, M. P. 2004. DNA repair factors and telomere-chromosome integrity in 
mammalian cells. Cytogenet Genome Res, 104, 116-22. 
HANDE, M. P., BALAJEE, A. S., TCHIRKOV, A., WYNSHAW-BORIS, A. & LANSDORP, P. M. 
2001. Extra-chromosomal telomeric DNA in cells from Atm(-/-) mice and 
patients with ataxia-telangiectasia. Hum Mol Genet, 10, 519-28. 
HANDE, P., SLIJEPCEVIC, P., SILVER, A., BOUFFLER, S., VAN BUUL, P., BRYANT, P. & 
LANSDORP, P. 1999. Elongated telomeres in scid mice. Genomics, 56, 221-3. 
HAO, Z. M., LUO, J. Y., CHENG, J., LI, L., HE, D., WANG, Q. Y. & YANG, G. X. 2005. 
Intensive inhibition of hTERT expression by a ribozyme induces rapid 
apoptosis of cancer cells through a telomere length-independent pathway. 
Cancer Biol Ther, 4, 1098-103. 
HARBORNE, J. B. 1966. The evolution of flavonoid pigments in plants. London: 
Academic Press 
 
HARLEY, C. B. 2008. Telomerase and cancer therapeutics. Nat Rev Cancer, 8, 167-79. 
HARLEY, C. B., FUTCHER, A. B. & GREIDER, C. W. 1990. Telomeres shorten during 
ageing of human fibroblasts. Nature, 345, 458-60. 
HARRISON, J. C. & HABER, J. E. 2006. Surviving the breakup: the DNA damage 
checkpoint. Annu Rev Genet, 40, 209-35. 
HASTAK, K., ALLI, E. & FORD, J. M. 2010. Synergistic chemosensitivity of triple-negative 
breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, 
gemcitabine, and cisplatin. Cancer Res, 70, 7970-80. 
HAYFLICK, L. 1965. The Limited in Vitro Lifetime of Human Diploid Cell Strains. Exp Cell 
Res, 37, 614-36. 
HAYFLICK, L. & MOORHEAD, P. S. 1961. The serial cultivation of human diploid cell 
strains. Exp Cell Res, 25, 585-621. 
216 
 
HEAPHY, C. M., SUBHAWONG, A. P., GROSS, A. L., KONISHI, Y., KOUPRINA, N., ARGANI, 
P., VISVANATHAN, K. & MEEKER, A. K. 2011. Shorter telomeres in luminal B, 
HER-2 and triple-negative breast cancer subtypes. Mod Pathol, 24, 194-200. 
HEMANN, M. T., STRONG, M. A., HAO, L. Y. & GREIDER, C. W. 2001. The shortest 
telomere, not average telomere length, is critical for cell viability and 
chromosome stability. Cell, 107, 67-77. 
HERBERT, B. S., WRIGHT, W. E. & SHAY, J. W. 2001. Telomerase and breast cancer. 
Breast Cancer Res, 3, 146-9. 
HERBIG, U., JOBLING, W. A., CHEN, B. P., CHEN, D. J. & SEDIVY, J. M. 2004. Telomere 
shortening triggers senescence of human cells through a pathway involving 
ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell, 14, 501-13. 
HILL, R. & LEE, P. W. 2010. The DNA-dependent protein kinase (DNA-PK): More than 
just a case of making ends meet? Cell Cycle, 9, 3460-9. 
HINES, W. C., FAJARDO, A. M., JOSTE, N. E., BISOFFI, M. & GRIFFITH, J. K. 2005. 
Quantitative and spatial measurements of telomerase reverse transcriptase 
expression within normal and malignant human breast tissues. Mol Cancer 
Res, 3, 503-9. 
HOEIJMAKERS, J. H. 2001. Genome maintenance mechanisms for preventing cancer. 
Nature, 411, 366-74. 
HOLYSZ, H., LIPINSKA, N., PASZEL-JAWORSKA, A. & RUBIS, B. 2013. Telomerase as a 
useful target in cancer fighting-the breast cancer case. Tumour Biol, 34, 1371-
80. 
HORNEBER, M., BUESCHEL, G., DENNERT, G., LESS, D., RITTER, E. & ZWAHLEN, M. 
2012. How many cancer patients use complementary and alternative 
medicine: a systematic review and metaanalysis. Integr Cancer Ther, 11, 187-
203. 
HSIEH, Y. J., LIN, L. C. & TSAI, T. H. 2006. Measurement and pharmacokinetic study of 
plumbagin in a conscious freely moving rat using liquid 
chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol 
Biomed Life Sci, 844, 1-5. 
HSU, H. L., GILLEY, D., GALANDE, S. A., HANDE, M. P., ALLEN, B., KIM, S. H., LI, G. C., 
CAMPISI, J., KOHWI-SHIGEMATSU, T. & CHEN, D. J. 2000. Ku acts in a unique 
way at the mammalian telomere to prevent end joining. Genes Dev, 14, 2807-
12. 
HSU, Y. L., CHO, C. Y., KUO, P. L., HUANG, Y. T. & LIN, C. C. 2006. Plumbagin (5-hydroxy-
2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in 
A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated 
phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther, 318, 
484-94. 
HUANG DA, W., SHERMAN, B. T. & LEMPICKI, R. A. 2009. Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 
4, 44-57. 
HUANG, S. H., XIONG, M., CHEN, X. P., XIAO, Z. Y., ZHAO, Y. F. & HUANG, Z. Y. 2008. 
PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the 
suppressive effects of cisplatin in liver cancer cells. Oncol Rep, 20, 567-72. 
HUANG, W. Y., CAI, Y. Z. & ZHANG, Y. 2010. Natural phenolic compounds from 
medicinal herbs and dietary plants: potential use for cancer prevention. Nutr 
Cancer, 62, 1-20. 
217 
 
IGNATIADIS, M. & SOTIRIOU, C. 2013. Luminal breast cancer: from biology to 
treatment. Nat Rev Clin Oncol. 
IMAMURA, T., HIKITA, A. & INOUE, Y. 2012. The roles of TGF-beta signaling in 
carcinogenesis and breast cancer metastasis. Breast Cancer, 19, 118-24. 
INBAR-ROZENSAL, D., CASTIEL, A., VISOCHEK, L., CASTEL, D., DANTZER, F., IZRAELI, S. 
& COHEN-ARMON, M. 2009. A selective eradication of human nonhereditary 
breast cancer cells by phenanthridine-derived polyADP-ribose polymerase 
inhibitors. Breast Cancer Res, 11, R78. 
INBARAJ, J. J. & CHIGNELL, C. F. 2004. Cytotoxic action of juglone and plumbagin: a 
mechanistic study using HaCaT keratinocytes. Chem Res Toxicol, 17, 55-62. 
IRSHAD, S., ASHWORTH, A. & TUTT, A. 2011. Therapeutic potential of PARP inhibitors 
for metastatic breast cancer. Expert Rev Anticancer Ther, 11, 1243-51. 
IWANO, T., TACHIBANA, M., RETH, M. & SHINKAI, Y. 2004. Importance of TRF1 for 
functional telomere structure. J Biol Chem, 279, 1442-8. 
JACINTO, F. V. & ESTELLER, M. 2007. Mutator pathways unleashed by epigenetic 
silencing in human cancer. Mutagenesis, 22, 247-53. 
JACKSON, J. K., HIGO, T., HUNTER, W. L. & BURT, H. M. 2008. Topoisomerase inhibitors 
as anti-arthritic agents. Inflamm Res, 57, 126-34. 
JACKSON, S. P. & BARTEK, J. 2009. The DNA-damage response in human biology and 
disease. Nature, 461, 1071-8. 
JAGTAP, P., SORIANO, F. G., VIRAG, L., LIAUDET, L., MABLEY, J., SZABO, E., HASKO, G., 
MARTON, A., LORIGADOS, C. B., GALLYAS, F., JR., SUMEGI, B., HOYT, D. G., 
BALOGLU, E., VANDUZER, J., SALZMAN, A. L., SOUTHAN, G. J. & SZABO, C. 
2002. Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-
ribose) synthetase: potent cytoprotective and antishock agents. Crit Care 
Med, 30, 1071-82. 
JAMSHIDI, M., BARTKOVA, J., GRECO, D., TOMMISKA, J., FAGERHOLM, R., AITTOMAKI, 
K., MATTSON, J., VILLMAN, K., VRTEL, R., LUKAS, J., HEIKKILA, P., BLOMQVIST, 
C., BARTEK, J. & NEVANLINNA, H. 2012. NQO1 expression correlates inversely 
with NFkappaB activation in human breast cancer. Breast Cancer Res Treat, 
132, 955-68. 
JELOVAC, D. & EMENS, L. A. 2013. HER2-directed therapy for metastatic breast cancer. 
Oncology (Williston Park), 27, 166-75. 
JEMAL, A., BRAY, F., CENTER, M. M., FERLAY, J., WARD, E. & FORMAN, D. 2011. Global 
cancer statistics. CA Cancer J Clin, 61, 69-90. 
JIANG, S., ZHANG, H. W., LU, M. H., HE, X. H., LI, Y., GU, H., LIU, M. F. & WANG, E. D. 
2010. MicroRNA-155 functions as an OncomiR in breast cancer by targeting 
the suppressor of cytokine signaling 1 gene. Cancer Res, 70, 3119-27. 
JIRICNY, J. 2006. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol, 7, 
335-46. 
KADDAR, T. & CARREAU, M. 2012. Fanconi anemia proteins and their interacting 
partners: a molecular puzzle. Anemia, 2012, 425814. 
KANG, S. S., KWON, T., KWON, D. Y. & DO, S. I. 1999. Akt protein kinase enhances 
human telomerase activity through phosphorylation of telomerase reverse 
transcriptase subunit. J Biol Chem, 274, 13085-90. 
KASTAN, M. B. & BARTEK, J. 2004. Cell-cycle checkpoints and cancer. Nature, 432, 316-
23. 
KAWIAK, A., PIOSIK, J., STASILOJC, G., GWIZDEK-WISNIEWSKA, A., MARCZAK, L., 
STOBIECKI, M., BIGDA, J. & LOJKOWSKA, E. 2007. Induction of apoptosis by 
218 
 
plumbagin through reactive oxygen species-mediated inhibition of 
topoisomerase II. Toxicol Appl Pharmacol, 223, 267-76. 
KAWIAK, A., ZAWACKA-PANKAU, J. & LOJKOWSKA, E. 2012. Plumbagin induces 
apoptosis in Her2-overexpressing breast cancer cells through the 
mitochondrial-mediated pathway. J Nat Prod, 75, 747-51. 
KAYASHIMA, T., MORI, M., YOSHIDA, H., MIZUSHINA, Y. & MATSUBARA, K. 2009. 1,4-
Naphthoquinone is a potent inhibitor of human cancer cell growth and 
angiogenesis. Cancer Lett, 278, 34-40. 
KELLEHER, C., KURTH, I. & LINGNER, J. 2005. Human protection of telomeres 1 (POT1) 
is a negative regulator of telomerase activity in vitro. Mol Cell Biol, 25, 808-
18. 
KENNEDY, R. D. & D'ANDREA, A. D. 2005. The Fanconi Anemia/BRCA pathway: new 
faces in the crowd. Genes Dev, 19, 2925-40. 
KHAW, A. K., SAMENI, S. & HANDE, M. H. Manuscript in preparation. Mechanism of 
action of Plumbagin in telomerase inhibition, telomere attrition, growth 
arrest and cell death of human brain tumor cells. 
KIM, C. H., PARK, S. J. & LEE, S. H. 2002. A targeted inhibition of DNA-dependent 
protein kinase sensitizes breast cancer cells following ionizing radiation. J 
Pharmacol Exp Ther, 303, 753-9. 
KIM, N. W., PIATYSZEK, M. A., PROWSE, K. R., HARLEY, C. B., WEST, M. D., HO, P. L., 
COVIELLO, G. M., WRIGHT, W. E., WEINRICH, S. L. & SHAY, J. W. 1994. Specific 
association of human telomerase activity with immortal cells and cancer. 
Science, 266, 2011-5. 
KLAPPER, W., QIAN, W., SCHULTE, C. & PARWARESCH, R. 2003. DNA damage 
transiently increases TRF2 mRNA expression and telomerase activity. 
Leukemia, 17, 2007-15. 
KOBOLDT DC, F. R., MCLELLAN MD, SCHMIDT H, KALICKI-VEIZER J, MCMICHAEL JF, 
FULTON LL, DOOLING DJ, DING L, MARDIS ER, WILSON RK, ALLY A, 
BALASUNDARAM M, BUTTERFIELD YS, CARLSEN R, CARTER C, CHU A, CHUAH 
E, CHUN HJ, COOPE RJ, DHALLA N, GUIN R, HIRST C, HIRST M, HOLT RA, LEE D, 
LI HI, MAYO M, MOORE RA, MUNGALL AJ, PLEASANCE E, ROBERTSON A, 
SCHEIN JE, SHAFIEI A, SIPAHIMALANI P, SLOBODAN JR, STOLL D, TAM A, 
THIESSEN N, VARHOL RJ, WYE N, ZENG T, ZHAO Y, BIROL I, JONES SJ, MARRA 
MA, CHERNIACK AD, SAKSENA G, ONOFRIO RC, PHO NH, CARTER SL, 
SCHUMACHER SE, TABAK B, HERNANDEZ B, GENTRY J, NGUYEN H, CRENSHAW 
A, ARDLIE K, BEROUKHIM R, WINCKLER W, GETZ G, GABRIEL SB, MEYERSON 
M, CHIN L, PARK PJ, KUCHERLAPATI R, HOADLEY KA, AUMAN J, FAN C, 
TURMAN YJ, SHI Y, LI L, TOPAL MD, HE X, CHAO HH, PRAT A, SILVA GO, IGLESIA 
MD, ZHAO W, USARY J, BERG JS, ADAMS M, BOOKER J, WU J, GULABANI A, 
BODENHEIMER T, HOYLE AP, SIMONS JV, SOLOWAY MG, MOSE LE, JEFFERYS 
SR, BALU S, PARKER JS, HAYES D, PEROU CM, MALIK S, MAHURKAR S, SHEN H, 
WEISENBERGER DJ, TRICHE T JR, LAI PH, BOOTWALLA MS, MAGLINTE DT, 
BERMAN BP, VAN DEN BERG DJ, BAYLIN SB, LAIRD PW, CREIGHTON CJ, 
DONEHOWER LA, GETZ G, NOBLE M, VOET D, SAKSENA G, GEHLENBORG N, 
DICARA D, ZHANG J, ZHANG H, WU CJ, LIU SY, LAWRENCE MS, ZOU L, 
SIVACHENKO A, LIN P, STOJANOV P, JING R, CHO J, SINHA R, PARK RW, 
NAZAIRE MD, ROBINSON J, THORVALDSDOTTIR H, MESIROV J, PARK PJ, CHIN 
L, REYNOLDS S, KREISBERG RB, BERNARD B, BRESSLER R, ERKKILA T, LIN J, 
THORSSON V, ZHANG W, SHMULEVICH I, CIRIELLO G, WEINHOLD N, SCHULTZ 
219 
 
N, GAO J, CERAMI E, GROSS B, JACOBSEN A, SINHA R, AKSOY B, ANTIPIN Y, 
REVA B, SHEN R, TAYLOR BS, LADANYI M, SANDER C, ANUR P, SPELLMAN PT, 
LU Y, LIU W, VERHAAK RR, MILLS GB, AKBANI R, ZHANG N, BROOM BM, 
CASASENT TD, WAKEFIELD C, UNRUH AK, BAGGERLY K, COOMBES K, 
WEINSTEIN JN, HAUSSLER D, BENZ CC, STUART JM, BENZ SC, ZHU J, SZETO CC, 
SCOTT GK, YAU C, PAULL EO, CARLIN D, WONG C, SOKOLOV A, THUSBERG J, 
MOONEY S, NG S, GOLDSTEIN TC, ELLROTT K, GRIFFORD M, WILKS C, MA S, 
CRAFT B, YAN C, HU Y, MEERZAMAN D, GASTIER-FOSTER JM, BOWEN J, 
RAMIREZ NC, BLACK AD, PYATT RE, WHITE P, ZMUDA EJ, FRICK J, 
LICHTENBERG TM, BROOKENS R, GEORGE MM, GERKEN MA, HARPER HA, 
LERAAS KM, WISE LJ, TABLER TR, MCALLISTER C, BARR T, HART-KOTHARI M, 
TARVIN K, SALLER C, SANDUSKY G, MITCHELL C, IACOCCA MV, BROWN J, 
RABENO B, CZERWINSKI C, PETRELLI N, DOLZHANSKY O, ABRAMOV M, 
VORONINA O, POTAPOVA O, MARKS JR, SUCHORSKA WM, MURAWA D, 
KYCLER W, IBBS M, KORSKI K, SPYCHAŁA A, MURAWA P, BRZEZIŃSKI JJ, PERZ 
H, ŁAŹNIAK R, TERESIAK M, TATKA H, LEPOROWSKA E, BOGUSZ-CZERNIEWICZ 
M, MALICKI J, MACKIEWICZ A, WIZNEROWICZ M, LE XV, KOHL B, NGUYEN VT, 
THORP R, NGUYEN VB, SUSSMAN H, BUI DP, HAJEK R, NGUYEN PH, TRAN VT, 
HUYNH QT, KHAN KZ, PENNY R, MALLERY D, CURLEY E, SHELTON C, YENA P, 
INGLE JN, COUCH FJ, LINGLE WL, KING TA, GONZALEZ-ANGULO AM, MILLS GB, 
DYER MD, LIU S, MENG X, PATANGAN M, WALDMAN F, STÖPPLER H, 
RATHMELL W, THORNE L, HUANG M, BOICE L, HILL A, MORRISON C, 
GAUDIOSO C, BSHARA W, DAILY K, EGEA SC, PEGRAM M, GOMEZ-FERNANDEZ 
C, DHIR R, BHARGAVA R, BRUFSKY A, SHRIVER CD, HOOKE JA, CAMPBELL JL, 
MURAL RJ, HU H, SOMIARI S, LARSON C, DEYARMIN B, KVECHER L, KOVATICH 
AJ, ELLIS MJ, KING TA, HU H, COUCH FJ, MURAL RJ, STRICKER T, WHITE K, 
OLOPADE O, INGLE JN, LUO C, CHEN Y, MARKS JR, WALDMAN F, 
WIZNEROWICZ M, BOSE R, CHANG LW, BECK AH, GONZALEZ-ANGULO AM, 
PIHL T, JENSEN M, SFEIR R, KAHN A, CHU A, KOTHIYAL P, WANG Z, SNYDER E, 
PONTIUS J, AYALA B, BACKUS M, WALTON J, BABOUD J, BERTON D, NICHOLLS 
M, SRINIVASAN D, RAMAN R, GIRSHIK S, KIGONYA P, ALONSO S, SANBHADTI 
R, BARLETTA S, POT D, SHETH M, DEMCHOK JA, SHAW KR, YANG L, ELEY G, 
FERGUSON ML, TARNUZZER RW, ZHANG J, DILLON LA, BUETOW K, FIELDING 
P, OZENBERGER BA, GUYER MS, SOFIA HJ, PALCHIK JD. 2012. Comprehensive 
molecular portraits of human breast tumours. Nature, 490, 61-70. 
KONDO, Y., KONDO, S., TANAKA, Y., HAQQI, T., BARNA, B. P. & COWELL, J. K. 1998. 
Inhibition of telomerase increases the susceptibility of human malignant 
glioblastoma cells to cisplatin-induced apoptosis. Oncogene, 16, 2243-8. 
KONDOH, K., TSUJI, N., ASANUMA, K., KOBAYASHI, D. & WATANABE, N. 2007. 
Inhibition of estrogen receptor beta-mediated human telomerase reverse 
transcriptase gene transcription via the suppression of mitogen-activated 
protein kinase signaling plays an important role in 15-deoxy-Delta(12,14)-
prostaglandin J(2)-induced apoptosis in cancer cells. Exp Cell Res, 313, 3486-
96. 
KONG, W., HE, L., RICHARDS, E. J., CHALLA, S., XU, C. X., PERMUTH-WEY, J., 
LANCASTER, J. M., COPPOLA, D., SELLERS, T. A., DJEU, J. Y. & CHENG, J. Q. 
2013. Upregulation of miRNA-155 promotes tumour angiogenesis by 




KONISHI, A. & DE LANGE, T. 2008. Cell cycle control of telomere protection and NHEJ 
revealed by a ts mutation in the DNA-binding domain of TRF2. Genes Dev, 22, 
1221-30. 
KUMAR, S., GAUTAM, S. & SHARMA, A. 2013. Antimutagenic and antioxidant 
properties of plumbagin and other naphthoquinones. Mutat Res, 755, 30-41. 
KUO, L. J. & YANG, L. X. 2008. Gamma-H2AX - a novel biomarker for DNA double-
strand breaks. In Vivo, 22, 305-9. 
KUO, P. L., HSU, Y. L. & CHO, C. Y. 2006. Plumbagin induces G2-M arrest and autophagy 
by inhibiting the AKT/mammalian target of rapamycin pathway in breast 
cancer cells. Mol Cancer Ther, 5, 3209-21. 
KYO, S., TAKAKURA, M., FUJIWARA, T. & INOUE, M. 2008. Understanding and 
exploiting hTERT promoter regulation for diagnosis and treatment of human 
cancers. Cancer Sci, 99, 1528-38. 
KYO, S., TAKAKURA, M., KANAYA, T., ZHUO, W., FUJIMOTO, K., NISHIO, Y., ORIMO, A. 
& INOUE, M. 1999. Estrogen activates telomerase. Cancer Res, 59, 5917-21. 
KYO, S., TAKAKURA, M., TAIRA, T., KANAYA, T., ITOH, H., YUTSUDO, M., ARIGA, H. & 
INOUE, M. 2000. Sp1 cooperates with c-Myc to activate transcription of the 
human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res, 28, 
669-77. 
KYTOLA, S., RUMMUKAINEN, J., NORDGREN, A., KARHU, R., FARNEBO, F., ISOLA, J. & 
LARSSON, C. 2000. Chromosomal alterations in 15 breast cancer cell lines by 
comparative genomic hybridization and spectral karyotyping. Genes 
Chromosomes Cancer, 28, 308-17. 
LAMY, E., GOETZ, V., ERLACHER, M., HERZ, C. & MERSCH-SUNDERMANN, V. 2013. 
hTERT: Another brick in the wall of cancer cells. Mutat Res, 752, 119-28. 
LAVARONE, E., PUPPIN, C., PASSON, N., FILETTI, S., RUSSO, D. & DAMANTE, G. 2013. 
The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic 
marks in thyroid cancer cell lines. Mol Cell Endocrinol, 365, 1-10. 
LEE, J. H., YEON, J. H., KIM, H., ROH, W., CHAE, J., PARK, H. O. & KIM, D. M. 2012. The 
natural anticancer agent plumbagin induces potent cytotoxicity in MCF-7 
human breast cancer cells by inhibiting a PI-5 kinase for ROS generation. PLoS 
One, 7, e45023. 
LEHMANN, B. D., BAUER, J. A., CHEN, X., SANDERS, M. E., CHAKRAVARTHY, A. B., SHYR, 
Y. & PIETENPOL, J. A. 2011. Identification of human triple-negative breast 
cancer subtypes and preclinical models for selection of targeted therapies. J 
Clin Invest, 121, 2750-67. 
LEI, R., TANG, J., ZHUANG, X., DENG, R., LI, G., YU, J., LIANG, Y., XIAO, J., WANG, H. Y., 
YANG, Q. & HU, G. 2013. Suppression of MIM by microRNA-182 activates 
RhoA and promotes breast cancer metastasis. Oncogene. 
LEU, J. I., DUMONT, P., HAFEY, M., MURPHY, M. E. & GEORGE, D. L. 2004. 
Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 
complex. Nat Cell Biol, 6, 443-50. 
LEVY, M. Z., ALLSOPP, R. C., FUTCHER, A. B., GREIDER, C. W. & HARLEY, C. B. 1992. 
Telomere end-replication problem and cell aging. J Mol Biol, 225, 951-60. 
LI, A. Y., LIN, H. H., KUO, C. Y., SHIH, H. M., WANG, C. C., YEN, Y. & ANN, D. K. 2011. 
High-mobility group A2 protein modulates hTERT transcription to promote 
tumorigenesis. Mol Cell Biol, 31, 2605-17. 
LI, J., SHEN, L., LU, F. R., QIN, Y., CHEN, R., LI, Y., ZHAN, H. Z. & HE, Y. Q. 2012. 
Plumbagin inhibits cell growth and potentiates apoptosis in human gastric 
221 
 
cancer cells in vitro through the NF-kappaB signaling pathway. Acta 
Pharmacol Sin, 33, 242-9. 
LI, Q., PETERSON, K. R., FANG, X. & STAMATOYANNOPOULOS, G. 2002. Locus control 
regions. Blood, 100, 3077-86. 
LIANG, Y., YAN, C. & SCHOR, N. F. 2001. Apoptosis in the absence of caspase 3. 
Oncogene, 20, 6570-8. 
LIEBER, M. R. 2008. The mechanism of human nonhomologous DNA end joining. J Biol 
Chem, 283, 1-5. 
LIM, L. Y., VIDNOVIC, N., ELLISEN, L. W. & LEONG, C. O. 2009. Mutant p53 mediates 
survival of breast cancer cells. Br J Cancer, 101, 1606-12. 
LINGER, B. R. & PRICE, C. M. 2009. Conservation of telomere protein complexes: 
shuffling through evolution. Crit Rev Biochem Mol Biol, 44, 434-46. 
LIU, J. P., CHEN, S. M., CONG, Y. S., NICHOLLS, C., ZHOU, S. F., TAO, Z. Z. & LI, H. 2010. 
Regulation of telomerase activity by apparently opposing elements. Ageing 
Res Rev, 9, 245-56. 
LIU, K., HODES, R. J. & WENG, N. 2001. Cutting edge: telomerase activation in human 
T lymphocytes does not require increase in telomerase reverse transcriptase 
(hTERT) protein but is associated with hTERT phosphorylation and nuclear 
translocation. J Immunol, 166, 4826-30. 
LIU, R. H. 2004. Potential synergy of phytochemicals in cancer prevention: mechanism 
of action. J Nutr, 134, 3479S-3485S. 
LOEB, L. A. & MONNAT, R. J., JR. 2008. DNA polymerases and human disease. Nat Rev 
Genet, 9, 594-604. 
LONDONO-VALLEJO, J. A. 2008. Telomere instability and cancer. Biochimie, 90, 73-82. 
LORD, C. J. & ASHWORTH, A. 2012. The DNA damage response and cancer therapy. 
Nature, 481, 287-94. 
LU, C., SHEN, Q., DUPRE, E., KIM, H., HILSENBECK, S. & BROWN, P. H. 2005. cFos is 
critical for MCF-7 breast cancer cell growth. Oncogene, 24, 6516-24. 
LU, D., KIRIYAMA, Y., LEE, K. Y. & GIGUERE, V. 2001. Transcriptional regulation of the 
estrogen-inducible pS2 breast cancer marker gene by the ERR family of 
orphan nuclear receptors. Cancer Res, 61, 6755-61. 
LU, J. J., BAO, J. L., WU, G. S., XU, W. S., HUANG, M. Q., CHEN, X. P. & WANG, Y. T. 
2013a. Quinones derived from plant secondary metabolites as anti-cancer 
agents. Anticancer Agents Med Chem, 13, 456-63. 
LU, M. H., LIAO, Z. L., ZHAO, X. Y., FAN, Y. H., LIN, X. L., FANG, D. C., GUO, H. & YANG, 
S. M. 2012. hTERT-based therapy: a universal anticancer approach (Review). 
Oncol Rep, 28, 1945-52. 
LU, W., ZHANG, Y., LIU, D., SONGYANG, Z. & WAN, M. 2013b. Telomeres-structure, 
function, and regulation. Exp Cell Res, 319, 133-41. 
LUO, J., SOLIMINI, N. L. & ELLEDGE, S. J. 2009. Principles of cancer therapy: oncogene 
and non-oncogene addiction. Cell, 136, 823-37. 
LUPIEN, M., EECKHOUTE, J., MEYER, C. A., WANG, Q., ZHANG, Y., LI, W., CARROLL, J. 
S., LIU, X. S. & BROWN, M. 2008. FoxA1 translates epigenetic signatures into 
enhancer-driven lineage-specific transcription. Cell, 132, 958-70. 
MACERA-BLOCH, L., HOUGHTON, J., LENAHAN, M., JHA, K. K. & OZER, H. L. 2002. 
Termination of lifespan of SV40-transformed human fibroblasts in crisis is due 
to apoptosis. J Cell Physiol, 190, 332-44. 
222 
 
MADISON, D. L., STAUFFER, D. & LUNDBLAD, J. R. 2011. The PARP inhibitor PJ34 causes 
a PARP1-independent, p21 dependent mitotic arrest. DNA Repair (Amst), 10, 
1003-13. 
MAGAN, N., ISAACS, R. J. & STOWELL, K. M. 2012. Treatment with the PARP-inhibitor 
PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells. 
Anticancer Drugs, 23, 627-37. 
MAGKLARA, A. & SMITH, C. L. 2009. A composite intronic element directs dynamic 
binding of the progesterone receptor and GATA-2. Mol Endocrinol, 23, 61-73. 
MAIRE, V., NEMATI, F., RICHARDSON, M., VINCENT-SALOMON, A., TESSON, B., 
RIGAILL, G., GRAVIER, E., MARTY-PROUVOST, B., DE KONING, L., LANG, G., 
GENTIEN, D., DUMONT, A., BARILLOT, E., MARANGONI, E., DECAUDIN, D., 
ROMAN-ROMAN, S., PIERRE, A., CRUZALEGUI, F., DEPIL, S., TUCKER, G. C. & 
DUBOIS, T. 2013. Polo-like kinase 1: a potential therapeutic option in 
combination with conventional chemotherapy for the management of 
patients with triple-negative breast cancer. Cancer Res, 73, 813-23. 
MANU, K. A., SHANMUGAM, M. K., RAJENDRAN, P., LI, F., RAMACHANDRAN, L., HAY, 
H. S., KANNAIYAN, R., SWAMY, S. N., VALI, S., KAPOOR, S., RAMESH, B., BIST, 
P., KOAY, E. S., LIM, L. H., AHN, K. S., KUMAR, A. P. & SETHI, G. 2011. Plumbagin 
inhibits invasion and migration of breast and gastric cancer cells by 
downregulating the expression of chemokine receptor CXCR4. Mol Cancer, 
10, 107. 
MARTINEZ, P. & BLASCO, M. A. 2011. Telomeric and extra-telomeric roles for 
telomerase and the telomere-binding proteins. Nat Rev Cancer, 11, 161-76. 
MASCIARELLI, S., FONTEMAGGI, G., DI AGOSTINO, S., DONZELLI, S., CARCARINO, E., 
STRANO, S. & BLANDINO, G. 2013. Gain-of-function mutant p53 
downregulates miR-223 contributing to chemoresistance of cultured tumor 
cells. Oncogene. 
MASUTANI, M. & FUJIMORI, H. 2013. Poly(ADP-ribosyl)ation in carcinogenesis. Mol 
Aspects Med. 
MASUTOMI, K., POSSEMATO, R., WONG, J. M., CURRIER, J. L., TOTHOVA, Z., MANOLA, 
J. B., GANESAN, S., LANSDORP, P. M., COLLINS, K. & HAHN, W. C. 2005. The 
telomerase reverse transcriptase regulates chromatin state and DNA damage 
responses. Proc Natl Acad Sci U S A, 102, 8222-7. 
MAYOR, S. 2004. Claim of human reproductive cloning provokes calls for international 
ban. BMJ, 328, 185. 
MCCARTHY, N. 2013. Metastasis: Going places with VHL. Nat Rev Cancer, 13, 78. 
MCCLINTOCK, B. 1942. The Fusion of Broken Ends of Chromosomes Following Nuclear 
Fusion. Proc Natl Acad Sci U S A, 28, 458-63. 
MCFADYEN, M. C., MELVIN, W. T. & MURRAY, G. I. 2004. Cytochrome P450 enzymes: 
novel options for cancer therapeutics. Mol Cancer Ther, 3, 363-71. 
MCKALLIP, R. J., LOMBARD, C., SUN, J. & RAMAKRISHNAN, R. 2010. Plumbagin-
induced apoptosis in lymphocytes is mediated through increased reactive 
oxygen species production, upregulation of Fas, and activation of the caspase 
cascade. Toxicol Appl Pharmacol, 247, 41-52. 
MCLAUGHLIN, S. A. 2013. Surgical management of the breast: breast conservation 
therapy and mastectomy. Surg Clin North Am, 93, 411-28. 
MCPHERSON, J. P., HANDE, M. P., POONEPALLI, A., LEMMERS, B., ZABLOCKI, E., 
MIGON, E., SHEHABELDIN, A., PORRAS, A., KARASKOVA, J., VUKOVIC, B., 
223 
 
SQUIRE, J. & HAKEM, R. 2006. A role for Brca1 in chromosome end 
maintenance. Hum Mol Genet, 15, 831-8. 
MEDUNJANIN, S., WEINERT, S., SCHMEISSER, A., MAYER, D. & BRAUN-DULLAEUS, R. 
C. 2010. Interaction of the double-strand break repair kinase DNA-PK and 
estrogen receptor-alpha. Mol Biol Cell, 21, 1620-8. 
MELANA, S. M., HOLLAND, J. F. & POGO, B. G. 1998. Inhibition of cell growth and 
telomerase activity of breast cancer cells in vitro by 3'-azido-3'-
deoxythymidine. Clin Cancer Res, 4, 693-6. 
MI, J., DZIEGIELEWSKI, J., BOLESTA, E., BRAUTIGAN, D. L. & LARNER, J. M. 2009. 
Activation of DNA-PK by ionizing radiation is mediated by protein 
phosphatase 6. PLoS One, 4, e4395. 
MICHELS, J., VITALE, I., GALLUZZI, L., ADAM, J., OLAUSSEN, K. A., KEPP, O., SENOVILLA, 
L., TALHAOUI, I., GUEGAN, J., ENOT, D. P., TALBOT, M., ROBIN, A., GIRARD, P., 
OREAR, C., LISSA, D., SUKKURWALA, A. Q., GARCIA, P., BEHNAM-MOTLAGH, 
P., KOHNO, K., WU, G. S., BRENNER, C., DESSEN, P., SAPARBAEV, M., SORIA, J. 
C., CASTEDO, M. & KROEMER, G. 2013. Cisplatin resistance associated with 
PARP hyperactivation. Cancer Res, 73, 2271-80. 
MICHISHITA, E., GARCES, G., BARRETT, J. C. & HORIKAWA, I. 2006. Upregulation of the 
KIAA1199 gene is associated with cellular mortality. Cancer Lett, 239, 71-7. 
MIN, J., CHOI, E. S., HWANG, K., KIM, J., SAMPATH, S., VENKITARAMAN, A. R. & LEE, 
H. 2012. The breast cancer susceptibility gene BRCA2 is required for the 
maintenance of telomere homeostasis. J Biol Chem, 287, 5091-101. 
MIRZAYANS, R., ANDRAIS, B., SCOTT, A. & MURRAY, D. 2012. New insights into p53 
signaling and cancer cell response to DNA damage: implications for cancer 
therapy. J Biomed Biotechnol, 2012, 170325. 
MISHRA, B. B. & TIWARI, V. K. 2011. Natural products: an evolving role in future drug 
discovery. Eur J Med Chem, 46, 4769-807. 
MISTELI, T. & SOUTOGLOU, E. 2009. The emerging role of nuclear architecture in DNA 
repair and genome maintenance. Nat Rev Mol Cell Biol, 10, 243-54. 
MITCHELL, J. R., WOOD, E. & COLLINS, K. 1999. A telomerase component is defective 
in the human disease dyskeratosis congenita. Nature, 402, 551-5. 
MITELMAN, F., JOHANSSON, B. & MERTENS, F. 2007. The impact of translocations and 
gene fusions on cancer causation. Nat Rev Cancer, 7, 233-45. 
MOCHIZUKI, Y., HE, J., KULKARNI, S., BESSLER, M. & MASON, P. J. 2004. Mouse 
dyskerin mutations affect accumulation of telomerase RNA and small 
nucleolar RNA, telomerase activity, and ribosomal RNA processing. Proc Natl 
Acad Sci U S A, 101, 10756-61. 
MOLASSIOTIS, A., FERNADEZ-ORTEGA, P., PUD, D., OZDEN, G., SCOTT, J. A., PANTELI, 
V., MARGULIES, A., BROWALL, M., MAGRI, M., SELVEKEROVA, S., MADSEN, E., 
MILOVICS, L., BRUYNS, I., GUDMUNDSDOTTIR, G., HUMMERSTON, S., 
AHMAD, A. M., PLATIN, N., KEARNEY, N. & PATIRAKI, E. 2005. Use of 
complementary and alternative medicine in cancer patients: a European 
survey. Ann Oncol, 16, 655-63. 
MOLL, U. M., WOLFF, S., SPEIDEL, D. & DEPPERT, W. 2005. Transcription-independent 
pro-apoptotic functions of p53. Curr Opin Cell Biol, 17, 631-6. 
MONDAL, S., BANDYOPADHYAY, S., GHOSH, M. K., MUKHOPADHYAY, S., ROY, S. & 
MANDAL, C. 2012. Natural products: promising resources for cancer drug 
discovery. Anticancer Agents Med Chem, 12, 49-75. 
224 
 
MONTANARO, L., CALIENNI, M., CECCARELLI, C., SANTINI, D., TAFFURELLI, M., PILERI, 
S., TRERE, D. & DERENZINI, M. 2008. Relationship between dyskerin 
expression and telomerase activity in human breast cancer. Cell Oncol, 30, 
483-90. 
MONTANO, M. M., BIANCO, N. R., DENG, H., WITTMANN, B. M., CHAPLIN, L. C. & 
KATZENELLENBOGEN, B. S. 2005. Estrogen receptor regulation of quinone 
reductase in breast cancer: implications for estrogen-induced breast tumor 
growth and therapeutic uses of tamoxifen. Front Biosci, 10, 1440-61. 
MORIN, G. B. 1989. The human telomere terminal transferase enzyme is a 
ribonucleoprotein that synthesizes TTAGGG repeats. Cell, 59, 521-9. 
MUKHERJEE, B., TELANG, N. & WONG, G. Y. 2009. Growth inhibition of estrogen 
receptor positive human breast cancer cells by Taheebo from the inner bark 
of Tabebuia avellandae tree. Int J Mol Med, 24, 253-60. 
MULLER, P. A., VOUSDEN, K. H. & NORMAN, J. C. 2011. p53 and its mutants in tumor 
cell migration and invasion. J Cell Biol, 192, 209-18. 
MULTANI, A. S., FURLONG, C. & PATHAK, S. 1998. Reduction of telomeric signals in 
murine melanoma and human breast cancer cell lines treated with 3'-azido-
2'-3'-dideoxythymidine. Int J Oncol, 13, 923-5. 
MUNCK, J. M., BATEY, M. A., ZHAO, Y., JENKINS, H., RICHARDSON, C. J., CANO, C., 
TAVECCHIO, M., BARBEAU, J., BARDOS, J., CORNELL, L., GRIFFIN, R. J., 
MENEAR, K., SLADE, A., THOMMES, P., MARTIN, N. M., NEWELL, D. R., SMITH, 
G. C. & CURTIN, N. J. 2012. Chemosensitization of cancer cells by KU-0060648, 
a dual inhibitor of DNA-PK and PI-3K. Mol Cancer Ther, 11, 1789-98. 
MUNOZ-GAMEZ, J. A., MARTIN-OLIVA, D., AGUILAR-QUESADA, R., CANUELO, A., 
NUNEZ, M. I., VALENZUELA, M. T., RUIZ DE ALMODOVAR, J. M., DE MURCIA, 
G. & OLIVER, F. J. 2005. PARP inhibition sensitizes p53-deficient breast cancer 
cells to doxorubicin-induced apoptosis. Biochem J, 386, 119-25. 
MUNOZ, P., BLANCO, R., DE CARCER, G., SCHOEFTNER, S., BENETTI, R., FLORES, J. M., 
MALUMBRES, M. & BLASCO, M. A. 2009. TRF1 controls telomere length and 
mitotic fidelity in epithelial homeostasis. Mol Cell Biol, 29, 1608-25. 
MUSGROVE, E. A., LEE, C. S., BUCKLEY, M. F. & SUTHERLAND, R. L. 1994. Cyclin D1 
induction in breast cancer cells shortens G1 and is sufficient for cells arrested 
in G1 to complete the cell cycle. Proc Natl Acad Sci U S A, 91, 8022-6. 
NAGARAJA, G. M., OTHMAN, M., FOX, B. P., ALSABER, R., PELLEGRINO, C. M., ZENG, 
Y., KHANNA, R., TAMBURINI, P., SWAROOP, A. & KANDPAL, R. P. 2006. Gene 
expression signatures and biomarkers of noninvasive and invasive breast 
cancer cells: comprehensive profiles by representational difference analysis, 
microarrays and proteomics. Oncogene, 25, 2328-38. 
NAKAMURA, T. M., MORIN, G. B., CHAPMAN, K. B., WEINRICH, S. L., ANDREWS, W. H., 
LINGNER, J., HARLEY, C. B. & CECH, T. R. 1997. Telomerase catalytic subunit 
homologs from fission yeast and human. Science, 277, 955-9. 
NASSIRPOUR, R., MEHTA, P. P., BAXI, S. M. & YIN, M. J. 2013. miR-221 promotes 
tumorigenesis in human triple negative breast cancer cells. PLoS One, 8, 
e62170. 
NEAL, J. A. & MEEK, K. 2011. Choosing the right path: does DNA-PK help make the 
decision? Mutat Res, 711, 73-86. 
NEILSEN, P. M., NOLL, J. E., MATTISKE, S., BRACKEN, C. P., GREGORY, P. A., SCHULZ, R. 
B., LIM, S. P., KUMAR, R., SUETANI, R. J., GOODALL, G. J. & CALLEN, D. F. 2013. 
225 
 
Mutant p53 drives invasion in breast tumors through up-regulation of miR-
155. Oncogene, 32, 2992-3000. 
NEVE, R. M., CHIN, K., FRIDLYAND, J., YEH, J., BAEHNER, F. L., FEVR, T., CLARK, L., 
BAYANI, N., COPPE, J. P., TONG, F., SPEED, T., SPELLMAN, P. T., DEVRIES, S., 
LAPUK, A., WANG, N. J., KUO, W. L., STILWELL, J. L., PINKEL, D., ALBERTSON, 
D. G., WALDMAN, F. M., MCCORMICK, F., DICKSON, R. B., JOHNSON, M. D., 
LIPPMAN, M., ETHIER, S., GAZDAR, A. & GRAY, J. W. 2006. A collection of 
breast cancer cell lines for the study of functionally distinct cancer subtypes. 
Cancer Cell, 10, 515-27. 
NOONAN, J. P. & MCCALLION, A. S. 2010. Genomics of long-range regulatory 
elements. Annu Rev Genomics Hum Genet, 11, 1-23. 
O'SHAUGHNESSY, J., YOFFE, M., OSBORNE, C., ET AL 2008. Triple negative breast 
cancer: a phase 2, multi-center, open-label, randomized trial of 
gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor. San 
Antonio Breast Cancer Symposium. Abstract 2120. 
O'SHAUGHNESSY, J. C. O., J. PIPPEN, M. YOFFE, D. PATT, G. MONAGHAN, C. ROCHA, 
V. OSSOVSKAYA, B. SHERMAN, C. BRADLEY; 2009. Efficacy of BSI-201, a poly 
(ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with 
gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative 
breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol, 
Abstract 3, 27. 
OECKINGHAUS, A. & GHOSH, S. 2009. The NF-kappaB family of transcription factors 
and its regulation. Cold Spring Harb Perspect Biol, 1, a000034. 
OGBOURNE, S. & ANTALIS, T. M. 1998. Transcriptional control and the role of silencers 
in transcriptional regulation in eukaryotes. Biochem J, 331 ( Pt 1), 1-14. 
OKAZAKI, K., NAKAYAMA, N., NARIAI, Y., NAKAYAMA, K., MIYAZAKI, K., MARUYAMA, 
R., KATO, H., KOSUGI, S., URANO, T. & SAKASHITA, G. 2012. Nuclear 
localization signal in a cancer-related transcriptional regulator protein NAC1. 
Carcinogenesis, 33, 1854-62. 
OMORI, S., TAKIGUCHI, Y., SUDA, A., SUGIMOTO, T., MIYAZAWA, H., TANABE, N., 
TATSUMI, K., KIMURA, H., PARDINGTON, P. E., CHEN, F., CHEN, D. J. & 
KURIYAMA, T. 2002. Suppression of a DNA double-strand break repair gene, 
Ku70, increases radio- and chemosensitivity in a human lung carcinoma cell 
line. DNA Repair (Amst), 1, 299-310. 
ORLANDO, L., SCHIAVONE, P., FEDELE, P., CALVANI, N., NACCI, A., CINEFRA, M., 
D'AMICO, M., MAZZONI, E., MARINO, A., SPONZIELLO, F., MORELLI, F., 
LOMBARDI, L., SILVESTRIS, N. & CINIERI, S. 2012. Poly (ADP-ribose) 
polymerase (PARP): rationale, preclinical and clinical evidences of its 
inhibition as breast cancer treatment. Expert Opin Ther Targets, 16 Suppl 2, 
S83-9. 
OSTERHAGE, J. L. & FRIEDMAN, K. L. 2009. Chromosome end maintenance by 
telomerase. J Biol Chem, 284, 16061-5. 
PADHYE, S., DANDAWATE, P., YUSUFI, M., AHMAD, A. & SARKAR, F. H. 2012. 
Perspectives on medicinal properties of plumbagin and its analogs. Med Res 
Rev, 32, 1131-58. 
PAN, Y. F., WANSA, K. D., LIU, M. H., ZHAO, B., HONG, S. Z., TAN, P. Y., LIM, K. S., 
BOURQUE, G., LIU, E. T. & CHEUNG, E. 2008. Regulation of estrogen receptor-
mediated long range transcription via evolutionarily conserved distal 
response elements. J Biol Chem, 283, 32977-88. 
226 
 
PAPADOPOULOS, K. 2006. Targeting the Bcl-2 family in cancer therapy. Semin Oncol, 
33, 449-56. 
PAPANIKOLAOU, V., ATHANASSIOU, E., DUBOS, S., DIMOU, I., PAPATHANASIOU, I., 
KITSIOU-TZELI, S., KAPPAS, C. & TSEZOU, A. 2011. hTERT regulation by NF-
kappaB and c-myc in irradiated HER2-positive breast cancer cells. Int J Radiat 
Biol, 87, 609-21. 
PARK, J. I., VENTEICHER, A. S., HONG, J. Y., CHOI, J., JUN, S., SHKRELI, M., CHANG, W., 
MENG, Z., CHEUNG, P., JI, H., MCLAUGHLIN, M., VEENSTRA, T. D., NUSSE, R., 
MCCREA, P. D. & ARTANDI, S. E. 2009. Telomerase modulates Wnt signalling 
by association with target gene chromatin. Nature, 460, 66-72. 
PARKIN, D. M., BRAY, F., FERLAY, J. & PISANI, P. 2005. Global Cancer Statistics, 2002. 
CA: A Cancer Journal for Clinicians, 55, 74-108. 
PARKINSON, E. K., FITCHETT, C. & CERESER, B. 2008. Dissecting the non-canonical 
functions of telomerase. Cytogenet Genome Res, 122, 273-80. 
PARKINSON, E. K. & MINTY, F. 2007. Anticancer therapy targeting telomeres and 
telomerase : current status. BioDrugs, 21, 375-85. 
PATRIDGE, E. V., ERIKSSON, E. S., PENKETH, P. G., BAUMANN, R. P., ZHU, R., SHYAM, 
K., ERIKSSON, L. A. & SARTORELLI, A. C. 2012. 7-Nitro-4-
(phenylthio)benzofurazan is a potent generator of superoxide and hydrogen 
peroxide. Arch Toxicol, 86, 1613-25. 
PEDDI, P., LOFTIN, C. W., DICKEY, J. S., HAIR, J. M., BURNS, K. J., AZIZ, K., FRANCISCO, 
D. C., PANAYIOTIDIS, M. I., SEDELNIKOVA, O. A., BONNER, W. M., WINTERS, T. 
A. & GEORGAKILAS, A. G. 2010. DNA-PKcs deficiency leads to persistence of 
oxidatively induced clustered DNA lesions in human tumor cells. Free Radic 
Biol Med, 48, 1435-43. 
PELLATT, A. J., WOLFF, R. K., TORRES-MEJIA, G., JOHN, E. M., HERRICK, J. S., 
LUNDGREEN, A., BAUMGARTNER, K. B., GIULIANO, A. R., HINES, L. M., 
FEJERMAN, L., CAWTHON, R. & SLATTERY, M. L. 2013. Telomere length, 
telomere-related genes, and breast cancer risk: the breast cancer health 
disparities study. Genes Chromosomes Cancer, 52, 595-609. 
PERALTA-LEAL, A., RODRIGUEZ-VARGAS, J. M., AGUILAR-QUESADA, R., RODRIGUEZ, 
M. I., LINARES, J. L., DE ALMODOVAR, M. R. & OLIVER, F. J. 2009. PARP 
inhibitors: new partners in the therapy of cancer and inflammatory diseases. 
Free Radic Biol Med, 47, 13-26. 
PEROU, C. M., SORLIE, T., EISEN, M. B., VAN DE RIJN, M., JEFFREY, S. S., REES, C. A., 
POLLACK, J. R., ROSS, D. T., JOHNSEN, H., AKSLEN, L. A., FLUGE, O., 
PERGAMENSCHIKOV, A., WILLIAMS, C., ZHU, S. X., LONNING, P. E., BORRESEN-
DALE, A. L., BROWN, P. O. & BOTSTEIN, D. 2000. Molecular portraits of human 
breast tumours. Nature, 406, 747-52. 
PLUMBAGIN, S. O. D. F. C. S. 1999. Summary of data for chemical selection. Plumbagin. 
NIH: Wash-ington, DC., 481-42-5. 
POLYAK, K. 2011. Heterogeneity in breast cancer. J Clin Invest, 121, 3786-8. 
POONEPALLI, A., BANERJEE, B., RAMNARAYANAN, K., PALANISAMY, N., PUTTI, T. C. & 
HANDE, M. P. 2008. Telomere-mediated genomic instability and the clinico-
pathological parameters in breast cancer. Genes Chromosomes Cancer, 47, 
1098-109. 
PORUBEK, D. 2013. CYP17A1: a biochemistry, chemistry, and clinical review. Curr Top 
Med Chem, 13, 1364-84. 
227 
 
POWOLNY, A. A. & SINGH, S. V. 2008. Plumbagin-induced apoptosis in human prostate 
cancer cells is associated with modulation of cellular redox status and 
generation of reactive oxygen species. Pharm Res, 25, 2171-80. 
POYNTER, K. R., SACHS, P. C., BRIGHT, A. T., BREED, M. S., NGUYEN, B. N., ELMORE, L. 
W. & HOLT, S. E. 2009. Genetic inhibition of telomerase results in sensitization 
and recovery of breast tumor cells. Mol Cancer Ther, 8, 1319-27. 
PURRELLO, M., DI PIETRO, C., VIOLA, A., RAPISARDA, A., STEVENS, S., GUERMAH, M., 
TAO, Y., BONAIUTO, C., ARCIDIACONO, A., MESSINA, A., SICHEL, G., 
GRZESCHIK, K. H. & ROEDER, R. 1998. Genomics and transcription analysis of 
human TFIID. Oncogene, 16, 1633-8. 
QAZI, A., PAL, J., MAITAH, M., FULCINITI, M., PELLURU, D., NANJAPPA, P., LEE, S., 
BATCHU, R. B., PRASAD, M., BRYANT, C. S., RAJPUT, S., GRYAZNOV, S., BEER, 
D. G., WEAVER, D. W., MUNSHI, N. C., GOYAL, R. K. & SHAMMAS, M. A. 2010. 
Anticancer activity of a broccoli derivative, sulforaphane, in barrett 
adenocarcinoma: potential use in chemoprevention and as adjuvant in 
chemotherapy. Transl Oncol, 3, 389-99. 
RADNAI, B., ANTUS, C., RACZ, B., ENGELMANN, P., PRIBER, J. K., TUCSEK, Z., VERES, B., 
TURI, Z., LORAND, T., SUMEGI, B. & GALLYAS, F., JR. 2012. Protective effect of 
the poly(ADP-ribose) polymerase inhibitor PJ34 on mitochondrial 
depolarization-mediated cell death in hepatocellular carcinoma cells involves 
attenuation of c-Jun N-terminal kinase-2 and protein kinase B/Akt activation. 
Mol Cancer, 11, 34. 
REDON, C. E., NAKAMURA, A. J., ZHANG, Y. W., JI, J. J., BONNER, W. M., KINDERS, R. 
J., PARCHMENT, R. E., DOROSHOW, J. H. & POMMIER, Y. 2010. Histone 
gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. 
Clin Cancer Res, 16, 4532-42. 
REIS-FILHO, J. S. & TUTT, A. N. 2008. Triple negative tumours: a critical review. 
Histopathology, 52, 108-18. 
RIBEIRO, E., GANZINELLI, M., ANDREIS, D., BERTONI, R., GIARDINI, R., FOX, S. B., 
BROGGINI, M., BOTTINI, A., ZANONI, V., BAZZOLA, L., FORONI, C., GENERALI, 
D. & DAMIA, G. 2013. Triple negative breast cancers have a reduced 
expression of DNA repair genes. PLoS One, 8, e66243. 
RILEY, T., SONTAG, E., CHEN, P. & LEVINE, A. 2008. Transcriptional control of human 
p53-regulated genes. Nat Rev Mol Cell Biol, 9, 402-12. 
RIOS, J. & PUHALLA, S. 2011. PARP inhibitors in breast cancer: BRCA and beyond. 
Oncology (Williston Park), 25, 1014-25. 
RODIER, F., KIM, S. H., NIJJAR, T., YASWEN, P. & CAMPISI, J. 2005. Cancer and aging: 
the importance of telomeres in genome maintenance. Int J Biochem Cell Biol, 
37, 977-90. 
ROGAKOU, E. P., PILCH, D. R., ORR, A. H., IVANOVA, V. S. & BONNER, W. M. 1998. DNA 
double-stranded breaks induce histone H2AX phosphorylation on serine 139. 
J Biol Chem, 273, 5858-68. 
ROOS, W. P. & KAINA, B. 2006. DNA damage-induced cell death by apoptosis. Trends 
Mol Med, 12, 440-50. 
ROSENZWEIG, K. E., YOUMELL, M. B., PALAYOOR, S. T. & PRICE, B. D. 1997. 
Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase 
inhibitors wortmannin and LY294002 correlates with inhibition of DNA-




ROSS, D. T., SCHERF, U., EISEN, M. B., PEROU, C. M., REES, C., SPELLMAN, P., IYER, V., 
JEFFREY, S. S., VAN DE RIJN, M., WALTHAM, M., PERGAMENSCHIKOV, A., LEE, 
J. C., LASHKARI, D., SHALON, D., MYERS, T. G., WEINSTEIN, J. N., BOTSTEIN, D. 
& BROWN, P. O. 2000. Systematic variation in gene expression patterns in 
human cancer cell lines. Nat Genet, 24, 227-35. 
ROUSE, J. & JACKSON, S. P. 2002. Interfaces between the detection, signaling, and 
repair of DNA damage. Science, 297, 547-51. 
ROYLE, N. J., MENDEZ-BERMUDEZ, A., GRAVANI, A., NOVO, C., FOXON, J., WILLIAMS, 
J., COTTON, V. & HIDALGO, A. 2009. The role of recombination in telomere 
length maintenance. Biochem Soc Trans, 37, 589-95. 
RUBIS, B., HOLYSZ, H., BARCZAK, W., GRYCZKA, R., LACINSKI, M., JAGIELSKI, P., 
CZERNIKIEWICZ, A., POLROLNICZAK, A., WOJEWODA, A., PERZ, K., BIALEK, P., 
MORZE, K., KANDULA, Z., LISIAK, N., MROZIKIEWICZ, P. M., GRODECKA-
GAZDECKA, S. & RYBCZYNSKA, M. 2012. Study of ABCB1 polymorphism 
frequency in breast cancer patients from Poland. Pharmacol Rep, 64, 1560-6. 
RUBIS, B., HOLYSZ, H., GLADYCH, M., TOTON, E., PASZEL, A., LISIAK, N., KACZMAREK, 
M., HOFMANN, J. & RYBCZYNSKA, M. 2013a. Telomerase downregulation 
induces proapoptotic genes expression and initializes breast cancer cells 
apoptosis followed by DNA fragmentation in a cell type dependent manner. 
Mol Biol Rep. 
RUBIS, B., HOLYSZ, H., GLADYCH, M., TOTON, E., PASZEL, A., LISIAK, N., KACZMAREK, 
M., HOFMANN, J. & RYBCZYNSKA, M. 2013b. Telomerase downregulation 
induces proapoptotic genes expression and initializes breast cancer cells 
apoptosis followed by DNA fragmentation in a cell type dependent manner. 
Mol Biol Rep, 40, 4995-5004. 
RUSSO, G. L. 2007. Ins and outs of dietary phytochemicals in cancer chemoprevention. 
Biochem Pharmacol, 74, 533-44. 
SAITO, K., YAGIHASHI, A., NASU, S., IZAWA, Y., NAKAMURA, M., KOBAYASHI, D., TSUJI, 
N. & WATANABE, N. 2002. Gene expression for suppressors of telomerase 
activity (telomeric-repeat binding factors) in breast cancer. Jpn J Cancer Res, 
93, 253-8. 
SAK, A., STUSCHKE, M., WURM, R., SCHROEDER, G., SINN, B., WOLF, G. & BUDACH, V. 
2002. Selective inactivation of DNA-dependent protein kinase with antisense 
oligodeoxynucleotides: consequences for the rejoining of radiation-induced 
DNA double-strand breaks and radiosensitivity of human cancer cell lines. 
Cancer Res, 62, 6621-4. 
SALHAB, M., JIANG, W. G., NEWBOLD, R. F. & MOKBEL, K. 2008. The expression of 
gene transcripts of telomere-associated genes in human breast cancer: 
correlation with clinico-pathological parameters and clinical outcome. Breast 
Cancer Res Treat, 109, 35-46. 
SAMENI, S., POONEPALLI, A. & HANDE, M. Manuscript in preparation. Plumbagin 
triggers DNA damage response mechanisms, telomere/telomerase dynamics 
and genome stability of human breast cancer cells. 
SAN FILIPPO, J., SUNG, P. & KLEIN, H. 2008. Mechanism of eukaryotic homologous 
recombination. Annu Rev Biochem, 77, 229-57. 
SAND, J. M., BIN HAFEEZ, B., JAMAL, M. S., WITKOWSKY, O., SIEBERS, E. M., FISCHER, 
J. & VERMA, A. K. 2012. Plumbagin (5-hydroxy-2-methyl-1,4-
naphthoquinone), isolated from Plumbago zeylanica, inhibits ultraviolet 
229 
 
radiation-induced development of squamous cell carcinomas. Carcinogenesis, 
33, 184-90. 
SANDUR, S. K., ICHIKAWA, H., SETHI, G., AHN, K. S. & AGGARWAL, B. B. 2006. 
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappaB 
activation and NF-kappaB-regulated gene products through modulation of 
p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis 
induced by cytokine and chemotherapeutic agents. J Biol Chem, 281, 17023-
33. 
SANDUR, S. K., PANDEY, M. K., SUNG, B. & AGGARWAL, B. B. 2010. 5-hydroxy-2-
methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 
activation pathway through induction of protein tyrosine phosphatase, SHP-
1: potential role in chemosensitization. Mol Cancer Res, 8, 107-18. 
SANDVICK, S., MCPHERSON, L., HASTAK, K., ALLI, E. & FORD, F. 2010. The Effect of 
PARP Inhibitor on Base Excision Repair inTriple Negative HCC1806 andLuminal 
MCF7 Breast Cancer Cell Lines. Stanford Summer Research Program. 
SCHNEIDER, C. A., RASBAND, W. S. & ELICEIRI, K. W. 2012. NIH Image to ImageJ: 25 
years of image analysis. Nat Methods, 9, 671-5. 
SCHREIBER, V., DANTZER, F., AME, J. C. & DE MURCIA, G. 2006. Poly(ADP-ribose): 
novel functions for an old molecule. Nat Rev Mol Cell Biol, 7, 517-28. 
SEIMIYA, H., OH-HARA, T., SUZUKI, T., NAASANI, I., SHIMAZAKI, T., TSUCHIYA, K. & 
TSURUO, T. 2002. Telomere shortening and growth inhibition of human 
cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and 
MST-1991. Mol Cancer Ther, 1, 657-65. 
SERRANO, D., BLEAU, A. M., FERNANDEZ-GARCIA, I., FERNANDEZ-MARCELO, T., 
INIESTA, P., ORTIZ-DE-SOLORZANO, C. & CALVO, A. 2011. Inhibition of 
telomerase activity preferentially targets aldehyde dehydrogenase-positive 
cancer stem-like cells in lung cancer. Mol Cancer, 10, 96. 
SESHADRI, P., RAJARAM, A. & RAJARAM, R. 2011. Plumbagin and juglone induce 
caspase-3-dependent apoptosis involving the mitochondria through ROS 
generation in human peripheral blood lymphocytes. Free Radic Biol Med, 51, 
2090-107. 
SEXTON, T., BANTIGNIES, F. & CAVALLI, G. 2009. Genomic interactions: chromatin 
loops and gene meeting points in transcriptional regulation. Semin Cell Dev 
Biol, 20, 849-55. 
SHAY, J. W. & BACCHETTI, S. 1997. A survey of telomerase activity in human cancer. 
Eur J Cancer, 33, 787-91. 
SHAY, J. W., PEREIRA-SMITH, O. M. & WRIGHT, W. E. 1991. A role for both RB and p53 
in the regulation of human cellular senescence. Exp Cell Res, 196, 33-9. 
SHAY, J. W. & WRIGHT, W. E. 2002. Telomerase: a target for cancer therapeutics. 
Cancer Cell, 2, 257-65. 
SHAY, J. W. & WRIGHT, W. E. 2005. Mechanism-based combination telomerase 
inhibition therapy. Cancer Cell, 7, 1-2. 
SHIEH, J. M., CHIANG, T. A., CHANG, W. T., CHAO, C. H., LEE, Y. C., HUANG, G. Y., SHIH, 
Y. X. & SHIH, Y. W. 2010. Plumbagin inhibits TPA-induced MMP-2 and u-PA 
expressions by reducing binding activities of NF-kappaB and AP-1 via ERK 
signaling pathway in A549 human lung cancer cells. Mol Cell Biochem, 335, 
181-93. 
SHILOH, Y. 2003. ATM and related protein kinases: safeguarding genome integrity. 
Nat Rev Cancer, 3, 155-68. 
230 
 
SHIPPEN-LENTZ, D. & BLACKBURN, E. H. 1990. Functional evidence for an RNA 
template in telomerase. Science, 247, 546-52. 
SHUKLA, S., WU, C. P., NANDIGAMA, K. & AMBUDKAR, S. V. 2007. The 
naphthoquinones, vitamin K3 and its structural analogue plumbagin, are 
substrates of the multidrug resistance linked ATP binding cassette drug 
transporter ABCG2. Mol Cancer Ther, 6, 3279-86. 
SIEGEL, R., NAISHADHAM, D. & JEMAL, A. 2012. Cancer statistics, 2012. CA Cancer J 
Clin, 62, 10-29. 
SINHA, S., PAL, K., ELKHANANY, A., DUTTA, S., CAO, Y., MONDAL, G., IYER, S., 
SOMASUNDARAM, V., COUCH, F. J., SHRIDHAR, V., BHATTACHARYA, R., 
MUKHOPADHYAY, D. & SRINIVAS, P. 2013. Plumbagin inhibits tumorigenesis 
and angiogenesis of ovarian cancer cells in vivo. Int J Cancer, 132, 1201-12. 
SIRAGAM, V., RUTNAM, Z. J., YANG, W., FANG, L., LUO, L., YANG, X., LI, M., DENG, Z., 
QIAN, J., PENG, C. & YANG, B. B. 2012. MicroRNA miR-98 inhibits tumor 
angiogenesis and invasion by targeting activin receptor-like kinase-4 and 
matrix metalloproteinase-11. Oncotarget, 3, 1370-85. 
SKVORTZOV, D. A., RUBZOVA, M. P., ZVEREVA, M. E., KISELEV, F. L. & DONZOVA, O. A. 
2009. The regulation of telomerase in oncogenesis. Acta Naturae, 1, 51-67. 
SLIJEPCEVIC, P. 2006. The role of DNA damage response proteins at telomeres--an 
"integrative" model. DNA Repair (Amst), 5, 1299-306. 
SLIJEPCEVIC, P. 2008. DNA damage response, telomere maintenance and ageing in 
light of the integrative model. Mech Ageing Dev, 129, 11-6. 
SMITH, L. M., WISE, S. C., HENDRICKS, D. T., SABICHI, A. L., BOS, T., REDDY, P., BROWN, 
P. H. & BIRRER, M. J. 1999. cJun overexpression in MCF-7 breast cancer cells 
produces a tumorigenic, invasive and hormone resistant phenotype. 
Oncogene, 18, 6063-70. 
SMOGORZEWSKA, A., KARLSEDER, J., HOLTGREVE-GREZ, H., JAUCH, A. & DE LANGE, T. 
2002. DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres 
in G1 and G2. Curr Biol, 12, 1635-44. 
SMOGORZEWSKA, A., VAN STEENSEL, B., BIANCHI, A., OELMANN, S., SCHAEFER, M. R., 
SCHNAPP, G. & DE LANGE, T. 2000. Control of human telomere length by TRF1 
and TRF2. Mol Cell Biol, 20, 1659-68. 
SOULE, H. D., MALONEY, T. M., WOLMAN, S. R., PETERSON, W. D., JR., BRENZ, R., 
MCGRATH, C. M., RUSSO, J., PAULEY, R. J., JONES, R. F. & BROOKS, S. C. 1990. 
Isolation and characterization of a spontaneously immortalized human breast 
epithelial cell line, MCF-10. Cancer Res, 50, 6075-86. 
SPILIANAKIS, C. G. & FLAVELL, R. A. 2004. Long-range intrachromosomal interactions 
in the T helper type 2 cytokine locus. Nat Immunol, 5, 1017-27. 
SPRUCK, C. H., DE MIGUEL, M. P., SMITH, A. P., RYAN, A., STEIN, P., SCHULTZ, R. M., 
LINCOLN, A. J., DONOVAN, P. J. & REED, S. I. 2003. Requirement of Cks2 for 
the first metaphase/anaphase transition of mammalian meiosis. Science, 300, 
647-50. 
SRINIVAS, P., GOPINATH, G., BANERJI, A., DINAKAR, A. & SRINIVAS, G. 2004. 
Plumbagin induces reactive oxygen species, which mediate apoptosis in 
human cervical cancer cells. Mol Carcinog, 40, 201-11. 
SUDA, T., TAKAHASHI, T., GOLSTEIN, P. & NAGATA, S. 1993. Molecular cloning and 
expression of the Fas ligand, a novel member of the tumor necrosis factor 
family. Cell, 75, 1169-78. 
231 
 
SUN, J., WATKINS, G., BLAIR, A. L., MOSKALUK, C., GHOSH, S., JIANG, W. G. & LI, R. 
2008. Deregulation of cofactor of BRCA1 expression in breast cancer cells. J 
Cell Biochem, 103, 1798-807. 
SZEPES, M., JANICSEK, Z., BENKO, Z., CSELENYAK, A. & KISS, L. 2013. Pretreatment of 
therapeutic cells with poly(ADP-ribose) polymerase inhibitor enhances their 
efficacy in an in vitro model of cell-based therapy in myocardial infarct. Int J 
Mol Med, 31, 26-32. 
TAMAKAWA, R. A., FLEISIG, H. B. & WONG, J. M. 2010. Telomerase inhibition 
potentiates the effects of genotoxic agents in breast and colorectal cancer 
cells in a cell cycle-specific manner. Cancer Res, 70, 8684-94. 
TAN, S. K., LIN, Z. H., CHANG, C. W., VARANG, V., CHNG, K. R., PAN, Y. F., YONG, E. L., 
SUNG, W. K. & CHEUNG, E. 2011. AP-2gamma regulates oestrogen receptor-
mediated long-range chromatin interaction and gene transcription. EMBO J, 
30, 2569-81. 
TENG, Y., MEI, Y., HAWTHORN, L. & COWELL, J. K. 2013. WASF3 regulates miR-200 
inactivation by ZEB1 through suppression of KISS1 leading to increased 
invasiveness in breast cancer cells. Oncogene. 
THASNI, K. A., RAKESH, S., ROJINI, G., RATHEESHKUMAR, T., SRINIVAS, G. & PRIYA, S. 
2008. Estrogen-dependent cell signaling and apoptosis in BRCA1-blocked BG1 
ovarian cancer cells in response to plumbagin and other chemotherapeutic 
agents. Ann Oncol, 19, 696-705. 
THASNI, K. A., RATHEESHKUMAR, T., ROJINI, G., SIVAKUMAR, K. C., NAIR, R. S., G, S., 
BANERJI, A., SOMASUNDARAM, V. & SRINIVAS, P. 2013. Structure activity 
relationship of plumbagin in BRCA1 related cancer cells. Mol Carcinog, 52, 
392-403. 
THOMSON, R. H. 1971. Naturally occurring quinones, London, New York,, Academic 
Press. 
TIWARI, S. B., PAI, R. M. & UDUPA, N. 2002. Temperature sensitive liposomes of 
plumbagin: characterization and in vivo evaluation in mice bearing melanoma 
B16F1. J Drug Target, 10, 585-91. 
TONG, W. M., HANDE, M. P., LANSDORP, P. M. & WANG, Z. Q. 2001. DNA strand break-
sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in 
telomere function, chromosome stability, and tumor suppression. Mol Cell 
Biol, 21, 4046-54. 
TONG, W. M., YANG, Y. G., CAO, W. H., GALENDO, D., FRAPPART, L., SHEN, Y. & WANG, 
Z. Q. 2007. Poly(ADP-ribose) polymerase-1 plays a role in suppressing 
mammary tumourigenesis in mice. Oncogene, 26, 3857-67. 
TOULANY, M., DITTMANN, K., FEHRENBACHER, B., SCHALLER, M., BAUMANN, M. & 
RODEMANN, H. P. 2008. PI3K-Akt signaling regulates basal, but MAP-kinase 
signaling regulates radiation-induced XRCC1 expression in human tumor cells 
in vitro. DNA Repair (Amst), 7, 1746-56. 
TURNER, N. C. & REIS-FILHO, J. S. 2006. Basal-like breast cancer and the BRCA1 
phenotype. Oncogene, 25, 5846-53. 
TUZUNER, B. M., OZTURK, T., KISAKESEN, H. I., ILVAN, S., ZERRIN, C., OZTURK, O. & 
ISBIR, T. 2010. CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their 
cooperative effects on breast cancer susceptibility. In Vivo, 24, 71-4. 
ULANER, G. A., HU, J. F., VU, T. H., ORUGANTI, H., GIUDICE, L. C. & HOFFMAN, A. R. 
2000. Regulation of telomerase by alternate splicing of human telomerase 
232 
 
reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium 
and myometrium. Int J Cancer, 85, 330-5. 
UNDERHILL, C., TOULMONDE, M. & BONNEFOI, H. 2011. A review of PARP inhibitors: 
from bench to bedside. Ann Oncol, 22, 268-79. 
URBANOWICZ-KACHNOWICZ, I., BAGHDASSARIAN, N., NAKACHE, C., GRACIA, D., 
MEKKI, Y., BRYON, P. A. & FFRENCH, M. 1999. ckshs expression is linked to cell 
proliferation in normal and malignant human lymphoid cells. Int J Cancer, 82, 
98-104. 
VAIRA, V., FAVERSANI, A., MARTIN, N. M., GARLICK, D. S., FERRERO, S., NOSOTTI, M., 
KISSIL, J. L., BOSARI, S. & ALTIERI, D. C. 2013. Regulation of lung cancer 
metastasis by Klf4-Numb-like signaling. Cancer Res, 73, 2695-705. 
VAN STEENSEL, B. & DE LANGE, T. 1997. Control of telomere length by the human 
telomeric protein TRF1. Nature, 385, 740-3. 
VAN STEENSEL, B., SMOGORZEWSKA, A. & DE LANGE, T. 1998. TRF2 protects human 
telomeres from end-to-end fusions. Cell, 92, 401-13. 
VERGHESE, E. T., DRURY, R., GREEN, C. A., HOLLIDAY, D. L., LU, X., NASH, C., SPEIRS, 
V., THORNE, J. L., THYGESEN, H. H., ZOUGMAN, A., HULL, M. A., HANBY, A. M. 
& HUGHES, T. A. 2013. MiR-26b is down-regulated in carcinoma-associated 
fibroblasts from ER positive breast cancers leading to enhanced cell migration 
and invasion. J Pathol. 
VEUGER, S. J., CURTIN, N. J., RICHARDSON, C. J., SMITH, G. C. & DURKACZ, B. W. 2003. 
Radiosensitization and DNA repair inhibition by the combined use of novel 
inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) 
polymerase-1. Cancer Res, 63, 6008-15. 
VEUGER, S. J., CURTIN, N. J., SMITH, G. C. & DURKACZ, B. W. 2004. Effects of novel 
inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein 
kinase on enzyme activities and DNA repair. Oncogene, 23, 7322-9. 
VULLIAMY, T. J., KNIGHT, S. W., MASON, P. J. & DOKAL, I. 2001. Very short telomeres 
in the peripheral blood of patients with X-linked and autosomal dyskeratosis 
congenita. Blood Cells Mol Dis, 27, 353-7. 
WAHLE, K. W., BROWN, I., ROTONDO, D. & HEYS, S. D. 2010. Plant phenolics in the 
prevention and treatment of cancer. Adv Exp Med Biol, 698, 36-51. 
WANG, C., MAYER, J. A., MAZUMDAR, A., FERTUCK, K., KIM, H., BROWN, M. & 
BROWN, P. H. 2011. Estrogen induces c-myc gene expression via an upstream 
enhancer activated by the estrogen receptor and the AP-1 transcription 
factor. Mol Endocrinol, 25, 1527-38. 
WANG, C. C., CHIANG, Y. M., SUNG, S. C., HSU, Y. L., CHANG, J. K. & KUO, P. L. 2008. 
Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen 
species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. 
Cancer Lett, 259, 82-98. 
WANG, F. & LEI, M. 2011. Human telomere POT1-TPP1 complex and its role in 
telomerase activity regulation. Methods Mol Biol, 735, 173-87. 
WANG, J., XIE, L. Y., ALLAN, S., BEACH, D. & HANNON, G. J. 1998. Myc activates 
telomerase. Genes Dev, 12, 1769-74. 
WANG, T., XIA, D., LI, N., WANG, C., CHEN, T., WAN, T., CHEN, G. & CAO, X. 2005. Bone 
marrow stromal cell-derived growth inhibitor inhibits growth and migration 
of breast cancer cells via induction of cell cycle arrest and apoptosis. J Biol 
Chem, 280, 4374-82. 
233 
 
WERNER, S., FREY, S., RIETHDORF, S., SCHULZE, C., ALAWI, M., KLING, L., VAFAIZADEH, 
V., SAUTER, G., TERRACCIANO, L., SCHUMACHER, U., PANTEL, K. & ASSMANN, 
V. 2013. Dual Roles of the Transcription Factor Grainyhead-like 2 (GRHL2) in 
Breast Cancer. J Biol Chem, 288, 22993-3008. 
WHITE, L. K., WRIGHT, W. E. & SHAY, J. W. 2001. Telomerase inhibitors. Trends 
Biotechnol, 19, 114-20. 
WIERER, M., VERDE, G., PISANO, P., MOLINA, H., FONT-MATEU, J., DI CROCE, L. & 
BEATO, M. 2013. PLK1 Signaling in Breast Cancer Cells Cooperates with 
Estrogen Receptor-Dependent Gene Transcription. Cell Rep, 3, 2021-32. 
WILLMORE, E., DE CAUX, S., SUNTER, N. J., TILBY, M. J., JACKSON, G. H., AUSTIN, C. A. 
& DURKACZ, B. W. 2004. A novel DNA-dependent protein kinase inhibitor, 
NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the 
treatment of leukemia. Blood, 103, 4659-65. 
WOJTYLA, A., GLADYCH, M. & RUBIS, B. 2011. Human telomerase activity regulation. 
Mol Biol Rep, 38, 3339-49. 
WONG, J. M., KUSDRA, L. & COLLINS, K. 2002. Subnuclear shuttling of human 
telomerase induced by transformation and DNA damage. Nat Cell Biol, 4, 731-
6. 
WONG, V. C., MA, J. & HAWKINS, C. E. 2009. Telomerase inhibition induces acute 
ATM-dependent growth arrest in human astrocytomas. Cancer Lett, 274, 151-
9. 
WONG, V. C., MORRISON, A., TABORI, U. & HAWKINS, C. E. 2010. Telomerase 
inhibition as a novel therapy for pediatric ependymoma. Brain Pathol, 20, 
780-6. 
WU, K. L., WILKINSON, S., REICH, N. O. & PETTUS, T. R. 2007. Facile synthesis of 
naphthoquinone spiroketals by diastereoselective oxidative [3 + 2] 
cycloaddition. Org Lett, 9, 5537-40. 
WU, Z. S., WU, Q., WANG, C. Q., WANG, X. N., HUANG, J., ZHAO, J. J., MAO, S. S., 
ZHANG, G. H., XU, X. C. & ZHANG, N. 2011. miR-340 inhibition of breast cancer 
cell migration and invasion through targeting of oncoprotein c-Met. Cancer. 
XIAO, A., LI, H., SHECHTER, D., AHN, S. H., FABRIZIO, L. A., ERDJUMENT-BROMAGE, H., 
ISHIBE-MURAKAMI, S., WANG, B., TEMPST, P., HOFMANN, K., PATEL, D. J., 
ELLEDGE, S. J. & ALLIS, C. D. 2009. WSTF regulates the H2A.X DNA damage 
response via a novel tyrosine kinase activity. Nature, 457, 57-62. 
XIN, Z. T., CARROLL, K. A., KUMAR, N., SONG, K. & LY, H. 2011. Transcriptional 
activation of TINF2, a gene encoding the telomere-associated protein TIN2, 
by Sp1 and NF-kappaB factors. PLoS One, 6, e21333. 
XIONG, J., FAN, S., MENG, Q., SCHRAMM, L., WANG, C., BOUZAHZA, B., ZHOU, J., 
ZAFONTE, B., GOLDBERG, I. D., HADDAD, B. R., PESTELL, R. G. & ROSEN, E. M. 
2003. BRCA1 inhibition of telomerase activity in cultured cells. Mol Cell Biol, 
23, 8668-90. 
XU, J., CHEN, Y. & OLOPADE, O. I. 2010. MYC and Breast Cancer. Genes Cancer, 1, 629-
40. 
XU, T. P., SHEN, H., LIU, L. X. & SHU, Y. Q. 2013. Plumbagin from Plumbago Zeylanica 
L induces apoptosis in human non-small cell lung cancer cell lines through NF- 
kappaB inactivation. Asian Pac J Cancer Prev, 14, 2325-31. 
YAMADA, M., TSUJI, N., NAKAMURA, M., MORIAI, R., KOBAYASHI, D., YAGIHASHI, A. 
& WATANABE, N. 2002. Down-regulation of TRF1, TRF2 and TIN2 genes is 
234 
 
important to maintain telomeric DNA for gastric cancers. Anticancer Res, 22, 
3303-7. 
YAN, W., WANG, T. Y., FAN, Q. M., DU, L., XU, J. K., ZHAI, Z. J., LI, H. W. & TANG, T. T. 
2014. Plumbagin attenuates cancer cell growth and osteoclast formation in 
the bone microenvironment of mice. Acta Pharmacol Sin, 35, 124-34. 
YANG, H. & CHEN, B. 2013. CD147 in ovarian and other cancers. Int J Gynecol Cancer, 
23, 2-8. 
YANG, N. S., SHYUR, L. F., CHEN, C. H., WANG, S. Y. & TZENG, C. M. 2004. Medicinal 
herb extract and a single-compound drug confer similar complex 
pharmacogenomic activities in mcf-7 cells. J Biomed Sci, 11, 418-22. 
YANG, S., LI, Y., GAO, J., ZHANG, T., LI, S., LUO, A., CHEN, H., DING, F., WANG, X. & LIU, 
Z. 2012. MicroRNA-34 suppresses breast cancer invasion and metastasis by 
directly targeting Fra-1. Oncogene. 
YANG, T. J. & HO, A. Y. 2013. Radiation therapy in the management of breast cancer. 
Surg Clin North Am, 93, 455-71. 
YOON, J. H., AHN, S. G., LEE, B. H., JUNG, S. H. & OH, S. H. 2012. Role of autophagy in 
chemoresistance: regulation of the ATM-mediated DNA-damage signaling 
pathway through activation of DNA-PKcs and PARP-1. Biochem Pharmacol, 
83, 747-57. 
YOU, H., KONG, M. M., WANG, L. P., XIAO, X., LIAO, H. L., BI, Z. Y., YAN, H., WANG, H., 
WANG, C. H., MA, Q., LIU, Y. Q. & BI, Y. Y. 2013. Inhibition of DNA-dependent 
protein kinase catalytic subunit by small molecule inhibitor NU7026 sensitizes 
human leukemic K562 cells to benzene metabolite-induced apoptosis. J 
Huazhong Univ Sci Technolog Med Sci, 33, 43-50. 
YU, G. L., BRADLEY, J. D., ATTARDI, L. D. & BLACKBURN, E. H. 1990. In vivo alteration 
of telomere sequences and senescence caused by mutated Tetrahymena 
telomerase RNAs. Nature, 344, 126-32. 
ZHAO, J., BILSLAND, A., JACKSON, K. & KEITH, W. N. 2005. MDM2 negatively regulates 
the human telomerase RNA gene promoter. BMC Cancer, 5, 6. 
ZHAO, S., MA, W., ZHANG, M., TANG, D., SHI, Q., XU, S., ZHANG, X., LIU, Y., SONG, Y., 
LIU, L. & ZHANG, Q. 2013. High expression of CD147 and MMP-9 is correlated 
with poor prognosis of triple-negative breast cancer (TNBC) patients. Med 
Oncol, 30, 335. 
ZHENG, W., XIE, D. W., JIN, F., CHENG, J. R., DAI, Q., WEN, W. Q., SHU, X. O. & GAO, Y. 
T. 2000. Genetic polymorphism of cytochrome P450-1B1 and risk of breast 
cancer. Cancer Epidemiol Biomarkers Prev, 9, 147-50. 
ZHU, X., KWON, C. H., SCHLOSSHAUER, P. W., ELLENSON, L. H. & BAKER, S. J. 2001. 
PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in 
endometrial carcinoma cells. Cancer Res, 61, 4569-75. 
ZIA, M. K., RMALI, K. A., WATKINS, G., MANSEL, R. E. & JIANG, W. G. 2007. The 
expression of the von Hippel-Lindau gene product and its impact on 
invasiveness of human breast cancer cells. Int J Mol Med, 20, 605-11. 
ZIV, Y., BIELOPOLSKI, D., GALANTY, Y., LUKAS, C., TAYA, Y., SCHULTZ, D. C., LUKAS, J., 
BEKKER-JENSEN, S., BARTEK, J. & SHILOH, Y. 2006. Chromatin relaxation in 
response to DNA double-strand breaks is modulated by a novel ATM- and 
KAP-1 dependent pathway. Nat Cell Biol, 8, 870-6. 
ZOU, Y., MISRI, S., SHAY, J. W., PANDITA, T. K. & WRIGHT, W. E. 2009. Altered states 
of telomere deprotection and the two-stage mechanism of replicative aging. 
Mol Cell Biol, 29, 2390-7. 
235 
 
ZVEREVA, M. I., SHCHERBAKOVA, D. M. & DONTSOVA, O. A. 2010. Telomerase: 
structure, functions, and activity regulation. Biochemistry (Mosc), 75, 1563-
83. 
 
